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ACT artemisinin based combination therapy 
ADHD attention deficit hyperactivity disorder 
ADS amorpha-4,11-diene synthase 
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ANOVA analysis of variance 
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COMT catechol-o-methyl transferase 
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COMT L low-activity COMT allele 
CT cognitive therapy 
CV% coefficient of variation 
CYP71AV1 amorpha-4,11-diene monooxygenase (cytochrome P450 enzyme) 
DAT dopamine transporter 
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DIGE difference gel electrophoresis 
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DNA deoxyribonucleic acid 
DRD2 dopamine D2 receptor 
DSM-IV-TR diagnostic and statistical manual of mental disorders - 4th  edition  – 
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ECD electrochemical detection 
ELSD evaporative light scattering detector 
ERP exposure response prevention 
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GPP geranyl diphosphate 
HAM-A Hamilton anxiety scale 
HAM-D Hamilton depression scale 
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HPLC high performance liquid chromatography 
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MSDB mass spectrometry protein sequence database 
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SD standard deviation 
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SRI serotonin reuptake inhibitors 
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1. Obsessive Compulsive Disorder: Introduction 
 
1.1. History 
A condition resembling obsessive compulsive disorder (OCD) has been recognized for more 
than three centuries. Through history, the view on OCD has been influenced by the 
intellectual and scientific climate of the period.  
 
Centuries ago, individuals with obsessive blasphemous or sexual thoughts were considered to 
be possessed. The logical treatment was one designed to exorcize the invading entity from the 
unfortunate soul who was possessed. 
 
With time, the explanation of the cause of obsessions and compulsions moved from a 
religious view to a medical one. The first description in psychiatric literature of a patient with 
obsessive-compulsive disorder is found in the writings of J.E.D. Esquirol in 1838[1]. He 
describes a female patient with kleptophobia and stresses the two characteristics of the 
continuous fight against the obsessive thoughts and the accompanying awareness of their 
ridiculous nature. 
 
Carl Westphal presented his paper “Uber Zwangvorstellungen” in 1877[2]. By linking 
compulsions to obsessions, Westphal was the first to characterize OCD with a definition very 
close to its current definition in contemporary diagnostic manuals. His definition comprises 
four criteria: 
1. integrity of intelligence 
2. absence of affective causal pathology 
3. intrusion of obsessive-compulsive representations against the subjects will and the 
inability to suppress them 
4. recognition of the bizarreness and abnormality of the representations 
 
By the beginning of the 20th century, theories of OCD shifted towards psychoanalytical 
explanations. With Freud's writings on psychoanalysis of the Rat Man[3], OCD was explained 
to be resulting from their emotional antecedents. As a result of these theories, treatment of 
OCD turned away from attempts to relieve the obsessional symptoms themselves and toward 
treatment of unconscious conflicts which were presumed to underlie the symptoms.  
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 Over the last few years, research on the biology of OCD grew exponentionally with ongoing 
studies of pharmacologic agents, neurosurgery, genetics, brain imaging, neuropsychological 
dysfunction and the association of OCD symptoms with other possibly related illnesses.  
 
Today, OCD is viewed mainly as a neuropsychiatric disease, and is classified by the 
“Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition – Text Revision” 
(DSM-IV-TR) as an anxiety disorder, and by the “International Statistical Classification of 
Diseases and Related Health Problems - 10th revision” (ICD-10) as a stand-alone disorder. 
The current definition of OCD, opposing obsessions (anxiety inducing) to compulsions 
(anxiety reducing) is largely derived from behavioral theories. From a neurochemical 
perspective, OCD is believed to be related to the serotonergic system[4]. From a neuro-
anatomical perspective, OCD is believed to be related to the hyperactivity of prefrontal-
striatal-thalamic circuitry[4].  
 
 
1.2. DSM-IV-TR 
The DSM-IV-TR, published by the American Psychiatric Association, is the handbook used 
most often in diagnosing mental disorders in the United States. The ICD-10 is a commonly-
used alternative internationally. 
 
The Diagnostic and Statistical Manual of Mental Disorders, presently in its fourth revised 
(IV-TR, 2000) edition, systemizes psychiatric diagnosis in five axes: 
Axis I: major mental disorders, developmental disorders and learning disabilities  
Axis II: underlying pervasive or personality conditions, as well as mental retardation  
Axis III: any non-psychiatric medical condition ("somatic")  
Axis IV: social functioning and impact of symptoms  
Axis V: Global Assessment of Functioning  
Common Axis I disorders include depression, anxiety disorders, OCD, bipolar disorder, 
attention deficit hyperactivity disorder (ADHD), and schizophrenia. Common Axis II 
disorders include borderline personality disorder, antisocial personality disorder, narcissistic 
personality disorder, and mild mental retardation. 
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For the diagnosis of OCD, the DSM-IV-TR requires that a patient has either obsessions or 
compulsions which are a significant source of distress; are time-consuming, or significantly 
interfere with the person's normal routine, occupational functioning, or usual social activities 
or relationships with others.  
At some point during the course of the illness, the patient must recognize that the obsessions 
or compulsions are excessive or unreasonable. This is not a necessary requirement for young 
children.  
 
The Quick Reference to the diagnostic criteria from DSM-IV-TR (2000) describes these 
obsessions and compulsions: 
 
Obsessions are defined by (1), (2), (3), and (4): 
1) Recurrent and persistent thoughts, impulses, or images that are experienced at some time 
during the disturbance, as intrusive and inappropriate and cause marked anxiety or distress.  
2) The thoughts, impulses, or images are not simply excessive worries about real-life 
problems.  
3) The person attempts to ignore or suppress such thoughts or impulses or to neutralize them 
with some other thought or action.  
4) The person recognizes that the obsessions are the product of his or her own mind. 
 
Compulsions are defined by (1) and (2): 
1) Repetitive behaviors that the person feels driven to perform in response to an obsession, or 
according to rules that must be applied rigidly.  
2) The behaviors or mental acts are aimed at checking. This can include mental compulsions 
such as praying, counting and repeating words silently. Such repetitive mental actions 
generally serve to decrease, prevent or reduce distress or some dreaded event or situation, 
however, these behaviors or mental acts either are not connected in a realistic way with what 
they are designed to neutralize or prevent, or are clearly excessive.  
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1.3. ICD-10 
The classification is created from the World Health Organization (WHO). OCD is described 
under chapter V “Mental and behavioral disorders”, subsection F40-48 “Neurotic, stress-
related and somatoform disorders” 
 
Obsessive-Compulsive Disorder 
The essential feature is recurrent obsessional thoughts or compulsive acts. Obsessional 
thoughts are ideas, images, or impulses that enter the patient's mind again and again in a 
stereotyped form. They are almost invariably distressing and the patient often tries, 
unsuccessfully, to resist them. They are, however, recognized as his or her own thoughts, even 
though they are involuntary and often repugnant. Compulsive acts or rituals are stereotyped 
behaviors that are repeated again and again. They are not inherently enjoyable, nor do they 
result in the completion of inherently useful tasks. Their function is to prevent some 
objectively unlikely event, often involving harm to or caused by the patient, which he or she 
fears might otherwise occur. Usually, this behavior is recognized by the patient as pointless or 
ineffectual and repeated attempts are made to resist. Anxiety is almost invariably present. If 
compulsive acts are resisted the anxiety gets worse.   
 
The ICD-10 defines several subtypes: 
• Predominantly Obsessional Thoughts Or Ruminations 
These may take the form of ideas, mental images, or impulses to act, which are nearly 
always distressing to the subject. Sometimes the ideas are an indecisive, endless 
consideration of alternatives, associated with an inability to make trivial but necessary 
decisions in day-to-day living. The relationship between obsessional ruminations and 
depression is particularly close and a diagnosis of OCD should be preferred only if 
ruminations arise or persist in the absence of a depressive episode. 
• Predominantly Compulsive Acts (Obsessional Rituals) 
The majority of compulsive acts are concerned with cleaning (particularly hand 
washing), repeated checking to ensure that a potentially dangerous situation has not 
been allowed to develop, or orderliness and tidiness. Underlying the overt behavior is 
a fear, usually of danger either to or caused by the patient, and the ritual is an 
ineffectual or symbolic attempt to avert that danger. 
• Mixed obsessional thoughts and acts 
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1.4. Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) 
The Y-BOCS is one of the most widely used OCD measures. It was developed in 1986 for the 
assessment of symptom severity and treatment outcome in OCD, and has since demonstrated 
excellent validity and reliability[5]. It is accompanied by the Y-BOCS symptom checklist (Y-
BOCS CL), which provides a comprehensive list of 64 obsessions and compulsions, classified 
in thirteen specific categories 
 
 
1.5. The OCD-cycle 
 
 
Figure 1: The OCD cycle 
 
Figure 1 is often used as a visual aid to understand why some patients go through hours of 
meticulous rituals, only to find some temporal relief and why they engage in all kinds of 
absurd and time-consuming behaviors which end up making them feel unhappy / restricted for 
having done them. 
 
The combination of having anxiety triggered, not being in control of this and finding relief 
through rituals that give you a sense of being in control, is making the effects of this OCD- 
cycle so powerful. This is why treatment (see chapter 1.4.) often includes some kind of 
behavioral therapy which tries to break the OCD-cycle by slowly but steadily taking away the 
section that brings the "relief". 
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1.6. Prevalence 
OCD usually begins in early adulthood with over half of the patients becoming symptomatic 
by age 25. It affects men and women in roughly equal number. Even within the last decade, 
OCD was considered to be extremely rare (approximately 0.05% of the population). One of 
the most recent prevalence studies (Swiss population) reports a prevalence rate of 3.5 % for 
OCD (males 1.7%, females 5.4%). The onset of obsessive compulsive symptoms was 18 
years (median); and in 70% before age 20. OCD was treated only in one third of cases[6]. 
The main reason for this “hidden epidemic” is that the patients want to keep it secret and 
don’t want to disclose their “crazy” symptoms. 
 
 
1.7. OCD: many manifestations 
A paper by Merlo et al.[7] gives an excellent overview of the most common obsession and 
compulsions. In extreme cases of OCD, these obsessions and compulsions can occupy the 
patient every hour of the day. The following table was adapted from the Yale-Brown 
Obsessive-Compulsive Scale and the Children’s Yale-Brown Obsessive-Compulsive Scale. 
 
Common 
obsessions in 
OCD 
OBSESSIVE CONCERNS 
Contamination Dirt; germs; animals/insects; illnesses; bodily waste; contaminants; household cleaners; 
“sticky” substances; spreading contamination, germs, illnesses, etc 
Aggression Harming self or others (even accidentally); causing harm to self or others due to thoughts or 
behaviors; acting upon aggressive impulses; blurting out inappropriate words/phrases; 
stealing or breaking things; causing something terrible to happen; frightening/violent images 
Sexual Forbidden/perverse sexual thoughts, images; disturbing sexual impulses, desires; 
homosexuality; molestation; sexual acts toward others 
Hoarding/saving Losing things; throwing away objects that might be important 
Magical thinking Lucky/unlucky numbers, colors, names, etc 
Health/body Contracting illness (especially if fatal or rare); appearance;  
physical abnormalities (real or imagined) 
Mortality/religion Dying and not going to Heaven; offending God; being sinful; morality/perfection; 
right/wrong 
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Miscellaneous Remembering certain things; saying things exactly right; not saying certain words/phrases 
Common 
compulsions in 
OCD 
COMPULSIVE RITUALS 
Washing & 
cleaning 
Excessive/ritualized hand washing, showering, bathing, tooth brushing, grooming, toileting; 
cleaning clothing/personal items; avoiding “contaminated” objects/places 
Checking Checking locks, alarms, school supplies, homework, toys, books, etc; checking associated 
with washing, dressing, undressing, somatic concerns; checking that did/will not harm self 
or others; checking that nothing terrible did/will happen; checking for mistakes 
Repeating Rewriting; rereading; recopying; retying (e.g., shoelaces); erasing; going in/out door or 
taking items in/out of schoolbag; getting up/down from seat; repeating words/phrases 
Counting Counting objects; mental counting (especially up to a “magic” number); counting steps, 
chewing, hair-brushing, etc 
Ordering/arranging Lining up objects in a certain way; arranging things in specific patterns; making 
objects/piles/groups “even”; making things symmetrical; “balancing” actions (eg, doing 
thing on the right and on the left) 
Hoarding & saving Keeping unimportant/unnecessary items and/or trash; storing items of no particular value; 
having difficulty throwing things away; sorting through trash to ensure that nothing 
important has been thrown away 
Superstitions Touching/tapping routines to prevent bad things from happening; avoiding stepping on 
cracks, lines, etc; avoiding “unlucky” objects/places 
Reassurance-
seeking 
Asking a parent to repeatedly answer the same questions; asking parents to describe what 
they are doing/planning to do; forcing family members to do things in a certain way or at a 
certain time; forcing family members to avoid certain things/activities 
Miscellaneous Mental rituals; needing to tell/ask/confess; ritualized eating behaviors; excessive list-
making; needing to touch/tap/rub; needing to do things until it feels “just right” hair-pulling; 
measures to prevent something bad from happening 
Table 1: The many manifestations of OCD 
 
 
1.8. High Comorbidity: Is OCD a discrete psychiatric disorder? 
• About half of the OCD patients meet criteria for another psychiatric disease[6]. If 
OCD rarely presents in isolation of other conditions, the validity to retain OCD as a 
separate diagnostic category is in doubt.  
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• Besides a high comorbidity with other psychiatric disorders, OCD itself also 
encompasses a wide range of mental and behavioral phenomena[7]. 
 
One of the largest studies to report on comorbid DSM-IV diagnoses in a sample of OCD 
patients is by Denys et al.[8]. This study examined the cross-sectional prevalence of comorbid 
DSM-IV axis I, and personality disorders in 420 outpatients with primary OCD. Forty-six 
percent of the patients were diagnosed with a comorbid disorder. Twenty-seven percent met 
the criteria for at least one comorbid axis I disorder, 15.6 for a comorbid personality disorder, 
and 20.4 for both a comorbid axis I disorder and a personality disorder. Associated axis I 
comorbidity did not affect clinical severity of OCD, but was related to higher levels of 
depression and anxiety, whereas axis II comorbidity impaired the overall functioning to a 
higher extend. As follows, the treatment planning and prognosis of OCD patients should be 
adapted according to their comorbid status.   
 
 
1.9. Does OCD represent different clinical subtypes? 
OCD is a complex and heterogeneous disorder that encompasses a wide range of mental 
behavioral phenomena[7]. Studying clinical subtypes may enhance the likelihood of 
delineating pathogenic mechanisms, neurobiological underpinnings or genetic transmissions. 
By consequence, the identification of homogeneous subgroups has been a focus of interest 
and extensive investigation. Distinct clinical subtypes have formerly been built upon 
demographic and clinical characteristics (sex, age of onset, course of the disease), nature of 
OCD symptoms (predominance of obsessions or compulsions, washers/checkers) or comorbid 
conditions (tic disorder, schizophrenia)[9]. 
 
Lately strategies for identifying clinical subtypes have focused on using factor analytical 
techniques on generally recognized OCD-scales. One of the largest factor analyses on OCD is 
by Denys et al.[9]. This study aimed to identify symptom dimensions in OCD, in order to 
reveal distinct clinical phenotypes. A factor analysis of the of the Y-BOCS checklist on item 
level was performed on data from 335 outpatients with primary OCD. The relationship of 
demographic and clinical characteristics with the resulting factor scores was examined. A 
principal components analysis identified five consistent symptom dimensions: 
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1. Contamination and cleaning 
2. Aggressive, sexual and religious obsessions 
3. Somatic obsessions and checking 
4. Symmetry and counting / arranging compulsions 
5. High risk assessment and checking 
 
Significant differences in sex distribution, age of onset, Y-BOCS scores, and familial 
prevalence of OCD in relation to symptom dimensions, which provide further evidence for 
distinct clinical phenotypes in OCD. 
 
 
1.10. Treatment 
Currently the most effective treatment for OCD is a combination of behavior therapy and 
pharmacotherapy[10-15]. This combined approach can be expected to improve the condition 
of most patients substantially, and occasionally completely, within a few months[16]. As a 
last resort, surgery to certain parts of the brain (psychosurgery) may be considered in certain 
severe cases resistant to all other treatments. 
 
1.10.1. Cognitive-Behavior Therapy 
Cognitive-behavioral therapy (CBT) refers to two distinct treatments: behavior therapy and 
cognitive therapy (CT). These treatments are increasingly offered in combination[13-17]. 
 
Usually, behavior therapy focuses on Exposure Response Prevention (ERP)[13] in which the 
patient is exposed to the feared situation or object and has to resist the urge to perform 
compulsions. Behaviorists regard compulsions as a form of learned avoidance, which are 
reinforced because they were perceived to reduce fear and anxiety. ERP begins with real life 
exposure to triggers that initiate the obsessive thoughts and accompanying anxiety. The 
typical ritual response is prevented and the patient remains in distress. With prolonged 
exposure to the triggering situation, unrelieved by compulsions, the patient habituates and his 
or her discomfort dissipates. Behavior therapy produces the largest changes in rituals, such as 
compulsive cleaning and checking, whereas changes in obsessive thoughts are less predictable. 
Behavior therapy is now regarded as the treatment of choice (in combination with 
pharmacotherapy) when behavioral rituals predominate[17]. 
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 CT helps the patients to identify and re-evaluate their obsessions and compulsions. For 
example, a patient who fears to shake hands may believe he will get infected. This 
interpretation of this fear can be challenged and re-evaluated so that shaking hands is no 
longer considered dangerous. CT can also help to re-evaluate the consequences of not 
performing compulsions, working towards eliminating them. 
 
1.10.2. Pharmacotherapy 
 
1.10.2.1. Serotonin hypothesis 
All Serotonin Reuptake Inhibitors (SRIs) have shown to be effective in OCD, and their 
exclusive efficacy has given grounds to the “serotonin hypothesis” that serotonin plays an 
important role in the pathogenesis of OCD[10, 18, 19]. The efficacy of clomipramine (like 
other tricyclics, clomipramine inhibits noradrenalin and serotonin uptake into central nerve 
terminals, possibly by blocking the membrane-pump of neurons, thereby increasing the 
concentration of transmitter monoamines at receptor sites) and Selective Serotonin Reuptake 
Inhibitors (SSRIs), such as paroxetine, fluvoxamine, fluoxetine, sertraline and citalopram in 
alleviating OCD symptoms has been firmly established in double-blind, placebo-controlled 
trials[16, 20-32]. However, this serotonergic hypothesis is not sufficient. It is clear that the 
dopaminergic mechanism is also implicated in the pathogenesis of OCD. 
 
There has been some debate in the literature about which treatment is more effective, 
clomipramine or the SSRIs, but most clinicians agree that the efficacy is comparable. 
However, the safety and tolerability of the SSRIs clearly make them first-line therapy[33-40]. 
There is no evidence yet that one SSRI is more effective than another, but individual patients 
may respond better to one drug over another[41]. 
 
1.10.2.2. SRIs with addition of antipsychotic drugs 
Although SRIs are the mainstay of treatment for OCD, at least 40% of the patients do not 
respond to an initial medication trial[42]. Moreover, patients who fail to respond to a 
treatment with a SRI have 25% less chance to achieve response with another SRI compared to 
a patient who previously responded to a SRI[43]. Clearly, an improved understanding of 
determinants of response to pharmacotherapy may help to develop more efficient treatment 
strategies in OCD.  
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In case of non-response or partial response to SRIs, evidence has accumulated that the 
addition of antipsychotic drugs to SRIs might lead to symptom improvement. To date, 
risperidone, olanzapine, and quetiapine were shown to be effective as add-on to SRIs in a 
number of case reports and open studies[44-48]. Double-blind, placebo-controlled studies 
have confirmed the efficacy of risperidone[49], olanzapine[50] and haloperidol[51] for SRI-
refractory OCD. Abovementioned studies also included OCD patients with comorbid 
disorders. The beneficial effect of the addition of  the atypical antipsychotic quetiapine for 
treatment of SRI refractory OCD patients without DSM-IV axis I comorbidity is described by 
a double-blind, randomized, placebo controlled trial by Denys et al.[52].  
 
1.10.2.3. Venlafaxine 
Drugs with potential activity against the symptoms of OCD are continually being investigated, 
and one that has received recent attention is venlafaxine, which is a structurally unique 
antidepressant agent. The drug and its active metabolite, O-desmethylvenlafaxine, are potent 
inhibitors of serotonin and noradrenalin reuptake and weakly inhibit dopamine reuptake. 
Serotonin reuptake inhibition is the most potent action of venlafaxine, so it occurs at lower 
doses. Higher doses cause the additional action of norepinephrine reuptake inhibition, 
whereas the highest doses are required for dopamine reuptake inhibition[41]. 
 
A number of meta-analyses have reported that treatment with clomipramine is more effective 
than treatment with SSRIs, an effect that has been attributed to its combined action at the 
serotonin and noradrenalin reuptake sites[53]. Since venlafaxine is also a potent inhibitor of 
the neuronal reuptake of both serotonin and noradrenalin, venlafaxine might be superior to 
SSRIs and clomipramine.  
 
A double-blind comparison of venlafaxine and paroxetine in OCD by Denys et al.[54] shows 
that venlafaxine was equally effective as paroxetine in treating patients with OCD. 
Venlafaxine may be a useful therapy for OCD, but is not superior to SSRIs. 
A single-blind comparison of venlafaxine and paroxetine in OCD by Albert et al.[55] shows a 
36% response for venlafaxine vs. 50% response for clomipramine. 
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1.10.2.4. The pathophysiology of OCD: a role for dopamine? 
Adding an atypical antipsychotic drug to SRIs has proven to be beneficial in a number of 
neuropsychiatric disorders, such as major depression, schizophrenia and OCD. Combination 
therapies appear to be effective mostly in treatment-resistant cases and produce a more rapid 
response, possibly because of pharmacological interaction. (See chapter 1.4.2.2.) 
 
Several studies provide in vivo evidence for abnormalities in the binding potential of the 
dopamine D2 receptor and the dopamine transporter (DAT). These studies suggest the direct 
involvement of the dopamine system in the pathophysiology of OCD.  
• Denys et al. quantitated the striatal dopaminergic D2 receptor binding by [123I] 
iodobenzamide single photon emission computerized tomography in ten medication-
free OCD patients and ten healthy controls, matched for age and gender. The 
dopamine D2 receptor binding in the left caudate nucleus (one of the basal ganglia 
nuclei involved with control of voluntary movement in the brain) was found to be 
significantly lower in the patients with OCD than in healthy controls[56]. 
• Van der Wee et al reported differences between OCD patients and healthy subjects in 
the [I-123]beta-CIT binding pattern for DAT in the left caudate and left putamen[57]. 
• Kim et al. showed that compared normal control adults, patients with OCD showed a 
significant increase of specific/non-specific DAT binding ratio in the right basal 
ganglia and a tendency towards an increase of specific/non-specific DAT binding ratio 
in the left basal ganglia[58]. 
• Hesse et al. showed a significantly reduced availability (corrected for age) of striatal 
DAT and of thalamic/hypothalamic, midbrain and brainstem serotonin transporter in 
OCD patients[59]. 
 
Several studies investigated the serotonin and/or dopamine levels in the brain after treatment 
with SRI, APD or a combination of them:  
• Zhang et al.[60] showed that the combination of olanzapine with fluoxetine may 
synergistically increase dopamine and noradrenergic levels in the rat prefrontal cortex.  
• Denys et al.[61] investigated the effects of combining the atypical antipsychotic drug 
quetiapine with an the SSRI fluvoxamine on extracellular serotonin and dopamine 
levels in the rat dorsal striatum (area involved in antipsychotic induced extrapyramidal 
symptoms), prefrontal cortex, nucleus accumbens (terminal dopaminergic areas 
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implicated in the pathophysiology of schizophrenia) and thalamus (may be of interest 
as it is implicated in the pathophysiology of OCD), by means of microdialysis coupled 
to high performance liquid chromatography (HPLC) with electrochemical detection.  
o Although neither quetiapine nor fluvoxamine in monotherapy affected 
dopamine levels in the prefrontal cortex and thalamus, the combination 
produced a significant increase of dopamine levels in both these brain areas.  
o It is worth noting that the administration of fluvoxamine plus quetiapine, did 
not result in augmented serotonin levels 
 
1.10.3. Psychosurgery 
Researchers have been studying repetitive transcranial magnetic stimulation[62], deep brain 
stimulation[63, 64] and neurosurgical approaches such as gamma-knife- and thermo-
capsulotomy[65] and frameless stereotactic subcaudate tractotomy[66] to learn if these 
procedures are effective in treating treatment-resistant OCD. Repetitive transcranial magnetic 
stimulation has possibilities not only as a therapy but also as an instrument that can help 
researchers describe the neurocircuitries involved in OCD[67].  
 
 
1.11. (Pharmaco)genetics of OCD 
1.11.1. Genetics of OCD 
Available evidence suggesting a genetic basis for OCD etiology includes: (a) twin studies 
with a concordance rate of approximately 50–60% in monozygotic twins compared to 10% in 
dizygotic twins[68, 69], and (b) family studies showing a significant aggregation of illness 
within families compared to population prevalence with an age corrected morbid risk as high 
as 35% in first-degree relatives[68, 70-76]. Furthermore, genome scan studies on OCD have 
identified a candidate region in 9p24 at marker D9S288[77, 78]. 
Because in all twin data reported to date, the concordance for monozygotic twins has always 
been <1.0, obsessive and compulsive behaviors are also influenced by nongenetic / 
environmental factors. Known environmental stressors are abuse, changes in living situation, 
illness, occupational changes or problems, school-related problems etc. 
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1.11.2. Pharmacogenetics of OCD 
Research, by which the treatment of patients is tuned on the basis of their genotype, is called 
pharmacogenetics. Strong evidence suggests that genetic variation plays an important role in 
inter-individual differences in medication response and toxicity. Gene variants of drug-
metabolizing enzymes can dramatically change the pharmacokinetics of a specific drug.  
Polymorphisms in genes (receptors, enzymes …) involved in the pharmacodynamics of a 
specific drug can also influence the clinical response.  
 
A high proportion of OCD patients treated with SSRIs respond inadequately. To circumvent 
this, it is often necessary to switch between different SSRIs to find a more suitable alternative. 
This trial and error approach, where patients often do not display a full therapeutic response 
until several weeks after initiation, is unfavorable. This makes SSRI treatment of OCD a 
classic example where pharmacogenetics could bring a solution. Reviews by Veenstra-
VanderWeele et al.[79] and Mancama et al.[80] give an overview of the role of 
pharmacogenetics in individualizing treatment with SSRIs and possible genetics influences on 
therapeutic response to drugs affecting the serotonin system. 
 
• Drug metabolizing enzymes: Reuptake inhibitors of serotonin (citalopram, 
fluvoxamine, fluoxetine, paroxetine, sertraline) and noradrenaline (reboxetine) or both 
(venlafaxine), are almost totally biotransformed before excretion[81]. Metabolism 
generally proceeds through sequential or parallel oxidative pathways. They interact 
strongly with the cytochrome P450 enzymes, being both substrates and, in some cases, 
inhibitors (possible drug-drug interactions e.g. with tricyclic antidepressants). 
Particularly well characterized is the significant effect of the CYP2D6 and CYP2C19 
polymorphisms on the pharmacokinetics of almost all tricyclic and many other 
antidepressants. The activities of these two enzymes are both bimodally distributed in 
the Caucasian population, allowing classification of individuals into extensive, 
intermediate and poor metabolizers. Some studies recommend dose adjustments for 
these antidepressants based on the CYP2D6 and/or CYP2C19 genotype of the 
patient[80-82]. 
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• Pharmacodynamics of SSRIs: Pharmacogenetic studies on the pharmacodynamics of 
SSRI response have primarily been focused on 5-HTT polymorphisms. Some studies 
suggest the possible involvement of 5-HT1A, 5-HT1B, 5-HT2A, 5-HT3 polymorphisms. 
The gene encoding tryptophan hydroxylase has also been proposed as a candidate, 
given its pivotal role in serotonin formation[80]. Chapter 4 describes a 
pharmacogenetic study designed to determine whether polymorphisms of the serotonin 
transporter (5-HTT) and the receptor genes 5-HT1B and 5-HT2A affect the efficacy of 
SRI treatment in OCD. 
 
 
1.11.3. Association studies 
An excellent review by Hemmings et al. describes the current status of association studies in 
obsessive-compulsive disorder[83]. During the last 2 decades, a large number of association 
studies have been dedicated to disentangle the genetic components that may be involved in 
the etiology of OCD. The preliminary and frequently inconsistent nature of the data 
represented in the majority of OCD psychiatric genetic-association studies may seem 
discouraging. Failure to confirm previously identified susceptibility loci could result from a 
number of reasons, including the potential for population admixture, the clinical heterogeneity 
of OCD, small sample sizes (and subsequent lack of power) or epistasis. 
 
Epistasis takes place when the action of one gene is modified by one or more other genes. The 
effect can occur directly at the genomic level, where one gene could code for a protein 
preventing transcription of the other gene. Alternatively, the effect can occur at the 
phenotypic level. For example, the gene causing albinism would hide the gene controlling the 
color of a person's hair. Epistasis in the statistical sense means a deviation from the additive 
effects of two or more loci and occurs at the population level. OCD has a complex 
multifactorial etiology. For this reason, it is not surprising that studies of the effects of single 
genes on OCD have often failed to replicate the original findings. This failure is because the 
impact of single alleles on the risk of OCD is dependent on genetic variations at other loci (i.e. 
gene-gene interactions) and on environmental factors (i.e. gene-environment interactions). 
Thus, studies that do not consider the appropriate genetic and/or environmental contexts may 
not identify important susceptibility loci. The identification and characterization of such gene-
gene and gene-environment interactions have been limited by a lack of powerful statistical 
methods and/or a lack of large enough sample sizes.[84]  
 23
A valid way to overcome the clinical heterogeneity of the patients and possibly epistasis 
would be to stratify the patient sample according to clinically defined sub-types, such as 
obsession and compulsion subtypes, age at onset of the disorder, and severity of the disorder. 
Unfortunately, the number of subjects decreases after stratification, thereby limiting the power 
of the studies. Of course, epistasis could also be tackled by analyzing as much polymorphisms 
as possible in the same study. 
 
In light of the putative role of the serotonergic, dopaminergic and possibly (nor)adrenergic 
system in OCD, following polymorphisms were analyzed in a sample of >100 OCD patients 
and a control sample of >100 ethnically matched Caucasian subjects by means of a case-
control study (See chapter 2 and 3). 
 
1.11.3.1. Taq IA polymorphism in the non-coding region flanking the 3’ end       
of the dopamine D2 receptor (DRD2) gene 
This polymorphism creates a restriction site for the Taq I restriction enzyme. The TaqIA1 
(uncut by Taq I restriction enzyme) allele has been associated with measures of low striatal 
dopamine receptor D2 density[85, 86]. 
 
The non-coding region flanking the 3’ end of the DRD2 gene (A region) contains nucleotide 
sequences that do not code for the structure of the receptor, but may have an important role in 
regulating the expression of the gene by its influence on the mRNA stability. On the other 
hand, the relationship between the Taq IA polymorphism and the phenotype data could be due 
to linkage between the DRD2 Taq IA polymorphism and another adjacent functional 
polymorphism. 
Figure 2: There are four broad 
‘superfamilies’ of receptors: (1) the 
channel-linked (ionotropic) receptors; (2) 
the G-protein coupled (metabotropic) 
receptors; (3) the kinase-linked receptors; 
and (4) receptors that regulate gene 
transcription. Dopamine receptors belong 
to the G-protein coupled superfamily. 
They are membrane receptors that have 7 
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transmembrane spanning α-helices. Dopamine binding to the ‘binding groove’ on the 
extracellular portion of the receptor activates the G-proteins, which initiate secondary 
messenger signaling pathways. The downstream effect will be either inhibitory or stimulatory, 
depending on the types of G-protein linked to the receptor – dopamine D1, D5 receptors (D1 
– like) are linked to stimulatory G-proteins, whereas dopamine D2, D3, D4 (D2 – like) are 
linked to inhibitory G-proteins. The D2 receptor exists as an autoreceptor and as a post-
synaptic receptor. Typical and atypical antipsychotics are dopamine D2-like antagonists[87]. 
 
 
Figure 3: Signal transduction mechanism of the dopamine receptor 
 
 
1.11.3.2. Catechol-O-Methyl Transferase (COMT) NlaIII high/low polymorphism 
This polymorphism is a G to A transition at codon 158 (creating a restriction site for the 
restriction enzyme NlaIII) of the COMT gene that results in a valine-to-methionine 
substitution in the enzyme. A valine results in a heat stable, high activity COMT variant, 
whereas a methionine results in a heat labile low activity variant[88]. 
 
COMT is involved in the breakdown of the catecholamine neurotransmitters, dopamine, 
epinephrine and norepinephrine. The enzyme introduces a methyl group to the catecholamine 
which is donated by S-adenosyl methionine (SAM). 
 
 
1.11.3.3. 1438 A/G polymorphism within the promoter region of the postsynaptic 
5-HT2A receptor 
This polymorphism has been associated with several behavioral disorders. The A to G 
transition at nucleotide 1438 creates a restriction site for the restriction enzyme MspI. 
 25
 The 5-hydroxytryptamine (5-HT)-1, 2, 4, 5, 6 and 7 receptors belong to the G-protein coupled 
superfamily. They are membrane receptors that have 7 transmembrane spanning α-helices. 5-
HT binding to the ‘binding groove’ on the extracellular portion of the receptor activates the 
G-proteins, which initiate secondary messenger signaling pathways. The downstream effect is 
either inhibitory or stimulatory, depending on the type of G-protein linked to the receptor – 5-
HT1 receptors are linked to inhibitory G-proteins, whereas 5-HT2, 4, 6 and 7 are linked to 
stimulatory G-proteins. The 5-HT2A receptor is the most important serotonergic receptor with 
respect to behavioral effects. 
 
 
1.11.3.4. 5-HT1Dβ: G861C polymorphism silent G-to-C substitution at nucleotide 
861 of the coding region of the 5-HT1DB  autoreceptor gene 
The 5-HT1Dβ  autoreceptor regulates the presynaptic inhibition of the serotonin release. 
 
This polymorphism is a G to C transition at nucleotide 861 (creating a restriction site for the 
restriction enzyme Hinc II) of the coding region of the 5-HT1Dβ gene. Because both alleles 
encode valine at this position (condons are GTC and GTG), the structure of the receptor is not 
changed by the polymorphism. However, there could be a linkage between the G861C 
polymorphism and another adjacent functional polymorphism. 
 
 
1.11.3.5. 5-HTTLPR: serotonin transporter gene (5-HTT) promoter 44-bp deletion 
The serotonin transporter protein causes reuptake of serotonin from the synapse. In this way, 
it influences the amount of serotonin present in the synapse, and thus the serotonin effects on 
the receiving neuron’s receptor. 
 
The short variant of this polymorphism reduces the transcriptional efficiency of the 5-HTT 
gene promoter, resulting in decreased 5-HTT expression and 5-HT reuptake[89]. 
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ABSTRACT 
 
Background: The successful use of serotonin reuptake inhibitors (SRIs) in 
obsessive-compulsive disorder (OCD) has led to the hypothesis that serotonin 
plays a pivotal role in the pathogenesis of OCD. The purpose of the present study 
was to investigate the role of the serotonin transporter (5-HTT) and serotonin 5-
HT1D and 5-HT2A receptor genes in OCD.  
Method: The distribution of polymorphic variants was analyzed in 156 OCD 
cases and 134 control individuals by means of case-control association studies. 
Potential relevant OCD phenotypes founded on age of onset, positive family 
history for OCD, clinical subtypes, comorbidity and symptom severity were 
stratified according to 5-HTT, 5-HT1D and 5-HT2A genotypes.  
Results: Patients did not show significant differences in genotype distribution and 
allele frequency for polymorphisms investigated relative to controls. However, 
taking in account OCD phenotypes, we found indication towards an association of 
the 5-HTTLPR S-allele with female OCD patients, and the 5-HT2A G-allele and 
GG genotype with patients with a positive family history of OCD and an early 
onset of disease.  
Conclusions: Our data yields interesting preliminary results as regards the genetic 
underpinnings of OCD phenotypes that warrant further discussion and 
investigation. 
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2.1. Introduction 
OCD is a common and severe, but still under-recognized psychiatric disorder. Family and 
twin studies have provided evidence for the involvement of a genetic factor in OCD[1-3]. 
Although very little is known about the disorder’s pathogenesis, serotonergic and 
dopaminergic pathways may be implicated[4]. A role for serotonin in the pathophysiology of 
OCD is supported by pharmacologic challenge studies and the unique efficacy of serotonin 
reuptake inhibitors. Although negative reports have been published, some studies have shown 
associations between OCD with the serotonin transporter (5-HTT), the 5-HT1D, 5-HT2A and 5-
HT2C genes[5]. In light of the putative role of the serotonin system in OCD, we tested the 
frequency of alleles and the distribution of genotypes of the polymorphism in the promoter 
region 5-HTT, the silent G-to-C substitution at nucleotide 861 of the coding region of the 5-
HT1D receptor gene and the -1438 A/G polymorphism of the 5-HT2A receptor gene in a OCD 
sample of 156 patients and of 134 ethnically matched Caucasian subjects from the 
Netherlands as control population. As of yet, the association between the 5HTTLPR and the -
1438 5HT2A polymorphism and OCD has been inconsistent, possibly reflecting sample–
related differences, diagnostic diversity and heterogeneity of the disorder and the 5-HT1B 
G861C polymorphism has not been investigated through a case-control study. Since OCD is 
clinically heterogeneous and this heterogeneity is likely to be due to etiologic heterogeneity 
we considered OCD phenotypes based on qualitative traits such as gender, positive family 
history of OCD, and age of onset of OCD symptoms.  
 
 
2.2. Material and methods  
 
2.2.1. Study sample  
The patient sample comprised 156 unrelated patients with OCD from consecutive referrals to 
the anxiety research unit of the department of psychiatry at the University Medical Centre 
Utrecht, who gave written informed consent for participation in this study that had been 
approved by the University of Utrecht Medical Ethical Review committee (Utrecht, The 
Netherlands). All patients were diagnosed with OCD according to DSM-IV criteria and the 
Mini-International Neuropsychiatric Interview (M.I.N.I.), a clinical and structured interview, 
was used to confirm the diagnosis[6]. Severity of obsessive-compulsive symptoms was rated 
with the Y-BOCS, depression with the Hamilton depression scale (HAM-D), and anxiety with 
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the Hamilton anxiety scale (HAM-A)[7-9]. Information on family history was obtained by 
direct interviews with the patients and the presence of vocal and/or motor tics was assessed 
during the clinical interview. The control sample was composed of 134 ethnically matched 
and unrelated Caucasian subjects from the Netherlands, selected among healthy volunteers. 
 
 Total sample 
(n=156) 
Gender (Male/female) 56/100 
Age on admission 36.6 ± 11.5 
Positive family history 43 
Mean age of onset  17.7 ± 8.3 
 ≤15 years age of onset 60 
 > 20 years age of onset 45 
Duration of illness  18.7 ± 11.6 
Symptom dimensions   
 Contamination fear and washing 23 
 Aggressive, sexual and religious obsessions 14 
 Somatic obsessions and checking 17 
 Symmetry and exactness 54 
 High risk assessment and checking 47 
Y-BOCS 24.9 ± 5.7 
HAM-D 9.5 ±  5.8 
HAM-A 1.6 ± 6.7 
Comorbid depressive disorder 24 
Comorbid anxiety disorder 13 
Table 1. Demographic and clinical characteristics of the patients sample 
 
2.2.2. Genotyping  
Blood samples were collected from each subject and frozen at – 80°. DNA was extracted from 
10 ml samples of peripheral blood according to standard procedures. The total number of 
subjects genotyped for the genes in this study was 310. All subjects were genotyped at the 
University of Ghent (Belgium) based on a coded identification number. The 5-HTT, 5-HT1D 
and 5-HT2A genotyping was performed following a standardized procedure.  
 
2.2.2.1. 5-HTT  
For the detection of the 44 bp insertion/deletion 5-HTTLPR polymorphism, the oligo-
nucleotide primers 5'-6FAM-GGCGTTGCCGCTCTGAATGC–3’ and 5'–AGGGACTGAGC 
TGGACAACCAC-3’ were used to amplify a 484/528 bp fragment comprising the 5-HTT-
linked polymorphic region. The polymerase chain reaction (PCR) reaction was performed 
according following conditions: 94°C for 1 min, 60 °C for 1min, 72°C for 1min40sec per 
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cycle, for a total of 35 cycles. The PCR products were analysed by capillary electrophoresis 
on an Applied Biosystems 3100 Genetic Analyser. 
 
2.2.2.2. 5-HT1D  
For detection of the 5-HT1B or (5-HT1Dβ) G861C polymorphism, the oligonucleotide primers 5' - 
GAAACAGACGCCCAACAGGAC - 3' and 5' -CCAGAAACCGCGAAAGAAGAT - 3' were used to 
amplify a 548 bp region comprising the G861C polymorphism site. The PCR reaction was performed 
under the following conditions: 90°C for 1 min, 55 °C for 2 min, 72°C for 3 min per cycle, for a total 
of 32 cycles. Digestion of 10µl of PCR product was accomplished by incubation for 4 hours with 10 
units of Hinc II restriction enzyme at 37°C. Digestion with Hinc II yields either two fragments (452 bp 
and 96 bp) for the G-allele or three fragments (310 bp, 142 bp and 96 bp) for the C-allele. The 
fragments resulting from the digestion were resolved on a 1.5% agarose gel and visualized by 
ethidium bromide staining. 
 
2.2.2.3. 5-HT2A  
For the detection of the 5-HT2A 1438G/A polymorphism within the promoter region of the 5-
HT2A receptor gene, the oligonucleotide primers 5'-6FAM-AAGCTGCAAGGTAGCAACA 
GC–3’ and 5'-NED-AACCAACTTATTTCCTACCAC-3’ were used to amplify a 468 bp 
region comprising the 5HT2A 1438G/A polymorphism site. The PCR reaction was performed 
under the following conditions: 95°C for 1 min, 47 °C for 1min, 72°C for 1min20sec per 
cycle, for a total of 40 cycles. Digestion of 10µl of PCR product was accomplished by 
overnight incubation with 10 units of Msp I restriction enzyme at 37°C. After incubation with 
Msp I, the 1438A allele remains intact while the 1438G allele is cut into a 223 bp piece 
(6FAM-labelled) and a 243 bp piece (NED-labeled). The fragments resulting from the 
digestion were analyzed by capillary electrophoresis on an Applied Biosystems 3100 Genetic 
Analyser.  
 
2.2.3. Data analysis 
The following statistical procedure was pursued. The genotypic pattern of distribution and the 
allele frequencies of the 5-HTT, 5-HT1D and 5-HT2A polymorphisms were analyzed in the 
whole sample comparing patients with controls. Second, a similar analysis was performed in a 
stratified sample according to gender comparing female patients with female controls. Third, 
patients with a positive family history for OCD were compared with controls and patients 
without a positive family history. Association tests were preformed by means of chi-square 
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tests for the comparison of allele and genotype frequencies between patients and comparisons 
subjects. Considering a partial Bonferroni’s correction, the p value for statistical significance 
would be 0.022 with an alpha of 0.05, 5 tests, 2 degrees of freedom, and a correlation 
correction factor of 0.5. The association between the distribution of the genotypes and allele 
frequencies with the subjects and expected frequencies to assess Hardy-Weinberg equilibrium 
were ascertained by cross-tabulation and 2 analysis. The data are presented as mean ± 
standard deviation (SD), and performed at 5% level of significance. All statistical analyses 
were conducted with the SPSS statistical package version 11.5.  
 
 
2.3. Results 
The patient sample was slightly skewed towards the female population (63%) with a mean ± 
SD age at admission of 36.6 ± 11.5 years for both sexes. (Table 1) The mean age at onset of 
obsessive-compulsive symptoms in our sample was 17.7 ± 8.3 years, with a length of illness 
of 18.7 ± 11.6 years at entry. Males had a significantly earlier onset of illness than females. 
(15.7 ± 8.0 years and 19.0 ± 8.3 years, respectively) ( 2 = 5.85, df=1, p=0.016) Twenty-four 
out of 60 patients with an early onset of illness had a positive family history for OCD. The 
mean Y-BOCS score for the whole sample was 24.9 ± 5.7, with a mean Y-BOCS obsession 
score of 12.5 ± 3.9 and a mean Y-BOCS compulsion score of 12.4 ± 3.8. Twenty-seven 
percent (43 patients) of the sample had a first-degree relative with OCD and nine patients (6 
males/3 females) reported comorbid tics at some time in their life. 
The genotypic pattern of distribution and the allele frequencies of the 5-HTT, 5-HT1D and 5-
HT2A polymorphisms are shown in table 2. The incidences of the polymorphisms of the 5-
HTT, 5-HT1D and 5-HT2A genes were similar in patients and controls, and no difference in 
frequencies of any of the alleles was observed between patients and controls. Both groups 
were in Hardy-Weinberg equilibrium at each locus investigated.  
When the sample was stratified by gender, there was a statistically significant higher 
frequency of the 5-HTTLPR S-allele in female patients (L= 0.53 and S=0.47) compared to 
female controls (L= 0.67 and S=0.33) ( 2 = 6.0, df =1, p=0.014) (OR 1.81, 95% CI 1.12-2.93). 
Patients with a positive family history of OCD (n=43) had a statistically significant 
predominance of the 5-HT2A GG genotype (AA= 16%, AG= 33%, GG= 51%) versus patients 
without genetic load for OCD (n=111) (AA= 21%, AG= 49%, GG= 30%) ( 2 = 6.2, df =2, 
p=0.043) (OR 2.42, 95% CI 1.35-4.33), and a higher frequency of the 5-HT2A G-allele (A= 
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0.32 and G=0.68) versus patients without genetic load for OCD (A= 0.45 and G=0.55) ( 2 = 
4.2, df =1, p=0.039) (OR 1.72, 95% CI 1.02-2.91), however the p-value failed to be statistical 
significant after Bonferroni’s correction. The subpopulation with a positive family history had 
also a statistically significant predominance of the 5-HT  GG genotype (AA= 16%, AG= 
33%, GG= 51%) versus controls (AA= 15%, AG= 57%, GG= 28%) (
2A
2 = 8.427, df =2, 
p=0.015) (OR 2.67, 95% CI 1.48-4.81). A comparable predominance of the 5-HT2A GG 
genotype that just failed to be statistically significant (AA= 23%, AG= 37%, GG= 40%) was 
observed in the subpopulation of patients with an early onset of disease relative to controls 
(AA= 15%, AG= 57%, GG= 28%) ( 2 = 6.5, df =2, p=0.038) (OR 1.71, 95% CI 0.94-3.09).  
 
Table 2. Allele frequencies and genotype distribution of the 5-HT1D,  5-HT2A receptor and 5-HTT 
polymorphisms. Two-sided P values were calculated from 3x2 and 2x2 contingency tables for 
the genotype and allele distributions using the 2-test. 
 n allele frequencies p-value  genotypes p-value  
5-HT1D  C G  CC CG GG  
Controls 117 0.30 0.70 0.647 7 (6.0%) 55 (47.0%) 55 (47.0%) 0.866 
Patients  141 0.28 0.72  8 (5.7%) 62 (44.0%) 71 (50.4%)  
         
5-HT2A  A G  AA AG GG  
Controls 116 0.43 0.57 0.776 17 (14.7%) 66 (56.9%) 33 (28.4%) 0.143 
Patients  154 0.42 0.58  30 (19.5%) 69 (44.8%) 55 (35.7%)  
         
5-HTT  L S  LL L/S SS  
Controls 134 0.58 0.42 0.607 48 (35.8%) 60 (44.8%) 26 (19.4%) 0.787 
Patients  156 0.56 0.44  50 (32.1%) 75 (48.1%) 31 (19.9%)  
         
 
 
2.4. Discussion  
The findings of this study provide no evidence for a general association between 5-HTT, 5-
HT1D and 5-HT2A, polymorphisms and OCD. However, assuming the heterogeneous character 
of OCD, we found some hints towards an association of the 5-HTTLPR S-allele with female 
OCD patients, and the 5-HT2A G-allele and GG genotype with patients with a positive family 
and an early onset of disease.  
The 5-HTTLPR gene has been studied extensively in OCD by means of case-control as well 
as family based studies. Except for Mc Dougle et al and Bengel et al who both reported an 
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association with the L allele, the majority of studies have been negative[10-13]. The 
association of the S-allele with female OCD patients in our study contrasts with previous 
reports, but is in line with the serotonin hypothesis of OCD. The S-allele has been related with 
relatively lower 5-HTT expression and lower serotonin transporter binding capacity than the 
L-allele[14, 15]. The S-allele also has been related with neuroticism and with an increased 
activation response in the right amygdale in response to fearful stimuli compared to the L-
allele[16, 17]. OCD patients show increased activation response to fearful stimuli, and single 
photon emission computed tomography (SPECT) studies recently have provided evidence for 
reduced 5-HTT densities in patients with OCD relative to controls[18]. OCD is thus expected 
to be associated predominantly with the S-allele of the 5-HTTLPR. It is not clear why the 
association of 5-HTT S- allele that we have found is restricted to female patients. Either the 
apparent specific association is a spurious finding as result of a type two error due to small 
sample sizes, or it might be explained by the heterogeneous nature of OCD. Gender-related 
differences have been observed regularly in obsessive-compulsive symptomatology. In 
general, women have been noted to exhibit more aggressive and contamination obsessions 
and cleaning rituals, while men tend to report more frequently primary obsessive slowness, 
sexual, exactness and symmetry obsessions and odd rituals[19]. Comorbidity studies have 
shown that depressive and eating disorders are more prevalent in female OCD patients[19]. A 
recent cluster analysis showed that impulsive OCD behavior such as compulsive shopping, 
kleptomania and eating disorders was linked with female gender, emotional abuse and 
susceptibility to early traumatic experiences. Sexually dimorphic associations in OCD have 
been found also with COMT, monoamine oxidase A (MAO-A), and 5-HT2A genes[20]. 
COMT and MAO-A genes were associated with male OCD patients whereas 5-HT2A genes 
were associated with female OCD patients. This suggests that genetic mechanisms operant in 
OCD may be gender specific. The association of 5-HTTLP S- allele with female patients 
might represent a particular OCD phenotype rooted in a specific OCD genotype.  
The -1438G/A polymorphism of the 5-HT2A receptor has been linked before with OCD. 
Enoch et al reported an association between the A-allele and female OCD patients, and 
Walitza et al between the A-allele and children and adults with OCD[21, 22]. Our results of 
an association with the 5-HT2A G-allele contradict both studies. Though differences in ages of 
onset may not account for these divergent results since both other studies pertain to a group of 
early onset patients, the discrepancy probably reflects dissimilarities in OCD phenotypes. The 
5-HT2A receptor is of particular relevance to OCD since 5-HT2A receptor-binding 
characteristics such as may discriminate between affected and unaffected OCD subjects in 
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families with OCD[23]. In addition, an increase in 5-HT2A receptor binding has been found in 
the caudate nuclei of 15 untreated patients with OCD[24]. At present, it is difficult to interpret 
the significance of a link wit the 5-HT2A promoter region since it is not known whether the -
1438 G and A alleles have functional implications[25]. Finally, it should be noted that the S-
allele of 5HTTLPR and the G-allele of the -1438 5HT2A polymorphism may be in linkage 
disequilibrium with the particular OCD phenotype. 
In conclusion, we have found that OCD in female patients was associated with the 5-HTTLPR 
S-allele and, that the subpopulation of patients with a positive family history of OCD and with 
an early onset of disease had a predominance of the 5-HT2A GG genotype. Our results should 
be interpreted with caution given the limited sample sizes and multiple testing. Nevertheless, 
they strengthen the argument that different OCD phenotypes may have different genetic 
susceptibilities, and add further evidence to the complex pattern of inheritance in OCD.  
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ABSTRACT 
 
Background: Mounting evidence suggests the involvement of the dopamine 
system in the pathophysiology of obsessive–compulsive disorder.  
Method: The relationship of the dopamine D2 receptor (DRD2) TAQI-A, and 
catechol-0-methyl-transferase (COMT) Nla III High/Low activity polymorphism 
to obsessive–compulsive disorder (OCD) was examined in a sample of 150 
patients and 150 controls.  
Results: OCD patients did not show significant differences in genotype 
distribution and allele frequency for polymorphisms investigated relative to 
controls. However, when the sample was stratified by gender, there was a mildly 
significantly predominance of the DRD2 A2A2 genotype (p = 0.049), and a 
higher frequency of the DRD2 A2 allele (p = 0.020) and low-activity COMT 
allele (p = 0.035) in male OCD patients compared to male controls. In addition, 
we observed an association of the DRD2 A2A2 genotype in patients with an 
early onset of disease (≤ 15 years) (p= 0.033).  
Conclusions: Our findings replicate previous reports and provide support for a 
potential role of the COMT and DRD2 locus in subgroup of male, early onset 
patients with OCD.  
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3.1. Introduction 
OCD is a common and severe, but still under-recognized psychiatric disorder. Family and 
twin studies have provided evidence for the involvement of a genetic factor in OCD[1, 2]. 
Although very little is known about the disorder’s pathogenesis, both serotonergic and 
dopaminergic pathways may be implicated. A role for dopamine in the pathophysiology of 
OCD is supported by the observation that pharmacological agents enhancing dopamine 
release such as methylphenidate, cocaine, and bromocriptine may induce obsessive-
compulsive symptoms[3-5]. In addition, evidence has accumulated that augmentation 
strategies with antipsychotics are beneficial for treatment-refractory OCD patients[6-8]. 
Recently, SPECT studies provided evidence for higher dopamine transporter densities and 
lower dopamine D2 binding ratios in patients with OCD relative to controls[9-11]. The 
combined results of these receptor-binding studies provide circumstantial in vivo evidence for 
an increased dopaminergic activity in OCD patients.  
Catechol-O-methyl transferase (COMT) is an enzyme that has a crucial role in the elimination 
of dopamine. Since COMT is involved in the inactivation of dopamine, and higher dopamine 
levels may be implicated in OCD, the COMT gene is an attractive candidate for OCD. The 
G→A transition in codon 158 of the COMT gene results in a valine to methionine substitution 
and is associated with a three- to fourfold decrease in enzyme activity (valine = high-activity, 
methionine = low-activity)[12]. It has already been reported by Karayiourgou et al.[13] that 
the low-activity COMT (COMT L) allele occurs significantly more frequently in male OCD 
patients, but opposing results have also been obtained[14-16]. In addition, one might theorize 
that lower densities of the D2 receptor in OCD patients are caused by genetic factors. The A1 
allele of TaqI A polymorphism in the D2 receptor (DRD2) gene locus has been suggested to 
be associated with reduced DRD2 receptor densities[17, 18].  Data on the DRD2 TaqI A 
polymorphism in OCD are limited, but Nicolini et al. found a higher frequency of the DRD2 
TaqI A2 allele in a small subgroup of OCD patients (n=12) with tics, when compared to 
controls[19].  
In light of the putative role of the dopamine system, and in particular the dopamine D2 
receptor in OCD, we tested the frequency of alleles and the distribution of genotypes of the 
DRD2 receptor TaqI A and of COMT genes in an OCD sample of 150 patients. As a control 
population, we tested 150 ethnically matched Caucasian subjects. As there is evidence for 
gender specificity of the D2 receptor and COMT gene and because previous findings have 
suggested gender differences in the clinical manifestation of OCD, males and females were 
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analyzed separately[15, 20-22]. We firstly hypothesized that OCD patients would have higher 
frequencies of the COMT L allele, resulting in higher synaptic dopamine levels. Secondly, we 
hypothesized that OCD patients would have higher frequencies of the DRD2 receptor TaqI 
A1 allele, resulting in lower synaptic DRD2 density. 
 
 
3.2. Material and methods  
 
3.2.1. Study sample  
The patient sample comprised 159 unrelated patients with OCD from consecutive referrals to 
the anxiety research unit of the department of psychiatry at the University Medical Centre 
Utrecht, who gave written informed consent for participation in this study that had been 
approved by the University of Utrecht Medical Ethical Review committee (Utrecht, The 
Netherlands). All patients were diagnosed with OCD according to DSM-IV criteria and the 
M.I.N.I., a clinical and structured interview, was used to confirm the diagnosis[23]. Severity 
of obsessive-compulsive symptoms was rated with the Y-BOCS, depression with the HAM-D, 
and anxiety with the HAM-A[24-26]. Information on family history was obtained by direct 
interviews with the patients and the presence of vocal and/or motor tics was assessed during 
the clinical interview. The control sample was composed of 151 ethnically matched and 
unrelated Caucasian subjects, selected among healthy volunteers. 
 
3.2.2. Genotyping and data analysis 
Blood samples were collected from each subject and frozen at – 80°. DNA was extracted from 
10 ml samples of peripheral blood according to standard procedures. The total number of 
subjects genotyped for the genes in this study was 310. All subjects were genotyped at the 
University of Ghent (Belgium) based on a coded identification number. The COMT and 
DRD2 genotyping was performed following a standard protocol.  
 
3.2.3. COMT  
For detection of the NlaIII polymorphism in codon 158, the following oligonucleotide primers were 
used (5' - TCACCATCGAGATCAACCCC - 3' and 5' -ACAACGGGTCAGGCATGCA - 3') to 
amplify a 96 bp region comprising the Val158Met polymorphism site. The PCR reaction was 
performed under the following conditions: 94°C for 30sec, 64 °C for 1min, 72°C for 1min per cycle, 
for a total of 35 cycles. Digestion of 9µl of PCR product was accomplished by incubation for 3 to 4 
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hours with 5 units of NlaIII restriction enzyme at 37°C. Digestion with NlaIII yields either two 
fragments (13 bp and 83 bp) for the Val-allele (COMT H) or three fragments (13 bp, 18 bp and 65 bp) 
for the Met-allele (COMT L). The fragments were resolved on a 2.5% agarose gel and visualized by 
ethidium bromide staining.(Karayiorgou et al. 1997)  
 
3.2.4. DRD2 
For the detection of the polymorphism in the TaqA site in the DRD2 gene the oligonucleotide primers 
(5'-CCGTCGACGGCTGGCCAAGTTGTCTA–3’ and 5'–CCGTCGACCCTTCCTGAGTGTCATCA 
-3’) were used to amplify a 310 bp region comprising the TaqA site[27]. The PCR reaction was 
performed under the following conditions: 94°C for 1 min, 50 °C for 1min, 72°C for 1,5min per cycle, 
for a total of 35 cycles. Digestion of 10µl of PCR product was accomplished by overnight incubation 
with 5 units of TaqI restriction enzyme at 65°C. After incubation with TaqI, the A1 allele remains 
intact while the A2 allele is cut into a 130 bp piece and a 180 bp piece. The fragments resulting from 
the digestion were resolved on a 1,5% agarose gel and visualized by staining with ethidium bromide.  
The association between the distribution of the genotypes and allele frequencies with the 
subjects, and expected frequencies to assess Hardy-Weinberg equilibrium, were ascertained 
by cross-tabulation and 2 analysis.  
 
 
3.3. Results 
The patient sample was slightly skewed towards the female population (63%) with a mean ± 
SD age at admission of 36.0 ± 11.0 years for both sexes. The mean age at onset of obsessive-
compulsive symptoms in our sample was 17.7 ± 8.3 years, with a length of illness of 18.0 ± 
11.0 years at entry. Males had a significantly earlier onset of illness than females. (15.7 ± 8.0 
years and 19.0 ± 8.3 years, respectively) ( 2 = 5.85, df=1, p=0.016) The mean Y-BOCS score 
for the whole sample was 24.9 ± 5.7, with a mean HAM-D score of 9.5 ± 5.8 and a mean 
HAM-A score of 11.6 ± 6.7. Twenty-seven percent (43 patients) of the sample had a first-
degree relative with OCD and nine patients (6 males/3 females) reported comorbid tics at 
some time in their life. 
The genotypic pattern of distribution and the allele frequencies of the DRD2 and COMT 
polymorphisms are shown in table 1 and 2. The representations of the polymorphism of the 
DRD2 receptor and the COMT gene were similar in patients and controls. No difference in 
frequencies of any of the alleles was observed between patients and controls. Both groups 
were in Hardy-Weinberg equilibrium at each locus investigated. 
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When the sample was stratified by gender, there was a statistically significant predominance 
of the DRD2 A2A2 genotype in the male patient group ( 2 = 6.0, df=2, p=0.049) and a higher 
frequency of the DRD2 A2 allele in male patients compared to male controls ( 2 = 5.4, df=2, 
p=0.020). In addition, a significant association was observed between the frequency of the 
COMT L allele and male patients ( 2 = 4.4, df=2, p=0.035). Although the frequency of the 
COMT LL genotype was higher in male patients (37.5%) compared to male controls (21%), 
the difference failed to reach statistical significance ( 2 = 4.6, df=2, p=0.10).  
 
 n allele frequencies p-value  genotypes p-value  
  A1 A2  A1A1 A1A2 A2A2  
Total sample Controls  135 0.20 0.80 0.218 5 (3.7%) 45 (33.3%) 85 (63.0%) 0.452 
 Patients  141 0.16 0.84  3 (3.7%) 40 (28.4%) 98 (69.5%)  
Males  Controls  67 0.22 0.78 0.020 2 (3.0%) 26 (38.8%) 39 (58.2%) 0.049 
 Patients  51 0.11 0.89  - 11 (21.6%) 40 (78.4%)  
Females  Controls  66 0.17 0.83 0.672 3 (4.5%) 17 (25.8%) 46 (69.7%) 0.692 
 Patients  88 0.19 0.81  3 (3.4%) 28 (31.8%) 57 (64.8%)  
Table 1. Allele frequencies and genotype distribution of the DRD2 TAQIA polymorphism 
 
 n allele frequencies p-value  genotypes p-value  
  L H  LL LH HH  
Total sample Controls  152 0.51 0.49 0.643 39 (25.7%) 77 (50.7%) 36 (23.7%) 0.779 
 Patients  158 0.53 0.47  46 (29.1%) 75 (47.5%) 37 (23.4%)  
Males  Controls  79 0.47 0.53 0.035 17 (21.5%) 40 (50.6%) 22 (27.8%) 0.100 
 Patients  56 0.60 0.40  21 (37.5%) 25 (44.6%) 10 (17.9%)  
Females  Controls  71 0.56 0.44 0.227 21 (29.6%) 37 (52.1%) 13 (18.3%) 0.440 
 Patients  99 0.49 0.51  24 (24.2%) 49 (49.5%) 26 (26.3%)  
Table 2. Allele frequencies and genotype distribution of the COMT polymorphism 
 
 
3.4. Discussion  
The findings of this study provide evidence for an association between the DRD2 TaqI A2 
allele and the low-activity COMT allele on the one hand, OCD on the other, in male OCD 
patients.  
Two previous studies have examined the association between the DRD2 TaqI A system and 
OCD. Nicolini et al. found no association in 67 patients with OCD, but observed a higher 
frequency of the A2 allele in a subgroup of OCD patients with tics (n=12)[19]. Billet et al.[28] 
did not find an association in a sample of 100 OCD patients either. Since the A1 allele of the 
DRD2 TaqI A system has been found to be associated with a variety of addictive, impulsive 
and compulsive disorders, the association of the A2 allele with our OCD-sample was 
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unexpected[29]. In addition, we presumed a higher frequency of the A1 allele, as it has been 
suggested that the A1 allele is associated with a mutation that decreases the D2 receptor 
expression. This latter suggestion has been recently confirmed by Pohjalainen et al.[30], but 
was contradicted by Laruelle et al.[31] At the moment, it is still unclear whether or not the Al 
allele is associated with lower D2 expression[17]. Since other reports of associations between 
the A2 allele and similar neuropsychiatric disorders are scarce, the association of the A2 allele 
in our sample is difficult to interpret. The A2 allele has previously been related to hyperactive 
and impulsive symptoms in attention deficit hyperactivity disorder (ADHD) in a sample of 
166 children and to compulsive smoking habits in 793 subjects[32, 33]. Interestingly, the 
ADHD sample comprised 81% males, and the association with compulsive smoking was only 
significant for males. This suggests that the A2A2 genotype of the DRD2 TaqI A system, 
regardless of the diagnosis, is associated with a broad spectrum of impulsive/compulsive 
symptoms in a gender specific manner. On the other hand, without further evidence of its 
functional significance, and in the absence of other studies reporting similar associations, our 
finding of the association of the A2A2 genotype and OCD in male patients warrants 
replication in other samples, as well as family-based designs.  
The COMT locus has been reported to be associated with OCD in several previous studies. 
Karayiourgou et al.[13, 15] found evidence for an association between the low-activity 
COMT allele and OCD in male OCD patients, in a case-control study and a family-based 
study, whereas Alsobrook et al.[34] found evidence pointing to an association between the 
low-activity COMT allele and OCD in female OCD patients. Niehaus et al.[35] reported a 
preponderance of COMT high/low heterozygotes in an Afrikaner population of 54 OCD 
patients, but did not observe gender differences. Schindler et al.[36] did not find an 
association between any particular allele and OCD, but found a tendency for an association 
with homozygosity at the COMT locus. Ohara et al.[16] did not find any association in a 
small sample of 24 Japanese patients and neither did Erdal et al.[14] in a sample of 59 
Turkish patients., A recent meta-analysis of the COMT gene in 144 OCD patients and 337 
controls showed insufficient evidence to support an association[37].  
On the other hand, since a higher prevalence of the low-activity COMT allele in OCD patients 
has been established in different independent samples, the finding of an association between 
COMT and OCD remains interesting. Especially because the results are compatible with the 
assumption that increased dopamine levels are associated with obsessive-compulsive 
symptoms. It is possible that subjects with a low-activity COMT genotype have a longer 
lasting and more effective dopamine release, which makes them more vulnerable to the 
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development of obsessive-compulsive symptoms. On the other hand, this is hard to reconcile 
with the observation that the association is gender specific. In this regard, it is remarkable that 
our results are strikingly similar to both reports by Karayiourgou et al.[13, 15], providing 
further evidence to the previously reported gender-selective association between COMT 
polymorphism and male patients. It is important to emphasize that in our control sample 
neither the COMT genotype distribution ( 2 = 4.6, df=2, p=0.1), nor the allele frequency ( 2 
= 4.6, df=2, p=0.1) differed significantly between males and females. The significance of a 
gender specific association may not be easily explained. Karayiourgou et al.[13, 15] proposed 
that females have evolved mechanisms to compensate for their lower levels of COMT activity 
and are therefore less vulnerable to developing OCD in association with a low-activity COMT 
genotype. On the other hand, as has been noted by Schindler et al.[36], the specific 
association in males may be a sampling phenomenon, since males typically demonstrate an 
earlier onset of OCD than females. In our sample, males (15.7 ± 8.0 years) had a significantly 
earlier age of onset than females (19.0 ± 8.3 years) and age of onset was significantly 
correlated with gender (r=0.18, p=0.033). Since only 10 out of 54 male patients had an onset 
of disease later than 21 years, the bias of age of onset cannot be excluded.  
To eliminate the possible confounding factor of age of onset, we dichotomized the patient 
population into an early-onset-group (≤ 15 years (n=60)), and a late-onset-group (≥ 21 years 
(n=45)). We found that the low-activity COMT genotype was significantly associated with 
the early-onset-group (36.7%), relative to late-onset-group (22.7%) ( 2 = 6.83, df=2, 
p=0.033), though allele frequencies did not significantly differ ( 2 = 0.13, df=1, p =0.71; data 
not shown). Fifty-five percent of the early-onset-group was female, which suggests that age of 
onset might be an independent factor in the association with the low-activity COMT genotype. 
Therefore, it is conceivable that both male gender and early age of onset represent different 
subgroups in OCD, which are independently related to the COMT gene.  
To summarize, this study suggests that DRD2 and COMT genes may be etiologically relevant 
in OCD, in a gender specific manner, and that early-onset-patients represent a genetically 
different subgroup. Further analysis of these phenotypic subtypes in larger samples is 
warranted to confirm our data.  
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ABSTRACT 
 
Objective: Serotonin reuptake inhibitors (SRIs) are the most effective pharmacological 
treatment currently available for patients with obsessive-compulsive disorder (OCD). Still, 
up to 40 to 60% of OCD patients do not respond to SRI treatment. The purpose of the 
present study was to determine whether polymorphisms of the serotonin transporter (5-
HTT), 5-HT1B and 5-HT2A receptor genes affect the efficacy of SRI treatment in OCD.  
Method: 91 outpatients with primary OCD according to DSM-IV criteria consented to the 
study and were randomly assigned in a 12-week, double-blind trial to receive dosages 
titrated upward to 300 mg/day of venlafaxine, or 60 mg/day of paroxetine. Primary 
efficacy was assessed by the change from baseline on the Yale-Brown obsessive-
compulsive scale (Y-BOCS), and response was defined as a ≥ 25 % reduction on the Y-
BOCS. Responders and non-responders were stratified according to 5-HTT, 5-HT1B and 
5-HT2A genotypes, and differentiated in paroxetine or venlafaxine treated groups.  
Results: In the whole group, 64% of responders carried the S/L genotype of the 5-
HTTLPR polymorphism (χ2 = 7.17, df=2, p=0.028). In the paroxetine treated patients, the 
majority of responders carried the G/G genotype of the 5-HT2A polymorphism (χ2 = 8.66, 
df=2, p=0.013), whereas in the venlafaxine treated patients, the majority of responders 
carried the S/L genotype of the 5-HTTLPR polymorphism (χ2 = 9.71, df=2, p=0.008).  
Conclusions: The results of this study suggest that response in paroxetine treated OCD 
patients is associated with the G/G genotype of the 5-HT2A polymorphism and in 
venlafaxine treated OCD patients with the S/L genotype of the 5-HTTLPR polymorphism.  
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4.1. Introduction  
Obsessive-compulsive disorder (OCD) is a common and severe, but still under-recognized 
psychiatric disorder. Although serotonin reuptake inhibitors (SRIs) are the most effective 
pharmacological treatment for OCD, up to 40 to 60% of OCD patients do not respond to 
treatment[1]. Even after a switch to a second SRI-treatment, 30 to 40% of OCD patients fail 
to respond[2]. Clearly, an improved understanding of determinants of response to SRIs would 
be immensely valuable to develop more efficient treatment strategies in OCD.  
Among a number of factors that have been proposed to determine treatment outcome with 
SRIs, genetic differences between patients may play a significant role[3]. In major depression, 
for example, it has been reported repeatedly that the short form (S-allele) of the 44-bp 
deletion/insertion functional polymorphism within the promoter region of the serotonin 
transporter gene (5-HTTLPR) is associated with impaired efficacy of SRIs[4]. In OCD, three 
studies have investigated the role of the 5-HTTLPR and treatment response. Mc Dougle et al 
found an association of the L-allele with poorer response to SRIs, whereas Billet et al and Di 
Bella et al failed to find a relation between response and 5-HTT genotypes[5-7]. Other 
receptors that might be involved in the therapeutic efficacy of SRIs are the terminal 5-HT1B 
autoreceptor and the postsynaptic 5-HT2A receptor. As of yet, neither polymorphisms of 5-
HT1B or 5-HT2A receptor genes have been investigated with regard to treatment response of 
SRIs in OCD.  
In this study we tested the hypothesis that variations of the 5-HTT (L-allele of the 5-
HTTLPR), 5-HT1B and 5-HT2A gene expressions are linked to treatment response with SRIs 
in OCD. We report the results of 91 patients who participated in 12-week, double-blind trial 
with paroxetine and venlafaxine and were assessed for the 44 bp insertion/deletion 5-
HTTLPR, the 5-HT1B (5-HT1Dβ) G861C, and the 5-HT2A 1438G/A polymorphism. 
 
 
4.2. Material and methods  
 
4.2.1. Study sample  
Ninety-one outpatients gave written informed consent for participation in this study that had 
been approved by the University of Utrecht Medical Ethical Review committee (Utrecht, The 
Netherlands). All patients were diagnosed with OCD according to DSM-IV criteria and the 
M.I.N.I., a clinical and structured interview, was used to confirm the diagnosis[8]. Severity of 
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obsessive-compulsive symptoms was rated with the Y-BOCS, depressive symptoms with the 
HAM-D, and anxiety with the HAM-A[9-11]. Only patients with a score of at least 18 on the 
Y-BOCS, or at least 12, if only obsessions or only compulsions were present, were included. 
Patients with a major depressive disorder or patients with a total score of 15 or more on the 
17-item Hamilton Depression Rating Scale (HAM-D) on admission were excluded. 
Information on family history of OCD and other psychiatric disorders was obtained by direct 
interviews with the patients and the presence of vocal and/or motor tics was assessed during 
the clinical interview.  
 
 Non Responders 
(n=32) 
Responders  
(n=56) 
Gender (Male/female) 14/18 20/36 
Age on admission 31.7 ± 12.0 34.1 ± 11.3 
Positive family history 11 19 
Mean age of onset  14.7 ± 9.3 17.2 ± 7.4 
 ≤15 years age of onset 12 33 
 > 20 years age of onset 20 23 
Y-BOCS baseline  26.8 ± 5.8 25.2 ± 5.2 
Y-BOCS endpoint 24.8 ± 5.7 13.2 ± 5.4 
Y-BOCS mean % decrease  6.8 ± 11.0 48.6 ± 18.0 
HAM-D 5.6 ± 10.7 7.8 ± 10.8 
HAM-A 7.4 ± 6.7 9.8 ± 7.5 
Paroxetine (n=40) 9 31 
Venlafaxine (n=44) 20 24 
Table 1. Demographic and clinical characteristics of the patients sample 
 
4.2.2. Study design 
Patients were randomly assigned to receive either paroxetine or venlafaxine XR for twelve 
weeks in a single-center, double blind controlled, and parallel-group study design. Paroxetine 
treatment was initiated at a dose of 15 mg/day, and gradually increased to 60 mg/day using a 
fixed dosing schedule. Venlafaxine treatment was initiated at a dose of 75 mg/day and 
gradually increased to 300 mg/day. Psychotropic drugs or psychotherapy were not allowed. 
Obsessive-compulsive symptoms were measured with the Y-BOCS, and response to treatment 
was prospectively defined as a ≥ 25% decrease in Y-BOCS score. Three out of ninety-one 
patients dropped out during the study because of lack of motivation or side effects. A detailed 
description of the study has been published earlier[12, 13].  
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4.2.3. Genotyping  
Blood samples were collected from each subject and frozen at – 80°. DNA was extracted from 
10 ml samples of peripheral blood according to standard procedures. The total number of 
subjects genotyped for the genes in this study was 88. In seven cases, the genotyping of the 5-
HT1B polymorphism failed, and in one case the genotyping of the 5-HTT polymorphism. All 
subjects were genotyped at the University of Ghent (Belgium) based on a coded identification 
number. The 5-HTT, 5-HT1B and 5-HT2A genotyping was performed following a standardized 
protocol.  
 
4.2.3.1. 5-HTT  
For the detection of the 44 bp insertion/deletion 5-HTTLPR polymorphism, the 
oligonucleotide primers 5'-6FAM-GGCGTTGCCGCTCTGAATGC–3’ and 5'–
AGGGACTGAGCTGGACAACCAC-3’ were used to amplify a 484/528 bp fragment 
comprising the 5-HTT-linked polymorphic region. The PCR reaction was performed 
according following conditions: 94°C for 1 min, 60 °C for 1min, 72°C for 1min40sec per 
cycle, for a total of 35 cycles. The PCR products were analysed by capillary electrophoresis 
on an Applied Biosystems 3100 Genetic Analyser. 
 
4.2.3.2. 5-HT1B 
For detection of the 5-HT1B or (5-HT1Dβ) G861C polymorphism, the oligonucleotide primers 
5' - GAAACAGACGCCCAACAGGAC - 3' and 5' -CCAGAAACCGCGAAAGAAGAT - 3' 
were used to amplify a 548 bp region comprising the G861C polymorphism site. The PCR 
reaction was performed under the following conditions: 90°C for 1 min, 55 °C for 2 min, 
72°C for 3 min per cycle, for a total of 32 cycles. Digestion of 10µl of PCR product was 
accomplished by incubation for 4 hours with 10 units of Hinc II restriction enzyme at 37°C. 
Digestion with Hinc II yields either two fragments (452 bp and 96 bp) for the G-allele or three 
fragments (310 bp, 142 bp and 96 bp) for the C-allele. The fragments resulting from the 
digestion were resolved on a 1.5% agarose gel and visualized by ethidium bromide staining. 
62  
 4.2.3.3. 5-HT2A 
For the detection of the 5-HT2A 1438G/A polymorphism within the promoter region of the 5-
HT2A receptor gene, the oligonucleotide primers 5'-6FAM-AAGCTGCAAGGTAGCAAC 
AGC–3’ and 5'-NED-AACCAACTTATTTCCTACCAC-3’ were used to amplify a 468 bp 
region comprising the 5HT2A 1438G/A polymorphism site. The PCR reaction was performed 
under the following conditions: 95°C for 1 min, 47 °C for 1min, 72°C for 1min20sec per 
cycle, for a total of 40 cycles. Digestion of 10µl of PCR product was accomplished by 
overnight incubation with 10 units of Msp I restriction enzyme at 37°C. After incubation with 
Msp I, the 1438A allele remains intact while the 1438G allele is cut into a 223 bp piece 
(6FAM-labelled) and a 243 bp piece (NED-labelled). The fragments resulting from the 
digestion were analysed by capillary electrophoresis on an Applied Biosystems 3100 Genetic 
Analyser.  
 
4.2.4. Data analysis 
The following statistical procedure was pursued. Firstly, the genotypic pattern of distribution 
and the allele frequencies of the 5-HTT, 5-HT1D and 5-HT2A polymorphisms were analyzed in 
the whole sample (N=88). Secondly, an analogous analysis was performed in the paroxetine 
treated patients (N=40), and in the venlafaxine treated patients (n=44) separately. Medication 
use and dose was uncertain in four patients and they were excluded from the treatment groups. 
The association between the distribution of the genotypes and allele frequencies with the 
responders and non-responders were assessed by cross-tabulation and χ2 analyses. One way 
analysis of variance (ANOVAs) were calculated to determine whether significant differences 
were present between genotypes in mean decrease of Y-BOCS scores. Considering a partial 
Bonferroni’s correction, the p value for statistical significance would be 0.020 with an alpha 
of 0.05, 6 tests, 2 degrees of freedom, and a correlation correction factor of 0.5. The data are 
presented as mean ± SD, and performed at 5% level of significance. All statistical analyses 
were conducted with the SPSS statistical package version 11.5. 
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4.3. Results 
Demographic variables and outcome measures are presented in table 1. The patient sample 
was slightly skewed towards the female population (63%). Fifty-six out of 88 patients (63%) 
were rated as responders, 31 out of 40 patients in the paroxetine group and 24 out of 44 
patients in the venlafaxine group. Four patients were not assigned to a particular treatment 
group (see methods section). There were no statistically significant differences between 
responders and non responders as regards gender, age, age of onset, family history, and 
baseline Y-BOCS, HAM-A, or HAM-D measures.  
Table 2. Allele frequencies and genotype distribution of the 5-HT1B-, 5-HT2A receptor, and 5-HT 
transporter polymorphisms in the whole sample (n=88) 
 n allele frequencies p-value genotypes p-value 
5-HT1B  C G  CC CG GG  
Non responders  30 0.23 0.74 0.273 1 (3.3%) 12 (40.0%) 17 (56.7%) 0.510 
Responders 51 0.31 0.69  4 (7.8%) 24 (47.1%) 23 (45.1%)  
         
5-HT2A  A G  AA AG GG  
Non responders  32 0.48 0.52 0.418 5 (15.6%) 21 (65.6%) 6 (18.8%) 0.144 
Responders 56 0.42 0.58  11 (19.6%) 25 (44.6%) 20 (35.7%)  
         
5-HTT  L S  LL L/S SS  
Non responders 32 0.55 0.45 0.551 12 (37.5%) 11 (34.4%) 9 (28.1%) 0.028 
Responders  55 0.50 0.50  10 (18.2%) 35 (63.6%) 10 (18.2%)  
 
In the whole sample (Table 2), a difference in genotype distribution of the 5-HTTLPR polymorphism 
was found between responders and non–responders. Sixty-four percent of the responders carried the 
S/L genotype of the 5-HTTLPR polymorphism compared to 18 % carrying the S/S genotype and 18 % 
carrying the L/L genotype. The difference just failed to be statistically significant after Bonferroni’s 
correction (χ2 = 7.17, df=2, p=0.028). When the mean Y-BOCS decrease was stratified by 5-HTTLPR 
genotype, a superior response was observed in the S/L  
genotype (37% decrease) versus the S/S genotype (28%) and the L/L genotype (29%), but the 
ANOVA failed to reach statistical significance (F 2,84= 1.2, p = 0.30). Allele frequencies of the 5-
HTTLPR polymorphism between responders and non–responders were not statistically significant 
different (χ2 = 0.05, df=1, p=0.71), and there were no significant differences between responders and 
non–responders in allele or genotype frequencies for the 5-HT1B and 5-HT2A polymorphisms in the 
whole sample. 
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  n allele frequencies p-value genotypes p-value 
5-HT1B  C G  CC CG GG  
Non responders  8 0.19 0.81 0.513 0 (0.0%) 3 (37.5%) 5 (62.50%) 0.625 
 28 0.27 0.73  3 (10.7%) 9 (32.1%) 16 (57.1%)  
5-HT2A  A G  AA AG GG  
Non responders  9 0.67 0.33 0.004 3 (33.3%) 5 (66.7%) 0 (0.0%) 0.013 
Responders 31 0.29 0.71  4 (12.9%) 10 (32.3%) 17 (54.8%)  
5-HTT  L S  LL L/S SS  
Non responders 9 0.56 0.44 0.772 3 (33.3%) 4 (44.4%) 2 (22.2%) 0.787 
Responders  30 0.52 0.48  7 (23.3%) 17 (56.7%) 6 (20.0%)  
Table 3. Allele frequencies and genotype distribution of the 5-HT1B-, 5-HT2A receptor, and 5-HT 
transporter polymorphisms in the paroxetine treated group (n=40). 
 
In the paroxetine treated patients (Table 3), the majority of responders carried the G/G genotype of the 
5-HT2A polymorphism (χ2 = 8.66, df=2, p=0.013). The association of a superior response with the G/G 
genotype was confirmed in the ANOVA when the mean Y-BOCS decrease was broken down 
according to the genotypes. Patients carrying the G/G genotype of the 5-HT2A polymorphism had a 
mean decrease of 51% on the Y-BOCS compared to 34% with the A/A genotype and 29% with the 
A/G genotype (F ,2.39= 4.95, p = 0.012). In general, responders carried predominantly the G-allele 
compared to non-responders (χ2 = 8.43, df=1, p=0.004) (OR 4.89 95% CI 1.59-15.02).  
 
 n allele frequencies p-value genotypes p-value 
5-HT1B  C G  CC CG GG  
Non responders  19 0.24 0.76 0.214 1 (5.3%) 7 (36.8%) 11 (57.9%) 0.221 
Responders 22 0.36 0.64  1 (4.5%) 14 (63.6%) 7 (31.8%)  
5-HT2A  A G  AA AG GG  
Non responders  20 0.40 0.60 0.087 2 (10.0%) 12 (60.0%) 6 (30.0%) 0.165 
Responders 24 0.58 0.42  7 (29.2%) 14 (58.3%) 3 (12.5%)  
5-HTT  L S  LL L/S SS  
Non responders 21 0.55 0.45 0.393 8 (40.0%) 6 (30.0%) 6 (30.0%) 0.008 
Responders  23 0.46 0.54  2 (8.3%) 18 (75.0%) 4 (16.7%)  
Table 4. Allele frequencies and genotype distribution of the 5-HT1B-, 5-HT2A receptor, and 5-HT 
transporter polymorphisms in the venlafaxine treated group (n=44).  
 
In the venlafaxine treated patients (Table 4), the majority of responders carried the S/L genotype of the 
5-HTTTLPR polymorphism (χ2 = 9.72, df=2, p=0.008). The ANOVA showed a difference in favor of 
the S/L genotype with a mean Y-BOCS decrease of 38 % compared to 24% in patients with the S/S 
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genotype and 15% in patients with the LL genotype, who had the worst outcome, but failed to be 
statistically significant after correction (F2, 43= 3.27, p = 0.04).  
Since the number of responder appeared to be correlated to the G/G genotype of the 5-HT2A 
polymorphism in the paroxetine treated patients, and to the S/L genotype of the 5-HTTLPR 
polymorphism in the venlafaxine treated patients, we analyzed thereupon responder rates in patients 
who had either one of the genotypes in the full sample. More than 81 % of the responders (45 out of 
55) carried either the G/G genotype of the 5-HT2A polymorphism or the S/L genotype of the 5-
HTTLPR polymorphism (χ2 = 8.1, df=1, p=0.004). All of patients (n=9) who carried both the G/G 
genotype of the 5-HT2A polymorphism and to the S/L genotype of the 5-HTTLPR polymorphism were 
responders. There was a statically significant difference between the mean Y-BOCS decrease of 49% 
in these patients compared to the remainder of patients (χ2 = 16.0, df=8, p=0.01). 
 
 
4.4. Discussion 
The main finding of this study is that OCD patients with the S/L genotype of the 5-HTTLPR 
polymorphism have a more favorable response following paroxetine and venlafaxine treatment. This 
effect was more pronounced for the venlafaxine treated patients, while response to paroxetine mainly 
was associated with the G/G genotype of the 5-HT2A polymorphism. The small group of patients (n=9) 
who both carried the S/L genotype of the 5-HTTLPR polymorphism and the G/G genotype of the 5-
HT2A polymorphism responded all to treatment.  
Three previous studies have investigated the role of the 5-HTTLPR and treatment response in OCD. 
Mc Dougle et al found in a sample of 33 patients a trend for an association of the L-allele with poorer 
response to SRIs (clomipramine, fluvoxamine, fluoxetine, sertraline and paroxetine)[5]. Billet et al 
examined retrospectively 72 patients after a 10-week trial with SRIs and found no association, and Di 
Bella et al failed to find a relation between response and 5-HTTLPR genotypes in a sample of 99 
patients following a standardized fluvoxamine treatment of 12 weeks[6, 7]. Our results are in line with 
the findings of Mc Dougle and do not suggest a better outcome with SRIs in carriers of the L/L 
genotype of the 5-HTTLPR, which is in flat contradiction with the majority of reports in mood 
disorders in which the presence of the L variant of the 5-HTTLPR has been related to a more favorable 
and faster response with SRIs[4]. On the other hand, in Asian populations, an association in the 
opposite direction was found with a better response for carriers of the S allele. In sum, our findings are 
in line with those of Mc Dougle et al but disagree with Billet et al and Di Bella et al and the majority 
of the studies in major depressive disorder (MDD) patients[6, 7]. It is possible that this discrepancy is 
due to pathophysiologic and neurobiological dissimilarities between OCD and MDD. It has been 
suggested that SRIs exert their beneficial effects with their typical delay of 6 to 8 weeks in OCD by 
down regulating 5-HT1B receptors in the orbito-frontal whereas in MDD a faster response is observed 
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probably due 5-HT auto-receptor desensitization in other brain areas such as the hippocampus and 
hypothalamus[14]. This supposition is appealing, but still needs to be confirmed.  
It is unclear exactly why the S/L genotype of the 5-HTTLPR would confer a favorable potential for 
a better response with SRIs in OCD. One might comprehend the connection of the L/L genotype with 
a superior response since it has been related to higher 5-HTT densities and hence an increased efficacy 
of SRIs. On the other hand, the L/L genotype of the 5-HTTLPR has been associated to placebo 
response as well, thereby questioning the rationale of the direct link between the 5-HTTLPR and 
therapeutic efficacy of SSRIs[4]. Furthermore, it still needs to be clarified whether or not the 5-
HTTLPR determines the number of 5-HTT in the human brain in vivo[15, 16]. Some studies have 
reported that L/L homozygous individuals had higher 5-HTT availability compared to S/L or S/S 
homozygous individuals in the raphe area, but others failed to find an association in the diencephalon, 
brainstam, and the thalamus[17-20]. Equally, post mortem studies did not detect any significant 
influence of 5-HTTLPR on 5-HTT density in the hippocampus or frontal cortex[21, 22]. Thus it would 
be premature to relate superior response of the S/L genotype carriers in OCD to lower 5-HTT 
densities since it still remains to be elucidated whether the 5-HTTLPR genotypes relate to 5–HTT 
function and hence different psychopharmacological mechanisms of SRIs. 
Except for Tot et al, who failed to find an association between the -1438G/A and T102C 
polymorphism of the 5-HT2A receptor in 52 patients following a 12 week trial with fluvoxamine, 
fluoxetine or sertraline, no further study has investigated the 5-HT2A receptor gene with regard to 
treatment response in OCD[23]. This is surprising since sensitization of the 5-HT2A receptor has been 
hypothesized to be a common mechanism of SRIs treatment[24, 25]. For example, Meyer et al have 
reported increased densities of the 5-HT2A receptor after paroxetine treatment. Massou et al, on the 
other hand, have found the opposite[26, 27]. A recent study in 54 Japanese patients with MDD failed 
to find a major role for the -1438G/A promoter polymorphism in therapeutic response to fluvoxamine, 
and similarly, Choi et al found no significant association between the 5-HT2A G-1438A genotype and 
treatment response[28, 29]. Thus far, it is unclear whether the -1438A/G promoter polymorphism 
results in functional effects[30]. Spurlock et al found no effect of the -1438A/G promoter 
polymorphism on basal or cAMP- and protein kinase C induced gene transcription in HeLa cells, and 
found no difference in lymphocyte 5-HT2A receptor mRNA expression between 1438A/A and G/G 
homozygotes[31]. Turecki et al, in a small postmortem study, reported higher prefrontal 5-HT2A 
receptor binding in subjects with the -1438A allele, but Bray et al failed to find a significant effect on 
5-HT2A receptor mRNA expression in post mortem brain tissue[32, 33].  
It is puzzling why response in paroxetine treated patients is related to the 5-HT2A receptor genotype 
and response in venlafaxine treated patients to the 5-HTTLPR. It has been reported that chronic 
treatment with paroxetine produces a significant desensitization in post synaptic 5-HT2A receptor 
function[26, 34]. On the other, the 5-HTT and 5-HT2A receptor are intimately linked, for example the 
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constitutive lack of the 5-HTT alters the density of the 5-HT2A receptor in a brain region specific 
manner, with an increase in the hypothalamus and decrease in the striatum[25, 35]. Thus, the apparent 
specific association of paroxetine and venlafaxine might be a spurious finding as result of a type two 
error due to the small sample sizes. Further investigation in larger samples might clarify this issue.  
In summary, this study suggests a better outcome in OCD after treatment with SRIs for patients 
carrying the S/L genotype of the 5-HTTLPR polymorphism. This effect was more pronounced for the 
venlafaxine treated patients, whereas response to paroxetine was associated with the G/G genotype of 
the 5-HT2A polymorphism. The small group of patients who both carried the S/L genotype of the 5-
HTTLPR polymorphism and the G/G genotype of the 5-HT2A polymorphism responded all to 
treatment. Our results indicate that 5-HT2A and 5-HTTLPR polymorphisms may be markers for 
treatment outcome in OCD. 
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1. Objective and strategy 
 
The objective of this study is to find genes of the plant Artemisia annua L. that are involved in 
the production of the antimalarial artemisinin. These genes do not necessarily have to code for 
the enzymes involved in the biosynthetic pathway, but can also be involved in the 
mechanisms influencing the amount of produced artemisinin. (e.g. genes involved in the 
formation of trichomes) 
 
Three strategies were followed to accomplish this challenge: a proteome analysis, a 
quantitative cDNA amplified fragment length polymorphism analysis (cDNA AFLP) and the 
construction of three full length Expressed Sequence Tag (EST) cDNA libraries. The results 
of these 3 strategies can be compared and complemented with each other. 
 
• We investigated the proteome of A. annua by identifying proteins that were 
differentially expressed between trichomes and whole leaf tissue. We also identified 
differentially expressed proteins between lower leafs and upper leafs of A. annua 
plants. In a third proteome analysis, we explored the proteins present in a one-minute 
chloroform extract of A. annua plants.  
Trichomes are considered to be the artemisinin factories of A. annua (chapter 2.2.2.). 
The upper leafs produce more artemisinin than the lower leafs (chapter 2.2.2.). The 
proteins that are upregulated in these samples might thus be involved in artemisinin 
production. With the chloroform extraction, the content of the capitate glands of the 
trichomes is extracted (chapter 4). These glands possibly contain proteins involved in 
artemisinin production. 
Proteins of interest were identified by tandem mass spectrometry. The fragmentation 
spectra were searched against the public Mass Spectrometry protein sequence 
DataBase (MSDB) and against the three EST libraries. Because only a few genes and 
proteins of A. annua have been characterized (chapter 2.3.1.2.), identification of 
proteins by searching public protein databases, is only possible due to homology with 
known proteins of other plants. 
For a general introduction on proteomics: see chapter 2.3.3. For the results of this 
study: see chapter 3 
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• Quantitative cDNA AFLP analysis is a genome-wide messenger RNA (mRNA) 
expression analysis. The level of mRNA expression was compared between samples 
of A. annua leafs, taken at different time points during a 72h time period after 
exposure to jasmonic acid (JA). Transcripts that are overexpressed by JA are possibly 
involved in the production of artemisinin, because the production of artemisinin is 
stimulated by JA (chapter 2.3.1.3). 
This analysis was conducted by the department of Plant Systems Biology of the 
“Vlaams interuniversitair instituut voor Biotechnologie” (VIB), Ghent University, 
Technologiepark 927, B-9052 Ghent, Belgium. 
For a general introduction on quantitative cDNA AFLP see chapter 2.3.2. For the 
results of this study: see chapter 3. 
 
• Construction of three EST cDNA libraries: one from poly-A RNA from flower buds of 
A. annua and one from poly-A RNA from the trichomes on the flower buds. A 
subtracted cDNA library using poly-A RNA from the flower buds and the trichomes 
was also constructed. ESTs that are present in the trichomes and not in the flower buds 
are possibly involved in the production of artemisinin because trichomes are 
considered to be the artemisinin factories of A. annua (chapter 2.2.2.).  
Searching for homologies between the EST sequences and sequences of known plant 
genes revealed a cDNA clone encoding a cytochrome P450 enzyme. This enzyme 
(CYP71AV1) was expressed and characterized in Saccharomyces cerevisiae and was 
found to catalyze three steps: oxidation of amorpha-4,11-diene to artemisinic alcohol, 
artemisinic alcohol to artemisinic aldehyde and artemisinic aldehyde to artemisinic 
acid (see chapter 2.3.1.1.).  
Proteins pointed out by the proteomics analysis and sequences obtained from the 
cDNA AFLP analysis were compared with the cDNA EST libraries. The most 
promising genes are of course those that are found to be differential in all three 
techniques. 
The cDNA library construction was performed by the Plant Biotechnology Institute, 
110 Gymnasium Place, Saskatoon, Canada and is described in a paper by Teoh et 
al.[1]. 
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To investigate which plant hormones trigger A. annua to produce more artemisinin, to check 
the correlation between the artemisinin content of A. annua leafs and the number of trichomes 
on these leafs, and to be able to check transformed plants or shoot cultures for enhanced 
artemisinin production, a quantitation method for artemisinin and its bioprecursors had to be 
developed. This resulted in the finding that a chloroform extract resulting from a one-minute 
immersion of fresh plant material in chloroform, could be used for high performance liquid 
chromatography – electrospray ionization – quadrupole time-of-flight tandem mass 
spectrometry analysis (HPLC – ESI – QTOF  MS/MS) without additional sample preparation 
steps. This research is described in chapter 4. 
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2. Introduction 
 
2.1. Malaria 
 
2.1.1. Malaria: a devastating disease with a long history 
Malaria has been described since the dawn of history. The symptoms of shivering, fever, and 
spleen enlargement are described in Egyptian (Ebers papyrus, 1570 B.C.) and Chinese (Nei 
Ching, The Canon of Medicine, 1700 B.C.) writings. The Corpus Hippocraticum (fifth 
century B.C.) describes the recurrence of fevers at regular intervals and the connection of the 
disease to marches. In the seventeenth century, Italians believed that breathing bad air (mal 
airia) arising from swamps was responsible for the disease, and in the first half of the 
nineteenth century the term malaria entered the English literature. The French physician 
Charles Louis Alphonse Laveran first identified the parasite under the microscope in 1880. In 
1899, the mystery of malaria transmission was solved independently, by Ronald Ross, an 
English physician working in India and Giovanni Battista Grassi, an Italian physician, who 
proved that the disease was spread by the bite of female mosquitoes of the genus 
Anopheles[2]. 
 
Today, malaria is one of the world’s most devastating parasitic diseases. There are at least 300 
million acute cases of malaria each year globally, resulting in more than a million deaths. 
Most of these cases occur in Africa, but large areas of Asia, Central, and South America have 
high incidences of the disease[3, 4]. 
  
2.1.2. Pathogenesis 
Human malaria is caused by four major Plasmodium species: falciparum, vivax, malariae and 
ovale. P. falciparum causes the large majority of the clinical cases and mortalities[5]. 
 
The development and spreading of the parasite, goes in 4 phases[6, 7]: 
1. A female anopheline mosquito carrying malaria (vector) takes a blood meal and 
injects haploid sporozoites (the infectious form of the parasite released from the 
anopheline mosquitoes salivary glands) into the blood stream. 
 
79 
 
 
Figure 1: Malaria cycle (Centers of Disease Control - http://www.dpd.cdc.gov/dpdx) 
 
2. The sporozoites enter the hepatocytes (liver cells) and initiate the exo-erythrocytic 
cycle in the liver. In the hepatocytes, the sporozoites undergo multiple asexual fissions, 
or schizogony, to produce thousands of infective, haploid merozoites.  
3. The infected hepatocytes rupture and the merozoites invade erythrocytes where they 
continue the asexual cycle (erythrocytic cycle). Periodically, the infected red blood 
cells lyse (causing fever, anemia, coma and possible death), and the merozoites invade 
fresh erythrocytes. In some infected erythrocytes, merozoites develop into 
gametocytes.  
4. When these gametocytes are ingested by mosquitoes, they initiate sexual development 
in the midgut. The female gametocytes exit the mosquito stomach after fertilization 
and form oocysts which produce sporozoites. These sporozoites migrate to the 
mosquito salivary glands and are passed into humans when the mosquito feeds.  
 
 
80 
The parasite is relatively protected from the immune system, because for most of his human 
life cycle, it resides in the liver and blood cells. Infected erythrocytes are however destroyed 
in the spleen. To avoid passage through the spleen, P. falciparum produces adhesive proteins 
on the surface of the infected erythrocytes, causing them to stick to the walls of small blood 
vessels. The parasite constantly switches between a broad repertoire of surface protein 
variants, making it difficult for the immune system to effectively develop antibodies against 
these proteins. High endothelial venules can get obstructed by infected erythrocytes, causing 
placental and cerebral malaria. In patients with cerebral malaria, infected erythrocytes can 
eventually breach the blood-brain barrier, which leads to coma and death[6, 7]. 
 
Other mammals as well as bird and reptiles also suffer from malaria. Only P. malariae can 
cause malaria both in humans and other higher primates. Other animal forms of malaria do 
not infect humans. P. falciparum, vivax and ovale are exclusive to humans. 
 
2.1.3. Treatment and resistance to treatment 
For many years, chloroquine was the antimalarial drug of choice in most parts of the world[8]. 
Multi-drug resistance of the Plasmodium strains to the cheapest and most widely used 
antimalarials such as chloroquine, mefloquine and sulfadoxine-pyrimethamine is one of the 
biggest challenges in the fight against malaria[3]. In parts of Southeast Asia, P. falciparum is 
now resistant to almost all antimalarial drugs and strains of chloroquine resistant P. vivax 
have emerged. In Africa, chloroquine resistance is widespread and resistance to 
sulphadoxine/pyrimethamine is being detected with increasing frequency[3, 9-12]. 
 
A. annua L. (sweet wormwood), a herb of the Asteraceae family has been used for centuries 
for the treatment of fever and malaria. Artemisinin is the main component responsible for this 
therapeutic effect[13]. Based on artemisinin, several semisynthetic derivatives such as 
artemether, arteether and artesunate have been produced (see chapter 2.2.4.). The World 
Health Organization (WHO) recommends that all countries experiencing resistance to 
conventional monotherapies should use combination therapies, preferably those containing 
artemisinin derivatives (ACTs or artemisinin based combination therapies)[14, 15]. 
 
In addition to the therapeutic benefits, artemisinin based combination therapies also bring a 
significant reduction in parasite transmission to Anopheles mosquitoes, particularly parasites 
carrying drug resistance genes. Artemisinin and it derivatives act against immature 
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gametocytes during the period of sequestration (7 days) that precedes emergence into the 
peripheral circulation as mature infectious gametocytes. In this way, they minimize the 
carriage of gametocytes, the parasite’s transmissible stage[16-18]. 
 
Clinically relevant artemisinin resistance has not been demonstrated, but it is likely to occur 
since artemisinin resistance has been obtained in laboratory models[19]. 
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 2.2. Artemisia annua L. 
 
2.2.1. Botany 
A. annua L. is one of nearly 400 species of the Asteraceae. The herb is native to Asia but now 
grows in nature in many other countries in Europe and North America. The generic name A. 
refers to Artemis, goddess of maternity, because in antiquity plants of this genus were used to 
control birth and regulate women’s menstrual disorders. The specific name annua reflects the 
annual cycle of the plant.  
   
Figure 1: A. annua before (left) and during flowering (right). The left picture is provided by the 
Wisconsin State Herbarium. The right picture is provided by www.delawarewildflowers.org. 
 
A. annua, commonly known in the United states by the names sweet or annual wormwood, 
can reach 2.0 meters in height. The plant is usually single-stemmed with alternate branches 
and alternate, deeply insected leaves ranging from 2.5 to 5.0 cm in length. Tiny yellow 
nodding flowers (capitula) only 2 to 3 mm across are displayed in lose panicles containing 
numerous bisexual florets in the centre and pistillate marginal florets. The plant is naturally 
cross pollinated by insect and wind action, which is unusual in the Asteraceae, and senesces 
after seeds are mature[20]. 
 
Non-glandular T-shaped trichomes and 10-celled biseriate glandular trichomes occur on 
leaves, stems and inflorescences[20]. The morphology and origin of the glandular trichomes 
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has been described for leaves[21] and capitula[22] using light and/or scanning electron 
microscopy. These glandular trichomes are known to contain essential oils. The essential oil 
(common to the Asteraceae) of A. annua contains at least 40 volatile compounds and several 
non-volatile sesquiterpenes, one of which is artemisinin[23].  
 
As artemisinin cannot be synthesized chemically in an economically feasible way, A. annua is 
the only practical source of this valuable drug[24]. Unfortunately, A. annua contains only 
very small amounts of artemisinin ranging from 0.001 to 1.54% of dry weight[25]. Several 
research programs have been set up trying to increase the concentration of artemisinin in A. 
annua by optimizing the growing and harvesting conditions, by selecting high yielding 
cultivars or by creating transgenic plants[24, 26]. 
 
 
2.2.2. Glandular trichomes as sites of artemisinin accumulation 
 
 
Figure 2: Artemisnin and structural analogs 
 
There is strong circumstantial evidence that artemisinin is produced in the glandular 
trichomes. Duke et al.[27] reported that a 5 seconds dip in chloroform extracted 97% of the 
artemisinin and 100% of artemisitene from A. annua. Light microscopy and transmission 
electron microscopy revealed that the 5 seconds dip results in collapse of the subcuticular 
cavity of the glands on the leaf surface without visible damage to the leaf epidermal cells. An 
A. annua biotype without glands contained neither artemisinin nor artemisitene. These results 
indicate that artemisinin and artemisitene present in foliar tissue are localized entirely in the 
subcuticular space of glands of A. annua. The fact that artemisinin is not detected in parts of 
the plant that do not bear glandular trichomes also support this hypothesis. 
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Bertea et al.[28] incubated intact gland cell clusters in the presence of [3H]farnesyl 
diphosphate and products of conversion were analyzed by radio-GC (gas chromatography 
coupled to detection of radioactive isotopes) and GC-MS (GC coupled to mass spectrometry). 
Radio-GC analysis showed a large radio-labeled amorpha-4,11-diene peak, indicating that the 
trichome cells contain amorpha-4,11-diene synthase and are able to perform the first step in 
the biosynthetic pathway of artemisinin[29]. 
 
Figure 3: Cyclization of farnesyl diphosphate by 4,11-amorphadienesynthase 
 
 
We used the quantitation method described in chapter 4 to test if the amount of artemisinin in 
a leaf correlates with the amount of glandular trichomes on the leaf. Samples were taken from 
the lower, middle and upper leaves of an approximately 2 months old, non-flowering A. 
annua plant. Microscopic inspection showed that the lower leafs had a much lower amount of 
trichomes per mm2 than the middle leafs. The upper leafs had the highest amount of trichomes 
per mm2. Table 1 shows the quantities of artemisinin and some its structural analogs 
(arteannuin B, artemisitene and artemisinic acid), present in the lower, middle and upper leafs 
of the same A. annua plant. As the amount of analyte present per gram of fresh leaf, is lowest 
in the lower leafs and highest in the upper leafs, there is a clear correlation with the number of 
trichomes present on these leafs. These results are completely in accordance with the results 
recently published by Zhang et al.[30], who report the difference between lower-, middle and 
upper leafs and who report a correlation coefficient of 0.987 between artemisinin content and 
the density of capitate glands on the surface of different plant tissues. 
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 Mean quantities  (µg/g) arteannuin B artemisitene artemisinin artemisinic acid
Lower leafs < LLOQ < LLOQ 16.58±2.01 38.00±0.47 
Middle leafs  84.83±15.86 < LLOQ 41.26±3.47 41.75±2.45 
Upper leafs 222.10±16.39 < LLOQ 94.50±0.96 52.63±1.75 
Table 1:  Quantities of artemisinin and some its structural analogs, present in the lower, 
middle and upper leafs of the same A. annua plant. The results are shown as the 
amount (µg) of analyte present in one gram of fresh plant material. Amounts below 
the lower limit of quantitation (LLOQ) are not shown. 
 
 
2.2.3. A. annua, the only economically feasible source of artemisinin 
The first published laboratory procedure for isolation of artemisinin is by Klayman et al. 
(1984)[31]. Air dried leaves were extracted with petroleum ether (bp=30 to 60°C), which was 
subsequently removed under vacuum. The residue was dissolved in chloroform to which 
acetonitrile was added to precipitate inert plant components such as sugar and waxes. The 
concentrated extract was then  chromatographed on a column of silica gel. Fractions with a 
high artemisinin content crystallized readily, recrystallization was achieved with cyclohexane 
or 50% ethanol. 
 
The most abundant sesquiterpene in A. annua is artemisinic acid, which can be 8-10 times 
more abundant than artemisinin[25, 32, 33] Vonwiller et al.[34] developed an efficient 
method to extract both artemisinic acid and artemisinin from the same material. Artemisinic 
acid can then be semi-synthetically converted to artemisinin, which greatly increases the yield 
of artemisinin[35]. 
 
None of the reported methods for the total stereospecific synthesis of artemisinin are 
economically feasible due to the complexity (up to 13 synthesis steps) and very low yields[32, 
36-40]. Recently Ro et al.[41] engineered a Saccharomyces cerevisiae yeast to produce high 
titers of artemisinic acid, opening perspectives of cost-effective semi-synthesis of artemisinin. 
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2.2.4. Artemisinin and derivatives 
Artemisinin, an endoperoxide-containing sesquiterpene lactone is a secondary metabolite 
produced by A. annua. Secondary metabolites give the plant a selective advantage. A huge 
variety of sesquiterpene lactones are known to act as insect deterrents, vertebrate poisons, etc. 
Endoperoxide-containing sesquiterpene lactones are however very uncommon. 
 
2.2.4.1. First-generation antimalarial endoperoxides 
Artemisinin is surprisingly stable for an endoperoxide. It can be heated up to 50°C above its 
melting point (200°C) for 2.5 min.[42]. In vitro tests showed that artemisinin and various 
derivatives are effective against P. falciparum at nanomolar concentrations and showed little 
cross-resistance with other antimalarial agents[43]. Adverse effects are rare in patients treated 
with artemisinin derivatives[19, 44]. In a prospective study of over 3500 patients in Thailand, 
there was no evidence for serious adverse events[45]. Artemisinin derivatives also appear to 
be safe for pregnant women[46, 47]. In several animal studies however, artemisinin 
derivatives have clearly shown to cause neurotoxicity at high doses[19]. 
 
Artemisinin has been formulated as tablets, capsules and suppositories. Since artemisinin is 
poorly soluble in water or oil and has a low bioavailability, water-soluble derivatives 
(artesunate and artelinate) and oil-soluble derivatives (artemether and arteether) have been 
synthesized, making it possible to prepare parenteral formulations[43]. All of these drugs 
have comparable efficacy. The choice of derivative should be based upon availability, cost 
and quality of the preparation. They are all well-tolerated in both adults and children, with no 
evidence to date of serious clinical toxicity[44].  
 
Several hundred other semisynthetic artemisinin derivatives have been prepared and tested: 
ethers or esters of dihydroartemisinin,  9-alkyl derivatives, 10-deoxoartemisinins, lactol ring-
contracted derivatives etc. (reviewed by Meshnick et al. [43]).  
 
2.2.4.2. Second-generation antimalarial endoperoxides 
The complex ring structure of artemisinin is not necessary for antimalarial activity; only the 
endoperoxide bridge is required. A group of simplified analogs, the trioxanes, also has 
antimalarial activity both in vitro and in vivo. These analogs all have the same endoperoxide-
containing six-membered ring found in artemisinin but are much simpler to synthesize and 
some of them have increased stability[43]. 
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A somewhat different group of endoperoxides are based on yingzhaosu, another endoperoxide 
containing compound discovered by Chinese scientists. One of these compounds, arteflene, is 
quite effective in infected patients with P. falciparum. Unfortunately, it was not superior to 
the semisynthetic artemisinin derivatives and it is not being developed further[43].  
 
2.2.4.3. Mechanism of action 
Artemisinin and its derivatives are toxic to malaria parasites at nanomolar concentrations, 
whereas micromolar concentrations are required for toxicity to mammalian cells. One reason 
for this selectivity is the enhanced uptake and concentration of the drug by P. falciparum 
infected erythrocytes to more than a 100 fold higher than uninfected erythrocytes. Artemisinin 
derivatives are hydrophobic and partition into biological membranes of the parasite[43].  
 
The endoperoxide bridge of artemisinin and its derivatives is necessary for antimalarial 
activity. Since peroxides are a known source of reactive oxygen species such as hydroxyl 
radicals and superoxide, this observation suggested that free radicals might be involved in the 
mechanism of action.  
 
There is no consensus on how the endoperoxide bridge breaks open to form free radicals and 
how these free radicals kill the parasites. Accumulating biological and chemical evidence 
supports the hypothesis that the formation of free radicals is heme-mediated. As the malaria 
parasite is rich in heme-iron, derived from the proteolysis of host cell hemoglobin, this could 
explain why artemisinin is selectively toxic to parasites. Once formed, the artemisinin derived 
free radicals appear to damage specific intracellular targets, possibly via alkylation. Possible 
mechanisms and targets are reviewed by Meshnick[19]. 
 
Research by Eckstein-Ludweg et al.[48] shows compelling evidence that artemisinins act by 
inhibiting the “sarco/endoplasmic reticulum Ca2+ - ATPase” orthologue (PfATPase6) of 
Plasmodium falciparum after activation in a non-heme-mediated Fe2+ dependent manner. The 
findings of Jambou et al.[49] support PfATPase6 as the target for artemisinins: A S769N 
PfATPase6 mutation in P. falciparum isolates from French Guiana was associated with raised 
(> 30 nmol/L) artemether IC50s (p>0.0001, Mann-Withney). 
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 2.3. Gene discovery: Which genes influence artemisinin 
production? 
 
2.3.1. Genes and biosynthesis of artemisinin 
 
2.3.1.1. Biosynthesis of artemisinin 
 
Figure 4: Simplified terpenoid biosynthetic scheme[50-52], supplemented with the 
artemisinin pathway proposed by Bouwmeester and co-workers (big blue arrows)[29, 53]. 
The oxidations catalyzed by CYP71AV1, the P450 enzyme characterized by Teoh et al.[1] is 
also indicated. 
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Artemisinin, an endoperoxide-containing sesquiterpene lactone is a secondary metabolite 
belonging to the category of the terpenes. Terpenes are the largest class of plant secondary 
metabolites with several thousands of representatives. These compounds are crucial to normal 
plant function and a major source for scientifically and commercially important chemicals, 
including pharmaceuticals (paclitaxel, artemisinin), flavors (menthol), food colors 
(carotenoids) and pesticides. Despite their great diversity, terpenoids are derived from two 
common precursors, isopentenyl diphosphate (IPP) and its isomer (catalyzed by isopentenyl 
diphosphate isomerase), dimethylallyl diphosphate (DMAPP). It has been established that 
higher plants have two independent biosynthetic pathways leading to the formation of IPP: the 
cytosolic mevalonate (MVA) pathway and the plastid-localized MVA-independent pathway. 
(Plastids are organelles responsible for photosynthesis, for storage of products like starch and 
for the synthesis of many classes of molecules such as fatty acids and terpenes) Terpene 
synthases, like farnesyl diphosphate synthase (FPPS), then convert IPP and DMAPP to linear 
prenyl diphosphates of different chain length, who are used to form the different terpenes[50, 
52]. Matsushita et al.[54] were the first to clone the A. annua FPPS gene. They determined 
that FPPS from A. annua was very similar to that of other plants. FPPS catalyzes sequential 
condensation reactions:  
 
Figure 5: DMAPP reacts with 3 IPP to form geranyl diphosphate 
Figure 6: Geranyl diphosphate reacts with 3 IPP to form farnesyl diphosphate (FPP) 
 
The post-FPP biosynthetic pathway of artemisinin is not yet completely elucidated. It is clear 
that the first dedicated step in the biosynthesis of artemisinin is the cyclization of FPP to 
amopha-4,11-diene by amorpha-4,11-diene synthase (ADS)[29]. ADS has now been cloned 
by several groups[55-57]. The amino acid sequence varies from 31 to 52% identity with other 
known angiosperm sesquiterpene cyclases[55, 56]. In vitro enzymatic assays demonstrated 
production of amorpha-4,11-diene from FPP[55].  
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Several authors have demonstrated that artemisinic acid and/or dihydroartemisinic acid are 
further intermediates in the formation of artemisinin[32, 58, 59]. With GC-MS, radio-GC, 
nuclear magnetic resonance (NMR) and enzyme assays, Bertea et al.[53] identified the 
intermediates and enzymes involved in the conversion of amorpha-4,11-diene to 
dihydroartemisinic acid. They propose the hydroxylation of amorpha-4,11-diene to 
artemisinic alcohol, followed by oxidation to artemisinic aldehyde, and reduction of the C11–
C13 double bond to dihydroartemisinic aldehyde and oxidation to dihydroartemisinic acid 
(see figure 2). Teoh et al.[1] constructed a cDNA library with trichome-specific ESTs and 
found a cDNA clone encoding a cytochrome P450 (CYP71AV1). The enzyme was expressed 
and characterized in a Saccharomyces cerevisiae yeast and was found to catalyze three steps: 
oxidation of amorpha-4,11-diene to artemisinic alcohol, artemisinic alcohol to artemisinic 
aldehyde and artemisinic aldehyde to artemisinic acid. 
 
The subsequent route to artemisinin and the genes involved herein, have not been 
characterized. Some papers propose complete biosynthetic pathways, others focus on an 
individual biosynthetic step. They are reviewed by Van Geldre et al.[60] and Liu et al.[51]. 
The following papers describe the in vivo evidence for possible biosynthetic steps or pathways: 
• Akhila et al.[61] studied the A. annua biosynthesis starting from isotopically labeled 
mevalonate. They suggested the following pathway: farnesyl pyrophosphate (FPP) → 
germacrene skeleton → dihydrocostunolide → cadinanolide → arteannuin B → 
artemisinin.  
• Sangwan et al.[62] reported the transformation of artemisinic acid to arteannuin B and 
artemisinin both in vivo and in a cell free system.  
• Nair et al.[63] reported the conversion of arteannuin B to artemisinin by cell-free leaf 
homogenate of A. annua. 
• Wallaart et al.[58, 64] isolated dihydroartemisinic acid (DHAA) and DHAA 
hydroperoxide in A. annua. DHAA can be chemically converted to artemisinin by 
photooxidation[35, 65] under conditions that may also be present in the living plant. 
DHAA hydroperoxide, which can very easily oxidize to artemisinin, is known as an 
intermediate of the photochemical oxidation of DHAA leading to artemisinin. The 
presence of DHAA and DHAA hydroperoxide in the plant and the conditions under 
which DHAA can be converted into DHAA hydroperoxide, provide evidence for a 
nonenzymatic, photochemical conversion of DHAA into artemisinin in A. annua. 
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2.3.1.2. Genes influencing biosynthesis in A. annua 
The genes related to artemisinin biosynthesis are reviewed by Weathers et al.[50] and are 
summarized in Table 3.  
 
Enzyme Function GenBank Ref. 
DXP synthase See figure 2 AF182286 [66, 67] 
DXP reductoisomerase See figure 2 AF182287 [66, 67] 
HMG-CoA reductase See figure 2 AF142473 [66, 67] 
FPP synthase See figure 2 AF112881 [26, 66, 67] 
Sesquiterpene cyclases (SQC): See figure 2   
 Epicedrol synthase See figure 2 AJ001539 [68, 69] 
 ADS See figure 2 AJ251751 [55, 69] 
 Β-caryophyllene synthase See figure 2 AF472361 [70] 
 Β-farnesene synthase See figure 2 AY835398 [71] 
 Putative SQC casc125 See figure 2 AJ271792 [72] 
 Putative SQC casc34 See figure 2 AJ271793 [72] 
 Putative SQC ses See figure 2 AAD3983
2
[73] 
Squalene synthase See figure 2 AY445506 [74] 
Squalene synthase fragment See figure 2 AF182286 [67] 
CYP71AV1 See figure 2 DQ31567
1
[1] 
Peroxidase 1  Stimulates: artemisinic acid→artemisinin AY208699 [75] 
B-pinene synthase GPP to B-pinene (monoterpene) AF276072 [76] 
(3R)-linalool synthase GPP to (3R)-linalool (terpene alcohol) AF154125 [77] 
Isopentenyl transferase Biosynthesis cytokinin phytohormones M91610 [78] 
Table 2: Genes related to artemisinin biosynthesis in A. annua L.[50] 
 
2.3.1.3. Phytohormones 
Artemisinin production can be influenced by exposure to exogenous phytohormones. The 
cytokinin 2-isopentenyladenine increased artemisinin levels in transformed roots of A. 
annua[79]. Artemisinin content is also increased in gibberellic acid (a phytohormone that can 
induce flowering) treated shoot cultures, and flowering plants[50]. 
 
One of the responses of plants to cytokinins is stimulation of shoot growth. Artemisinin is 
produced in shoots, so it was reasonable to measure the effect of cytokinins on artemisinin 
production in A. annua. Geng et al.[78] transferred the ipt gene (considered to be an enzyme 
at a rate-limiting step in the cytokinin biosynthesis[80]) into A. annua. Results showed that 
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two cytokinins were elevated 2- to 3-fold and artemisinin increased 30-70% compared with 
the control. 
 
We used the quantitation method described in chapter 3 to investigate which of the 4 plant 
hormones tested (see below) triggered the highest artemisinin production in A. annua plants 
of only a few weeks old. Table 2 shows the quantities of artemisinin and some its structural 
analogs (arteannuin B, artemisitene and artemisinic acid), present in plants treated with 6-
benzyl aminopurine (BAP), jasmonic acid (JA), gibberellic acid (GA3) and thidiazuron (TDZ). 
For each plant hormone, 3 ways of administration (local administration, administration by 
spraying the whole plant and administration by pouring the hormone into the soil of the plant) 
and a control were analyzed. The only plant hormone that clearly triggered artemisinin 
production was jasmonic acid. 
 
Quantities  (µg/g) arteannuin B Artemisitene artemisinin Artemisinic 
BAP local administration 63 < LLOQ 16 81 
BAP total administration 24 < LLOQ < LLOQ 116 
BAP soil administration  40 < LLOQ 15 260 
BAP control 88 < LLOQ 33 891 
JA local administration 180 < LLOQ 85 711 
JA total administration 111 < LLOQ 31 179 
JA soil administration  228 < LLOQ 107 758 
JA control 45 < LLOQ < LLOQ 624 
GA3 local administration 28 < LLOQ 12 38 
GA3 total administration 12 < LLOQ < LLOQ 58 
GA3 soil administration  48 < LLOQ 15 639 
GA3 control 49 < LLOQ 14 645 
TDZ local administration 18 < LLOQ < LLOQ 77 
TDZ total administration 53 < LLOQ 16 59 
TDZ soil administration  77 < LLOQ 27 59 
TDZ control 30 < LLOQ < LLOQ 712 
Table 3:  Quantities of artemisinin and some of its structural analogs, present in A. annua 
plants after treatment with BAP, JA, GA3 and TDZ. The results are shown as 
the amount (µg) of analyte present in one gram of fresh plant material. 
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2.3.1.4. Flowering 
Several reports state that the highest artemisinin content occurs just before or at full 
flowering[50]. Wang et al.[81] investigated whether such a linkage does indeed exist by 
altering the plant flowering time through transgenics. They transferred the flowering promoter 
factor (fpf1) from A. thaliana into A. annua via A. tumefaciens. No differences in artemisinin 
content were detected between the flowering transgenic plants and the non-flowering non-
transgenic plants. This work suggest that flowering is not a necessary factor for increased 
artemisinin content in A. annua. 
 
2.3.1.5. Metabolic engineering of artemisinin 
Although several highly efficient transformation and regeneration systems for A. annua have 
been published (reviewed be Liu et al.[51]), only a few interesting transgenic A. annua 
varieties have been created. 
 
Chen et al.[26] used an Agrobacterium tumefaciens-mediated transformation system to 
transfer cDNA FPPS (placed under a CaMV 35S promoter) into A. annua. The artemisinin 
content in the transgenic plants regenerated from the shoot lines was about 2-3 times higher 
than in the control. Han et al.[82] did a similar experiment. 
 
Martin et al.[83] introduced the ADS gene into E. coli together with the mevalonate 
isoprenoid pathway from Saccharomyces cerevisiae, to construct a bacterial system producing 
the artemisinin precursor amorpha-4,11-diene from acetyl-CoA. The transformed E. coli was 
reported to produce around 100 mg of amorpha-4,11-diene per liter of culture in 12h. These E. 
coli strains can serve as platform hosts for the production of essentially any terpenoid for 
which the genes are known. 
 
Lindahl et al.[84] transformed Saccharomyces cerevisiae with the gene encoding for ADS. 
The plasmid and genome-transformed yeasts produced 600 and 100 µg/l of the artemisinin 
precursor amorpha-4,11-diene, respectively, during a 16-days' batch cultivation. 
 
Ro et al.[41] report the engineering of Saccharomyces cerevisiae to produce high titers (up to 
100 mg/l) of artemisinic acid using an engineered mevalonate pathway, ADS, and a novel 
cytochrome P450 monooxygenase (CYP71AV1)[1]. The synthesized artemisinic acid is 
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transported out and retained on the outside of the engineered yeast, meaning that a simple and 
inexpensive purification process can be used to obtain the desired product. 
 
 
2.3.2. Gene discovery: cDNA AFLP 
Quantitative cDNA AFLP analysis is a genome-wide mRNA expression analysis. It is an 
invaluable tool for identifying and analyzing genes involved in, or controlling various 
biological responses. Although DNA microarrays provide a convenient tool for genome-wide 
expression analysis, their use is limited to organisms for which the complete genome 
sequence or a large cDNA collection is available. For other organisms, including most plant 
species, DNA fragment analysis based methods, such as cDNA-AFLP, provide a more 
appropriate tool for genome-wide expression analysis. A review by Breyne and Zabeau[85] 
discusses and compares the merits and drawbacks of the major technologies for genome-wide 
expression analysis. 
 
 Figure 7: Outline of the cDNA-AFLP 
procedure[85] 
• Messenger RNA (mRNA) is converted into double 
stranded cDNA using a biotinylated oligo-dT primer.  
• After digestion with a first restriction enzyme, the 3′ 
termini of the cDNA are recovered by binding to 
streptavidin beads.  
• Following digestion with a second enzyme, 
restriction fragments are released that serve as 
polymerase chain reaction (PCR) templates.  
• After ligation of site-specific adapters, primers that 
match the adapter sequences and that carry selective 
nucleotides at their 3′ end are used to amplify subsets 
of the transcript fragments. Following amplification, 
fragments of between 50 and 500 bases are separated 
and displayed on polyacrylamide gels. 
After • the fragments have been excised out of the gel,  
they can be sequenced and compared with genomic 
 
databases or EST libraries. The sequence tags can 
also be used to de novo sequence the complete 
mRNA. 
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The principal advantage of cDNA-AFLP compared to microarrays are that it allows genome-
or studying biological processes in plant species, cDNA AFLP presents another advantage 
.3.3. Gene discovery: Proteomics 
ic rization of the entire protein complement of a 
ew transcriptomics technologies permit simultaneous examination of thousands of 
.3.3.1. Technology 
mics technologies: gel-based and gel-free proteomics. Two 
wide expression analysis in any species without prior sequence knowledge and that both 
known and unknown genes can be analyzed. Gel analysis of the amplified fragments (see 
figure 5) reveals which fragments are differentially expressed. These fragments can be 
sequenced and the resulting sequence tags can be compared to existing genomic databases and 
EST libraries. If no mach is found, the sequence tag can be used to clone the unknown gene. 
 
F
compared to microarrays. The high levels of redundancy in plant genomes will likely remain a 
major obstacle for detailed microarray studies. Fragment-based technologies, such as cDNA-
AFLP, overcome the problem caused by redundancy, and will continue to be the best 
alternative for performing in-depth analyses of gene expression in plant species. 
 
 
2
Proteom s stands for the large-scale characte
cell, tissue or organism. Proteomics studies can be subdivided in three main areas of interest: 
An expression proteomics analysis is designed to identify all the protein species present in a 
proteome of a cell, tissue or organism at a certain time. In structural proteomics the focus is 
on identifying the molecular structure. Functional proteomics describes the changes in protein 
abundance and modifications during a biological process. 
 
N
transcripts. However, the complex regulatory routes, from post-translational modifications to 
protein turnover cannot be studied at the cDNA level. The proteome approach is necessary to 
help answer questions of functional analysis. Several reviews address the application of 
proteomics to plant biology[86-98]. Some of them address the technical aspects of plant 
proteomics[99-101]. 
 
2
There are 2 main proteo
dimensional gel electrophoresis (2-DE) for the separation and visualization of proteins has 
been the standard proteomics technique during the past decade. Over the last years, several 
gel-free proteomics techniques have been developed to either complement 2-DE or to entirely 
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replace the gel based techniques. A review by Baggerman et al.[102] summarizes the most 
important gel-free and gel-based proteomics techniques and compares their advantages and 
drawbacks. A review by Tilleman et al.[103] discusses the basics of the current proteomics 
technologies. This chapter offers background information on the gel based technique used in 
chapter 3. 
 
2-DE is a high resolution method for separating proteins in two dimensions; according to their 
soelectric focusing: After the proteins have been extracted from the tissue sample, they are 
-D gel visualization: In order to visualize the separated proteins, 2-D gels can be stained 
igestion and identification: After protein spots have been picked from the gels, they are 
isoelectric point (pI) in the first dimension and according to their size (molecular weight) in 
the second dimension. Exploring differences in spot intensity or tracking protein spots that 
appear or disappear on gels derived from experimental and control conditions is the main goal 
of functional proteomics.   
 
I
brought into a small gel strip that contains an immobilized pH gradient (IPG). When an 
electric field is applied over this IPG strip, the proteins migrate along the pH gradient in the 
strip until they reach their pI. The strip is then applied onto a polyacrylamide gel and the 
proteins are subsequently size-separated by electrophoresis.  
 
2
with a variety of different stains: Coomassie Blue (cheap, low sensitivity: 10ng per protein 
spot), silver stains (sensitive, 0.5-1ng per protein spot, very small linear range, time-
consuming protocol, less compatible with mass spectrometry identification), radio-active 
labeling (very sensitive, hazardous and expensive) and the current state of the art fluorescent 
dyes like Sypro Ruby (sensitive, 1ng per protein spot, large linear range, extremely easy to 
use, compatible with MS identification)[104, 105]. To study post-translational modifications, 
dyes can be used that selectively stain glycoproteins (e.g. Pro-Q Emerald 488 glycoprotein 
stain), phosphoproteins and other modified proteins[105]. The ‘difference gel electrophoresis’ 
(DIGE) approach is gaining interest. This approach allows to fluorescently label (with cyanine 
dyes Cy2, Cy3, Cy4) as many as 3 different complex protein populations prior to mixing them 
together and running them on the same 2-D gel[105]. 
 
D
digested using a sequence-specific protease (e.g. trypsin). The resulting mixture of peptides is 
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desalted and analyzed by MS (producing a “peptide mass fingerprint”) or MS/MS (producing 
an amino acid sequence tag). MS and MS/MS analysis can complement each other.  
 
A “peptide mass fingerprint” (PMF) is the result of the cleavage of a particular protein using a 
sequence-specific protease such as trypsin. The masses from the resulting peptides can be 
measured by MS. Usually matrix assisted laser desorption ionization (MALDI) is used to 
produce a “peptide mass fingerprint”. MALDI produces singly charged peptide ions leading 
to a less convoluted spectrogram than the multiple charged peptides ions resulting from 
electrospray ionization (ESI). 
 
In MS/MS analysis, the double charged peptide ions are one-by-one selected out of a mixture 
of peptides ions by the first mass analyzer of the mass spectrometer. Between the first and the 
second analyzer, the peptides are fragmented by collision with an inert gas. During these 
energetic collisions of the selected peptide and the collision gas, bonds are broken along the 
peptide backbone. In most applications, this leads to so called b and y ions, which indicate 
fragmentation at the amide bond with charge retention on the N or C terminus, respectively. 
The masses of the resulting fragments are analyzed by the second mass analyzer. Each peptide 
fragment in the spectrum differs from its neighbor by only one amino acid. It is therefore 
possible to determine the amino acid sequence by considering the mass difference between 
the neighboring peaks in a series. Usually ESI is used to produce an peptide MS/MS spectrum. 
In contrast with MALDI, ESI produces peptides ions with 2 (or more) positive charges, 
making it possible to deduct the amino acid sequence both from the b and the y ions. 
 
The experimental PMF or MS/MS spectrum is matched against a calculated PMF or MS/MS 
spectrum for all peptides in the database (e.g. Mascot, SEQUEST). A score is calculated for 
each match: the higher the score, the lower the probability that the match is a random event. 
To be significant, the score has to be higher than a calculated threshold. The threshold is the 
score resulting from the probability for which the expectancy for a match is 5%. 
 
2.3.3.2. Combining proteomic en genetic studies in plants 
Reviews by Thiellement et al.[87, 106] focuses on the various, mainly genetic, applications of 
the proteomics in plants: characterization of individuals or lines, estimation of genetic 
variability within and between populations, establishment of genetic distances that can be 
used in phylogenetic studies, characterization of mutants and localization of the genes 
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encoding the revealed proteins. Main focus is on proteomics as an invaluable tool for 
deciphering the function and role of the genes that are or will be sequenced: Innumerable 
proteins have been described, whose relative abundance depends on the conditions (light, heat, 
cold, hormones, pathogens, etc.), and on the developmental stages or organs. As far as these 
proteins can be sequenced (e.g. partially by MS/MS), the corresponding genes that may exist 
in the databases as ESTs may thus be further characterized and tentative functions may be 
proposed. 
 
Transcriptomics tools, such as cDNA microarrays and cDNA AFLP are usefully 
complemented by proteomics, since the amounts of a protein and of its mRNA are not 
necessarily correlated. When studying conditions with high and low artemisinin production, a 
protein that is overexpressed under one of the conditions, does not necessarily imply an 
overexpression of its mRNA. While a proteomics study will point to this protein, a 
transcriptomics study might not point to the corresponding mRNA. 
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ABSTRACT. 
 
The proteome of A. annua was investigated to discover candidate genes related to 
artemisinin production. We identified proteins that were differentially expressed between 
trichomes and whole leaf tissue. We also identified differentially expressed proteins 
between lower and upper leafs of A. annua plants. In a third proteome analysis, we 
explored the proteins present in a one-minute chloroform extract of A. annua plants. 
Trichomes are considered to be the artemisinin factories of A. annua. Upper leafs produce 
more artemisinin than the lower leafs. Proteins that are upregulated in these samples might 
thus be involved in artemisinin production. With the chloroform extraction, the content of 
the capitate glands of the trichomes is extracted. These glands possibly contain proteins 
involved in artemisinin production. 
 
Proteins of interest were identified by tandem mass spectrometry. The fragmentation 
spectra were searched against the public Mass Spectrometry protein sequence DataBase 
(MSDB) and against three Expressed Sequence Tag (EST) libraries (one from flower buds 
of A. annua, one from the trichomes on the flower buds and one being the result of a 
cDNA subtraction of both plant tissues). To narrow down the results to the most valid 
gene candidates, the proteome data was compared with a cDNA Amplified Fragment 
Length Polymorphism (AFLP) analysis that investigated samples of A. annua leafs, taken 
at different points during a 72h time period after exposure to jasmonic acid (JA). We were 
able to compile a list of EST candidates, which could be useful for further investigation.  
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3.1. Introduction 
 
Multi-drug resistance of the Plasmodium strains to the cheapest and most widely used 
antimalarials such as chloroquine, mefloquine and sulfadoxine-pyrimethamine is one of the 
biggest challenges in the fight against malaria[1]. The World Health Organization (WHO) 
recommends that all countries experiencing resistance to conventional monotherapies should 
use combination therapies, preferably those containing artemisinin derivatives (ACTs – 
artemisinin-based combination therapies)[2, 3]. As artemisinin cannot be synthesized 
chemically in an economically feasible way, A. annua is the only practical source of this 
valuable drug[4]. Unfortunately, A. annua contains only very small amounts of artemisinin 
ranging from 0.001 to 1.54% of dry weight[5]. Several research programs have been set up 
trying to increase the artemisinin content in A. annua by optimizing the growing and 
harvesting conditions, by selecting high yielding cultivars or by creation of transgenic 
plants[4, 6]. 
 
The objective of this study is to discover genes of the plant A. annua L. that are involved in 
the production of artemisinin. These genes do not necessarily have to code for the enzymes 
involved in the biosynthetic pathway, but can also be involved in the mechanisms influencing 
the amount of produced artemisinin (e.g. genes involved in the formation of trichomes). Three 
strategies were followed to accomplish this challenge: a proteome analysis, quantitative 
cDNA Amplified Fragment Length Polymorphism analysis (cDNA AFLP) and the 
construction of three full length Expressed Sequence Tag (EST) cDNA libraries. The results 
of these 3 strategies can be compared and complemented with each other. 
 
• We investigated the proteome of A. annua by identifying proteins that were 
differentially expressed between trichomes and whole leaf tissue. We also identified 
differentially expressed proteins between lower leafs and upper leafs of A. annua plants. In a 
third proteome analysis, we explored the proteins present in a one-minute chloroform extract 
of A. annua plants. Trichomes are considered to be the artemisinin factories of A. annua[7]. 
The upper leafs produce more artemisinin than the lower leafs[8]. The proteins that are 
upregulated in these samples might thus be involved in artemisinin production. With the 
chloroform extraction, the content of the capitate glands of the trichomes is extracted[9]. 
These glands possibly contain proteins involved in artemisinin production. 
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Proteins of interest were identified by tandem mass spectrometry. The fragmentation spectra 
were searched against the public MSDB database and against the three EST libraries. Because 
only a few genes and proteins of A. annua have been characterized, identification of proteins 
by searching public protein databases, is only possible due to homology with known proteins 
of other plants. 
 
• Quantitative cDNA AFLP analysis is a genome-wide messenger RNA (mRNA) 
expression analysis. The level of mRNA expression was compared between samples of A. 
annua leafs, taken at different time points during a 72h time period after exposure to JA. 
Transcripts that are overexpressed by JA are possibly involved in the production of 
artemisinin, because the production of artemisinin is stimulated by JA. 
This analysis was conducted by the department of Plant Systems Biology of the “Vlaams 
interuniversitair instituut voor Biotechnologie” (VIB), Ghent University. 
 
• Construction of three full length EST cDNA libraries: one from poly-A RNA from 
flower buds of A. annua and one from poly-A RNA from the trichomes on the flower buds. A 
subtracted cDNA library using poly-A RNA from the flower buds and the trichomes was also 
constructed. ESTs that are present in the trichomes and not in the flower buds are possibly 
involved in the production of artemisinin because trichomes are considered to be the 
artemisinin factories of A. annua[7]. Searching for homologies between the EST sequences 
and sequences of known plant genes revealed a cDNA clone encoding a cytochrome P450 
enzyme. This enzyme (CYP71AV1) was expressed and characterized in Saccharomyces 
cerevisiae and was found to catalyze three steps: oxidation of amorpha-4,11-diene to 
artemisinic alcohol, artemisinic alcohol to artemisinic aldehyde and artemisinic aldehyde to 
artemisinic acid. The cDNA library construction was performed by the Plant Biotechnology 
Institute, Saskatoon, Canada and is described in a paper by Teoh et al.[1]. 
 
This paper focuses on the abovementioned proteome studies. To narrow down the results to 
the most valid gene candidates, we compared the proteome data with the cDNA AFLP 
analysis. Doing so, we were able to compile a list of EST candidates, which could be useful 
for further investigation. 
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3.2. Experimental  
 
3.2.1. Chemicals 
Following chemicals of analytical grade were used in the course of the proteome analysis: 
Acetonitrile MS grade (Biosolve, Valkenswaard, The Netherlands), Ammonium Bicarbonate 
(NH4HCO3) (Sigma-Aldrich, Bornem, Belgium), 3-[(3-Cholamidopropyl)-dimethyl- 
ammonio]-1-propane sulfonate (CHAPS) (MP Biomedicals, Illkirch, France), DL-
Dithiothreitol electrophoresis grade (MP Biomedicals, Illkirch, France), Chloroform (Arcos, 
Geel, Belgium), Formic acid (FA) MS grade (Biosolve, Valkenswaard, The Netherlands), 
Glycerol (MP Biomedicals, Illkirch, France), Hydrochloric acid 37% (HCl) (Sigma-Aldrich, 
Bornem, Belgium), Iodoacetamide (MP Biomedicals, Illkirch, France), Potassium chloride 
(KCl) (Sigma-Aldrich, Bornem, Belgium), Sodium Dodecyl Sulfate (SDS) (MP Biomedicals, 
Illkirch, France), Sucrose (Sigma-Aldrich, Bornem, Belgium), Thiourea (Arcos, Geel, 
Belgium), 2-Amino-2-(hydroxymethyl)-1,3-propandiol (TRIS) (Sigma-Aldrich, Bornem, 
Belgium). Following for synthesis grade chemicals were used: 2-mercaptoethanol, Acetic acid 
and Methanol (Merck, Whitehouse Station, USA). Purified water of 18.2 MΩ/cm was 
obtained from a Milli-Q system from Millipore. 
 
3.2.2. A. annua samples for differential proteome analysis 
Twelve 2-DE gels were compared in two individual statistical analyses. Table 1 gives an 
overview of the analyzed samples and of the groups that were compared in the statistical 
analyses.  
 
To prepare the samples, plants were grown under controlled conditions (21 °C; 12h day/12h 
night regime). Seeds were kindly provided by the National Botanic Garden of Belgium 
(Meise, Belgium). Trichome samples were prepared from one-month-old plants as described 
by Gershenzon et al.[10, 11] and McConkey et al.[12]. Leaf samples were harvested from the 
same plants. 
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 G
el N
um
ber 
Characteristics Number of 
spots on 
gel 
Group
Trichomes  
vs.  
Group 
Upper  
vs.  
Remarks 
0 Trichomes taken from leafs only, after flowering N/A   Sample too small 
1 Trichomes taken from leafs only, before flowering 526 Group 1   
2 Trichomes taken from whole plant, after flowering 573 Group 1   
3 Trichomes taken from whole plant, before flowering 652 Group 1   
4 Trichomes taken from leafs only, before flowering – sample 2 430 Group 1   
5 Trichomes taken from whole plant, before flowering – sample 2 572 Group 1   
6 Trichomes taken from whole plant, after flowering – sample 2 577 Group 1   
7 Upper leafs, after flowering 573 Group 2 Group 1  
8 Upper leafs, during flowering 615 Group 2 Group 1  
9 Upper leafs, before flowering 561 Group 2 Group 1  
10 Lower leafs, after flowering 643 Group 2 Group 2  
11 Lower leafs, during flowering 575 Group 2 Group 2  
12 Lower leafs, before flowering 459 Group 2 Group 2  
Table 1: Overview of the 2-DE gels compared during statistical analysis 
 
3.2.3. A. annua samples for proteome analysis of chloroform extract 
To investigate the proteins present in a one-minute chloroform extract, 3 2-DE gels were 
prepared from chloroform extracts from three individual one-month-old plants. The plants 
were grown under controlled conditions (21 °C; 12h day/12h night regime). For each sample, 
an entire plant was used. 
 
3.2.4. Protein extraction 
The protein content of the 6 trichome samples and the 6 whole leaf samples was extracted as 
described by Bauw and Van Montagu[13]. For each sample, the plant material was grinded to 
powder in liquid nitrogen. Hundred fifty mg of the powder was transferred to an Eppendorf 
cup and homogenized during 1 minute using an Ultra-Turrax T8 homogenizer (Ika-Werke, 
Stanfer, Germany) in protein extraction buffer. The protein extraction buffer consisted of 
0.7M sucrose, 0.5M TRIS, 30mM HCl, 0.1M KCl and 1% 2-mercaptoethanol. Immediately 
before use, a cocktail of phosphatase inhibitors (cocktail 1 and cocktail 2, Sigma-Aldrich, 
Bornem, Belgium), endonuclease (Sigma-Aldrich, Bornem, Belgium) and protease inhibitors 
(Complete Mini tablets, Roche diagnostics, Vilvoorde, Belgium) were added to the protein 
extraction buffer.  
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For the proteome analysis of a one-minute chloroform extract, an entire plant was cut into 
large pieces and transferred into a 250 ml flask. The plant material was shaken for one minute 
in 100 ml of chloroform, after which the chloroform was transferred to another flask. The 
chloroform was evaporated to dryness under a nitrogen flow, while keeping the temperature at 
1 °C. 
After all the chloroform was evaporated, the proteins in the residue were extracted with 10 ml 
ReadyPrep Sequential Extraction reagent 3 (Biorad, Hercules, USA). Before use, 0.7M 
sucrose, a cocktail of phosphatase inhibitors (cocktail 1 and cocktail 2, (Sigma-Aldrich, 
Bornem, Belgium), endonuclease (Sigma-Aldrich, Bornem, Belgium) and protease inhibitors 
(Complete Mini tablets, Roche diagnostics, Vilvoorde, Belgium) were added to the protein 
extraction buffer. The subsequent extraction steps are described by Bauw and Van 
Montagu[13]. 
 
3.2.5. Two-dimensional gel electrophoresis 
2-DE was performed according to Görg A. et al.[14] with minor adjustments. For each sample, 
the complete yield of the protein extraction was dissolved in 360µl of rehydration buffer 
solution containing 7M urea, 2M thiourea, 4% CHAPS, 100mM DTT and 2% Carrier 
Ampholyte solution (Ampholene pH3.5-10, Amersham Biosciences, Uppsala, Sweden). This 
solution was used to rehydrate an immobilized pH gradient strip (IPG) with a linear pH 
gradient from pH 3 to pH 10 (Readystrip, Biorad, Hercules, USA). After the overnight in-gel 
rehydration, the proteins in the strip are focused at their isoelectric point on the Protean 
isoelectric focusing system (Biorad, Hercules, USA) at 18°C, starting at 100V for 6h, 
followed by linear ramping to 250V over 2h, linear ramping to 500V over 2h, linear ramping 
to 1 kV over 2h, linear ramping to 3kV over 2h, rapid ramping to 10 kV in 3.5h and steady 
state at 10 kV for 65 kVh. After the isoelectric focusing, the strips were equilibrated for 2x15 
minutes. During the first 15 minutes, the strips were gently shaken in equilibration buffer 
(50mM TRIS - HCl buffer pH 8.8, 6M urea, 30% v/w glycerol, 2% SDS) with addition of 
1.5% v/w DTT. During the second 15 minutes, the strips are gently shaken in equilibration 
buffer with addition of 4% v/w iodoacetamide. After equilibration, the IPG strips were placed 
on a polyacrylamide gel (10% T, 3.3% C). These gels were subjected to electrophoresis in a 
vertical Protean II Multi Cell electrophoresis system (Biorad, Hercules, USA) at 16mA/gel for 
30 minutes and 32mA/gel for approximately 6 hours at 10°C.  After electrophoresis, the gels 
were fixed for 30 minutes in a 10% methanol – 7% acetic acid solution and stained overnight 
with Sypro Ruby (Biorad, Hercules, USA). 
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3.2.6. Gel scanning and image analysis 
2-DE gels stained with Sypro Ruby were scanned and digitized with the QuantityOne 4.4.1. 
software on a Versadoc Imaging system (Biorad, Hercules, USA). For each gel, exposure time 
was adjusted until 1 spot became oversaturated.  
 
3.2.7. Data analysis and statistical analysis 
The images of the 12 gels (see table 1) were analyzed with PDQuest 2D-analysis Software 
v7.1 (Biorad, Hercules, USA). All gels were matched to each other creating a match set 
standard image containing the match information of all spots on all gels. In order to compare 
protein expression levels across the 12 gels, the intensity of the spots on each gel was 
normalized to the total intensity of all spots in each gel image. The PDQuest software was 
used to perform a Mann-Whitney Signed-Rank test (trichomes group versus leafs group) and 
a Student’s T-test (upper leafs group versus lower leafs group) on the log transformed 
intensity data of the spots. Spots of which the intensities were statistically higher (p < 0.05) in 
the trichomes group or the upper leafs group (see table 1), were selected for further 
identification by mass spectrometry. 
 
For the expression proteomics analysis of a one-minute chloroform extract, no statistical 
analysis was done. Instead, as much different spots as possible were excised from the three 
different gels. In this experiment we tried to identify as much proteins as possible that are 
present in the chloroform extract. 
 
3.2.8. Protein identification by mass spectrometry 
Spots of interest were excised from the 2-DE gels obtained from samples 4 to 6 (see table 1). 
The excised spots were washed twice with 100µl 50% acetonitrile / 25mM NH4HCO3, 
followed by a reduction with 10mM DDT / 25mM NH4HCO3, an alkylation with 100mM 
iodoacetamide / 25mM NH4HCO3, and a final wash step with 100µl 50% acetonitrile / 25mM 
NH4HCO3. After the wash buffer was removed, the gel pieces were dehydrated with 100% 
acetonitrile and rehydrated in 20µl 25mM NH4HCO3 containing 10ng/µl sequence grade 
modified trypsin (Promega, Madison, USA) for 30 minutes on ice. In-gel digestion with 
trypsin was continued over night at 37°C. Peptides were extracted with 100µl 50% 
acetonitrile / 50% H2O for 30 minutes, followed by extraction with 100µl 100% acetonitrile 
and pooled. The extracts were completely dried under vacuum and dissolved in 23µl 0.1% 
TFA. 
 115
3.2.9. Identification by ESI mass spectrometry 
Using column switching, 20µl of the peptide solution was injected on a nano-LC system 
(Dionex, Sunnyvale, USA) coupled to a Q-Tof Ultima mass spectrometer (Waters, Milford, 
USA) fitted with an electrospray ionization source. The sample was loaded and desalted on an 
Atlantis dC18 Trap column (Waters, Milford, USA) at a flow-rate of 10µl/min and eluted on a 
C18 Pepmap100 (75 µm i.d. × 15 cm, 3 µm, Dionex, Sunnyvale, USA) at a flow-rate of 150 
nl/min. The data was acquired with the Masslynx software 4.1. from Waters operating in the 
“automatic function switching” mode.  
 
Fragmentation spectra, resulting from tandem mass spectrometry on the detected peptides, 
were searched against the MSDB database using the Mascot search engine 
(http://www.matrixscience.com). Using the ProteinLynx software from Waters, the spectra 
were also searched against the 3 EST libraries described by Teoh et al.[1]. 
 
3.2.10. Comparison of the proteomics and the AFLP data 
We compared the differential proteins resulting from the proteome analysis with the 
differentially expressed sequences from the cDNA AFLP analysis, allowing us to point out 
cDNA EST clones of which their possible involvement in artemisinin biosynthesis is 
supported by both analyses. To be able to do this comparison, we compiled a database 
containing all nucleic acid sequences pointed out by the proteome analysis. This database 
contains the sequences of the genes of the proteins that were annotated to the spots by the 
mascot search engine, the EST sequences that were annotated to the spots by the ProteinLynx 
software and the complete coding sequence of the gene annotated to these EST sequences by 
the NCBI BLAST algorithm. 
 
All 830 differential AFLP sequences were blasted against this database (NCBI BLASTN 
algorithm 2.2.15). Blasts with an E-value below 0.0001 were considered informative. Blasts 
with an E-value between 0.0001 and 0.001, were taken into consideration if multiple AFLP 
sequences were linked to the same protein spot. 
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3.3. Results and discussion 
 
3.3.1. Protein extraction 
Proteome analysis of plants tissues poses some challenges because plant tissues have a low 
protein content and have high levels of components interfering with 2-DE analysis (lipids, 
sugars, organic acids, etc.). Like other essential oil producing plants, A. annua tissues 
(especially trichomes) are characterized by a high lipid content. 
 
Three protein extraction protocols were tested in an attempt to optimize the protein extraction: 
• The ReadyPrep Sequential Extraction kit (Biorad, Hercules, USA). 
• A TRIS-HCl extraction proven to be the best of 4 methods tested by Audrius et al.[15] 
for protein extraction from Citrus leafs. 
• Extraction protocol described by Bauw and Van Montagu[13] including a phenol 
extraction. 
 
The ReadyPrep Sequential Extraction kit and the TRIS-HCl extraction proved to be 
unsatisfactory. In search for a method which is more suitable to extract proteins from samples 
with a high lipid content, the extraction protocol by Bauw and Van Montagu[13] was 
evaluated. This method has been used by Tilleman et al. for protein extraction from brain 
tissues[16, 17], which are also characterized by a high lipid content. For the extraction of 
trichomes and leaf tissue, this method yielded between 459 and 643 of analyzable spots per 2-
DE gel (see table 1).  
 
An adaptation of the method by Bauw and Van Montagu[13] was used to extract proteins 
from the waxy and oily residue after evaporation of a one-minute chloroform extract. The 
protein extraction buffer had to be replaced by the ReadyPrep Sequential Extraction reagent 3. 
This reagent is optimized for the extraction of lipophilic proteins. Unlike the protein 
extraction buffer, this reagent was able to dissolve most of the residue. All other steps in the 
protocol were performed as described[13]. The adapted protocol yielded 150 spots on each of 
the gels. 
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3.3.2. Proteins annotated by MSMS analysis 
 
 Number of 
differential 
spots 
Number of 
differential 
spots that are 
upregulated 
Number of 
excised, 
digested and 
analyzed spots 
Number of 
annotated 
spots 
Trichomes versus whole leaf 250 115 101 83 
Upper versus lower leafs 25 12 9 8 
Proteins in one minute chloroform extract N/A N/A 118 66 
Table 2: Numbers of upregulated, analyzed and annotated spots for each proteome study 
 
Amorpha-4,11-diene synthase and CYP71AV1 are the only two proteins that are known to be 
essential to artemisinin biosynthesis in A. annua. The identification of spots to be one of these 
enzymes, can be considered as a proof-of-concept for the proteome study.  In the differential 
study between trichomes and whole leaf tissue, two upregulated spots are identified as 
amorpha-4,11-diene synthase. None of the spots identify as CYP71AV1. 
 
A comprehensive list of the annotated spots for the three proteome studies can be found in 
appendix 1-3 for the trichomes-versus-leafs study, the upper-versus-lower leafs study and the 
chloroform extract study respectively. Spots that identified as histones, chaperonins, 
proteasomes, porins, DNA binding proteins, Ribulose-1,5-bisphosphate carboxylase and 
ATPases, were omitted from the list. This list shows several candidate ESTs which could be 
useful for further investigation: transketolases, cytochrome P450 enzymes, dehydrogenases, 
etc. 
 
3.3.3. Comparison of the proteomics and the AFLP data 
To narrow down the results to the most valid gene candidates, we compared the proteome and 
the AFLP data. We were able to compile a short list of EST candidates (see Table 3), that 
could be useful for further investigation. The BLAST results for the three proteome studies 
can be found in appendix 4-6 for the trichomes-versus-leafs study, the upper-versus-lower 
leafs study and the chloroform extract study respectively. 
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 EST candidates Annotation of EST 
Trichomes vs. whole GSTSUB_047_A04 glucose acyltransferase [Solanum berthaultii] 
 AAGST_08_G09 glyceraldehyde 3-phosphate dehydrogenase [Linum usitatissimum] 
 AAGST_013_H10 thioredoxin/transketolase fusion protein [synthetic construct] 
 AAGST_018_B10 caffeic acid O-methyltransferase II [Nicotiana tabacum] 
 AAGST_029_C10 catalase 2 [Helianthus annuus] 
 AAGST_032_A11 monodehydroascorbate reductase [Mesembryanthemum crystallinum] 
 AAFB_013_C07 plastidic aldolase NPALDP1 [Nicotiana paniculata] 
Upper vs. lower leafs AAFB_015_D05 glycolate oxidase/ oxidoreductase [Arabidopsis thaliana] 
 AAFB_015_H07 Cytochrome b6-f [Pisum sativum] 
Chloroform extract GSTSUB_009_C06 N/A 
 AAGST_010_C02 caffeic acid O-methyltransferase [Rosa chinensis var. spontanea] 
 AAGST_010_C05 hypothetical protein MtrDRAFT_AC151668g11v1 [Medicago 
 AAGST_020_B07 putative hypersensitive-induced response protein [Oryza sativa] 
 AAGST_032_F11 MADS-box transcription factor CDM41 [Chrysanthemum x morifolium] 
 AAFB_014_H05 Chlorophyll a-b binding protein 
Table 3: EST candidates supported by both the proteome and the AFLP analyses 
 
3.3.4. Prospectives 
The proposed EST candidates can be used to discover genes involved in the production of 
artemisinin. Several strategies can be followed to validate the candidate genes: 
 
• Fluorescent mRNA in situ hybridization: A fluorescent labeled RNA probe 
complementary to the mRNA of a candidate gene can be used to localize the mRNA 
within tissue sections of A. annua. If the probes only hybridize in the trichomes and 
not in other cell types, this would be an extra indication for the involvement of this 
gene in artemisinin production. 
• The overexpression in trichomes of the mRNA of a candidate gene could be validated 
using real time PCR. 
• Candidate genes, proposed to be involved in the biosynthesis of artemisinin, could be 
expressed in Saccharomyces cerevisiae[18]. Microsomes of this yeast can be assayed 
with possible substrates to determine the catalytic function of the recombinant protein. 
• A. annua plants could be transformed with the candidate genes. Transformed A. annua 
plants producing more artemisinin is the ultimate validation of the involvement of the 
candidate gene. 
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3.4. Conclusions 
 
Using a proteome approach, we identified proteins which are upregulated in trichomes 
compared to whole leaf tissue and in upper leafs compared to lower leafs. We were also able 
to identify several proteins which are present in a one-minute chloroform extract of whole A. 
annua plants. The fragmentation spectra of the proteins resulting from the proteomics analysis 
were searched against the public MSDB database and against three EST libraries (one from 
flower buds of A. annua, one from the trichomes on the flower buds and a subtracted library). 
This search resulted in several candidate ESTs which could be useful for further investigation 
in the quest for artemisinin related genes: transketolases, cytochrome P450 enzymes, 
dehydrogenases, etc. 
 
To narrow down the results to the most valid gene candidates, the proteome data was 
compared with a cDNA AFLP analysis on samples of A. annua leafs, taken at different points 
during a 72h time period after exposure to jasmonic acid. This approach allowed us to 
compile a list of EST candidates of which their possible involvement in artemisinin 
biosynthesis is supported by both analyses.  
 
Further investigation by fluorescent mRNA in situ hybridization, real time PCR, expression in 
Saccharomyces cerevisiae, and/or creation of transformed A. annua plants, is needed to 
validate these results.  
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ABSTRACT. 
 
This study reports the development and validation of a rapid, sensitive and selective assay 
for the quantitation of artemisinin, arteannuin B, artemisitene and artemisinic acid in 
Artemisia annua L. by reversed phase High Performance Liquid Chromatography (HPLC) 
Electrospray (ESI) Quadrupole – Time Of Flight (Q-TOF) tandem mass spectrometry 
(MS/MS). A recovery of >97% for all analytes was achieved by immersing one gram of 
fresh plant material in chloroform for one minute. This result supports the hypothesis that 
artemisinin and some of its structural analogs present in the leaves A. annua L. are 
localized entirely in the subcuticular space of the glands on the surface of the leaves. We 
validated the use of this chloroform extract, without additional sample preparation steps, 
for quantitative Q-TOF MS/MS. No ion suppression (matrix effect) resulting from 
interference with other compounds was detected. For every concentration within the range 
of the standard curve (0.1 to 3.00 µg/ml), accuracy was between 85% and 115%. Within- 
and between-day variations for the analysis of A. annua L. samples were <20%. 
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4.1. Introduction 
Malaria is one of the world’s most important parasitic diseases. There are at least 300 million 
acute cases of malaria each year globally, resulting in more than a million deaths[1, 2]. Multi-
drug resistance of the Plasmodium strains to the cheapest and most widely used antimalarials 
such as chloroquine, mefloquine and sulfadoxine-pyrimethamine is one of the biggest 
challenges in the fight against malaria[1]. 
 
Artemisia annua L. (sweet wormwood), a herb of the Asteraceae family has been used for 
centuries for the treatment of fever and malaria[3]. Artemisinin, an endoperoxide-containing 
sesquiterpene lactone, is the main component responsible for this therapeutic effect. Based on 
artemisinin, several semi-synthetic derivatives such as artemether, arteether and artesunate 
have been produced[3]. The WHO recommends that all countries experiencing resistance to 
conventional monotherapies should use combination therapies, preferably those containing 
artemisinin derivatives (ACTs – artemisinin-based combination therapies)[4, 5]. 
 
As artemisinin cannot be synthesized chemically in an economically feasible way, A. annua is 
the only practical source of this valuable drug[6]. Unfortunately, A. annua contains only very 
small amounts of artemisinin ranging from 0.001 to 1.54% of dry weight[7]. Several research 
programs have been set up trying to increase the concentration of artemisinin in A. annua by 
optimizing the growing and harvesting conditions, by selecting high yielding cultivars or by 
creating transgenic plants[6, 8]. To study the content of artemisinin and its biosynthetic 
precursors in plants, we developed a very simple extraction method followed by HPLC – ESI 
MS/MS. 
 
Several other methods have been reported for the extraction, chromatography and detection of 
artemisinin and its structural analogs in A. annua. Liquid solvent extraction of dried plant 
material is currently the most commonly applied technique.  Also more complicated 
extraction techniques such as Super Critical Fluid Extraction (SFE), (Pressurized Solvent 
Extraction (PSE) and Microwave-assisted Extraction (MAE) have been used. For the 
quantitation of artemisinin a large array of techniques have been developed including thin 
layer chromatography (TLC), high performance liquid chromatography with UV detection 
(HPLC-UV), HPLC with electrochemical detection (HPLC-ECD), HPLC with evaporative 
light scattering detector (HPLC-ELSD), gas chromatography with flame ionization detector 
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(GC-FID), GC coupled to mass spectrometry (GC-MS), GC coupled to tandem mass 
spectrometry (GC-MS/MS), supercritical fluid chromatography with FID (SFC-FID), ELSD 
(SFC-ELSD) or MS (SFC-MS) and capillary electrophoresis with UV detection (CE-UV). A 
review by Christen et al.[9] gives an excellent overview of these techniques and discusses 
some of them in more detail.  
 
Some of these methods such as TLC, EC and UV-detection (artemisinin is UV-transparent 
therefore derivatisation is required) are time-consuming and not suited for routine analysis. 
More important is the fact that most of these methods lack specificity (TLC, UV-detection, 
FID, ECD, ELSD). As an A. annua plant extract may contain hundreds of components, some 
structural analogues of artemisinin, good specificity of the detector is essential.  
The high sensitivity and selectivity of MS and certainly MS/MS present a major advantage for 
the detection of specific components in plant extracts. Several GC-MS[10, 11], HPLC-
MS[12-15] and HPLC-MS/MS[16] methods have been developed to analyze artemisinin and 
its derivatives in blood, plasma or serum. For analysis of A. annua extracts a SFC-MS method 
has been reported[17]. 
 
To our knowledge, we report the first MS/MS method developed to analyze artemisinin and 
its biosynthetic precursors in A. annua. The main advantages of our method are not only the 
excellent specificity but also the extremely short and efficient sample preparation. 
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4.2. Experimental  
 
4.2.1. Chemicals 
Pure reference standard of artemisinin, 98% was obtained from Sigma-Aldrich (Bornem, 
Belgium). The other reference standards arteannuin B, artemisitene and artemisinic acid were 
kindly provided by the Walter Reed Army Institute of Research (Washington, USA). The 
internal standard (I.S.) β-artemether was a gift from Arenco Pharmaceutica N.V. (Geel, 
Belgium). LC-MS grade absolute methanol was obtained from Biosolve (Valkenswaard, the 
Netherlands). Analytical grade chloroform was obtained from Acros (Geel, Belgium). 
Analytical grade ammonium acetate, analytical grade sodium acetate and acetic acid (99.8%) 
were obtained from Sigma-Aldrich (Bornem, Belgium). Purified water of 18.2 MΩ/cm was 
obtained from a Milli-Q system (Millipore, Belgium). 
 
4.2.2. Artemisia annua L. plants 
The plants were grown under controlled conditions (21 °C; 12h day/12h night regime). Seeds 
were kindly provided by the National Botanic Garden of Belgium (Meise, Belgium). 
 
4.2.3. Analytical Standards 
Individual stock solutions (1 mg/ml) of artemisinin, arteannuin B, artemisitene, artemisinic 
acid and internal standard β-artemether were prepared by accurately weighing required 
amounts into separate volumetric flasks and dissolving in appropriate volumes of methanol. 
Analytical standards were prepared as a mixture of each analyte (0.1 µg/ml to 3 µg/ml each) 
and the internal standard (0.4 µg/ml) by serial dilution of stock solutions in methanol – 1 mM 
ammonium acetate buffer adjusted to pH 5 with acetic acid (50 – 50 v/v). 
 
4.2.4. Sample Preparation 
Extraction was performed by immersing one gram of plant material in 6 ml chloroform for 
one minute. An aliquot of 10 µl of this extract was then dissolved in 1 ml methanol – 1 mM 
ammonium acetate buffer adjusted to pH 5 with acetic acid (50 – 50 v/v) containing 0.4 µg/ml 
of the I.S. β-artemether. This procedure was carried out on the plants of interest: Artemisia 
annua L. (Asteraceae) and the negative controls Artemisia Absinthium L. (Asteraceae), 
Mentha spicata L. (Lamiaceae) and Mentha piperita L. (Lamiaceae). 
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4.2.5. Liquid Chromatography 
A Waters Alliance 2695 HPLC system was used to deliver the mobile phase [pump A, 1 mM 
ammonium acetate buffer adjusted to pH 5 with acetic acid; pump B, 100% methanol] for 
gradient elution at a flow rate of 0.2 mL/min. The initial composition of 50:50 was maintained 
for 1 minute; next the methanol content was increased linearly to 80% over a period of 6 min 
and maintained for 18 minutes. Re-equilibration time was 10 min between runs. The sample 
injection volume was 100 µl for all samples. Chromatographic separations were achieved on 
an Alltech Ultrasphere C18 IP 5µm column (150 x 2.1 mm) protected by a Waters XTerra MS 
C18 5µm guard column (10 x 2.1). A LC Packings ACUrate ICP-04-20 post-column splitter 
was used to divert one-fourth of the effluent into the electrospray LC-MS interface. 
 
4.2.6. Q-TOF mass spectrometry 
Mass spectrometric detection was performed on a Q-TOF Ultima mass spectrometer 
(Micromass, Manchester, UK) equipped with an electrospray source operating in positive 
mode (ESP+). The ESI capillary voltage was set at 2.7 kV. The source and desolvation 
temperatures were optimized at 130 and 300 °C, respectively. Nitrogen was used as 
desolvation gas with a flow rate of 500 L/h. MS/MS analysis was performed using argon (0.9 
bar) as the collision gas. An MS/MS method was used to quantify artemisinin (m/z 283 → 
219+229+247+265), arteannuin B (m/z 249 → 185+189+203+231), artemisitene (m/z 281 → 
217+227+245+263), artemisinic acid (m/z 252 → 189+199+217) and β-artemether (m/z 316 
→ 267+284+307). Cone voltage had an optimum at 40V for all components. The collision 
energy was optimized at 7 eV for artemisinin, 10 eV for arteannuin B, 7 eV for artemisitene, 
11 eV for artemisinic acid and 7 eV for β-artemether. Data acquisition and analysis were 
carried out using Masslynx version 4.0. software. Analytical standard curves (second-order 
polynomic regression) were calculated using analyte to I.S. peak area ratios. The 
concentrations of the respective analytes in test samples are interpolated from the standard 
curves using the analyte to I.S. peak area ratios from the test samples. 
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4.3. Results and discussion 
 
4.3.1. Sample preparation 
Most plant extraction methods start with lyophilisation or drying of the plant material, 
followed by extraction with an organic solvent such as hexane or toluene[9]. As all cells are 
disrupted by these extraction methods, all soluble components are extracted from the plant. 
These extracts contain a massive amount of components (e.g. chlorophyll) interfering with 
HPLC (clogging) and MS (matrix effect). Additional sample preparation has to be performed 
prior to HPLC – MS/MS. Unfortunately these additional steps (solid phase extraction, 
filtering, evaporation steps) are not only time-consuming, but are also a possible source of 
variations in recovery. 
In the specific case of the extraction of artemisinin and its bioprecursors from A. annua, these 
problems can be avoided. Duke et al.[18] reported that a 5 seconds dip in chloroform 
extracted 97% of the artemisinin and 100% of artemisitene from A. annua. In the report by 
Duke et al., quantitation was performed by HPLC-UV after derivatisation. Light microscopy 
and Transmission Electron Microscopy revealed that the 5 seconds dip results in collapse of 
the subcuticular cavity of the glands on the leaf surface but did not disrupt cell membranes. 
An A. annua biotype without glands contained neither artemisinin nor artemisitene[18]. These 
results indicate that artemisinin and artemisitene present in foliar tissue are localized entirely 
in the subcuticular space of glands of A. annua.  
 
We hypothesized that this chloroform extract can be analyzed on a mass spectrometer without 
additional sample preparation steps as it contains only a very small quantity of interfering 
components (e.g. chlorophyll) compared to plant extracts where the plant material is 
lyophilized, dried or grinded. 
 
4.3.2. Extraction time 
We decided to prolong the extraction time as long as possible to break open as much glands as 
possible without introducing interfering compounds. After an extraction time of one minute, 
chlorophyll starts to be released into the chloroform, indicating that cells with interfering 
compounds begin to break open. Figure 1 shows a picture of glandular trichomes before and 
after a 1 minute chloroform extraction. The cuticle is crumpled after chloroform extraction. 
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The epidermal cells are unaffected by the treatment. The extraction time of one minute was 
validated during the recovery studies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1: Picture of a glandular trichome on a leaf of A. annua L. before (A and B) and after (C and D) 
chloroform extraction. The cuticle is crumpled after chloroform extraction. The epidermal cells are unaffected by 
this treatment. Black bar is 10 µm. 
 
 
4.3.3. Recovery 
Two different experiments were done to asses the recovery. In a first experiment, 15 equal 
samples of one gram fresh A. annua leaves were prepared, 5 of which were spiked with 60 µl 
of a 10 mg/ml methanol solution of each analyte. Immediately after evaporation of the 
methanol, all 15 samples were analyzed. The recoveries of the 5 spiked samples were 
calculated as the ratio between the measured quantity and the spiked quantity increased with 
the mean quantity of the analytes in the 10 unspiked samples. Table 1 shows the mean of the 
recoveries for the different analytes (>97% for each analyte). 
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Spiked quantities  (µg/ml) arteannuin B artemisitene artemisinin artemisinic acid
Mean quantity unspiked samples1 0.37 0.06 0.17 0.42 
Spiked quantity2  1.00 1.00 1.00 1.00 
Total quantity in spiked samples3 1.37 1.06 1.17 1.42 
Recovered quantities (µg/ml) arteannuin B artemisitene artemisinin artemisinic acid
Spiked sample 14 1.47 (107.39%) 1.13 (106.30%)  1.24 (106.12%) 1.44 (100.87%) 
Spiked sample 24 1.27 (93.01%) 0.97 (91.27%) 1.06 (90.23%) 1.26 (88.49%) 
Spiked sample 34 1.51 (110.53%) 1.22 (115.15%) 1.28 (109.37%) 1.52 (106.66%) 
Spiked sample 44 1.14 (83.47%) 0.89 (83.70%) 0.96 (81.59%) 1.19 (83.48%) 
Spiked sample 54 1.31 (95.74%) 1.01 (95.14%) 1.15 (98.55%) 1.56 (109.45%) 
Mean spiked samples (µg/ml) 5 1.34 (98.03%) 1.04 (98.31%) 1.14 (97.17%) 1.39 (97.79%)
Standard deviation (µg/ml)  0.15 (11.03%) 0.13 (12.46%) 0.13 (11.42%) 0.16 (11.35%) 
Table 1: Recovery from spiked samples: Fifteen equal samples of one gram fresh A. annua leaves were prepared. 
Ten samples were not spiked and analyzed1. Five samples were spiked with each analyte2. The total quantity of 
the analytes present in the spiked samples was calculated as the sum of the spiked quantity and the mean quantity 
of the analytes in the 10 unspiked samples3. The spiked samples were analyzed and the individual4 and mean5 
absolute recoveries (% recovery between brackets) were calculated. Quantities are presented as the concentration 
after sample preparation (multiply by 600 to obtain quantities in µg analyte / g fresh plant material).   
 
This very high recovery (> 97%) of the spiked amounts does not imply a high recovery of the 
amounts present in the plant. The recovery of the amounts present in the plant with our 
method, cannot be measured directly. Therefore, we estimated this recovery in a second 
experiment by comparing the recovery achieved with a previous described extraction 
method[19] before and after our one-minute chloroform extraction. Six equal samples of one 
gram fresh leaf material were prepared. Three of them were extracted following a previously 
described extraction method[19]. Briefly, this method consists of an extraction with 2 x 3 ml 
toluene after lyophilisation and pulverization of the plant material followed by a normal-phase 
Silica gel solid-phase extraction (SPE). An aliquot of 1 ml of plant extract was passed through 
the 500 mg Silica gel column, followed by washing with 2 ml petroleum ether - diethyl ether 
(9:1) and elution with 2 x 0.5 ml acetonitrile. The eluate was evaporated to dryness under N2 
and reconstituted in 1 ml methanol – ammonium acetate buffer (50 – 50 v/v) for further 
analysis. Note that compared to our method, the analytes are a 100 fold more concentrated by 
this SPE. The other three samples were subjected to exactly the same extraction protocol, but 
after they were first extracted by our method (one minute chloroform extraction). Table 2 
gives and overview of the results. The amount of artemisinin, arteannuin B and artemisinic 
acid found in the plant material after chloroform treatment was less than 3% compared to the 
amount found in the three non-pretreated samples. This experiment shows that >97% of 
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artemisinin, arteannuin B, and artemisinic acid is extracted by a one minute dip in chloroform. 
As a one minute dip in chloroform is the only sample preparation step in our method, we 
conclude that a recovery of >97% can be achieved by our method. For artemisitene, the 
results are less conclusive as the measured quantity after chloroform extraction falls below the 
lower limit of quantitation (LLOQ). Nevertheless, the experiment gives a good indication of a 
high recovery of artemisitene. 
 
 arteannuin B artemisitene artemisinin Artem. acid
Mean quantity WITHOUT preceding chloroform extraction (µg/ml)1 58.64 0.28 24.17 72.07 
Mean quantity AFTER preceding chloroform extraction (µg/ml)2 3.60 0.02 (< LLOQ) 1.58 5.53 
Quantity not extracted by preceding chloroform extraction 6.14% 6.80% 6.55% 7.68% 
Residual chloroform in samples after chloroform extraction3 > 5% > 5% > 5% > 5% 
Recovery > 98.86% > 98.20% > 98.45% > 97.32% 
Table 2: Recovery with chloroform extraction of Artemisia annua leaves: Six equal samples of one gram fresh 
leaf material were prepared. Three of them were extracted following a previously described extraction 
method[19] which uses extraction with toluene after lyophilisation and pulverization of the plant material1. The 
other three samples were extracted in exactly the same way but after they were first extracted for one min with 
chloroform2. The percentage of the chloroform which sticks to the plant material after chloroform extraction 
(accounting for a part of the not-extracted percentage) was gravimetrically determined3. Quantities are presented 
as the concentration after sample preparation (multiply by 6 to obtain quantities in µg analyte / g fresh plant 
material). 
 
4.3.4. Chromatography 
During flow injection analysis on the Q-TOF MS, [M+Na]+ adducts were found to be far 
more intense than [M+H]+ or [M+NH4]+ adducts. At first we tried to intensify the [M+Na]+ 
adducts, reducing other adducts by using sodium acetate buffer and performing analysis on 
the [M+Na]+ adducts. This approach was abandoned due to variation caused by build up of 
sodium acetate deposits on the ion sampling cone of the mass spectrometer. Finally we 
decided to use ammonium acetate buffer and to perform MS/MS analysis on the [M+H]+ 
(artemisinin, artemisitene, arteannuin B) or [M+NH4]+ (artemisinic acid, artemether) adducts. 
A total of 3 isocratic and 25 gradient elutions were compared, testing varying methanol - 
buffer ratios and testing varying gradient speeds. The method with the highest peak resolution 
was chosen. The reproducibility of the retention times was very dependent on the buffer 
concentration. Increasing the buffer concentration from 0.1 mM to 1 mM greatly enhanced the 
reproducibility of the retention times, resulting in a variation of less than 25 seconds. By 
varying the pH of the ammonium acetate buffer, the retention time of artemisinic acid can be 
 131
influenced. Peak resolution was optimal at pH 5. Using final conditions, all analytes were 
separated from each other with peak resolutions from 1.0 to 2.4 (Fig. 2).  
The column and guard column were stable for at least 1000 injections. No signs of column 
deterioration have been detected yet. 
 
Figure 2: Chromatogram with retention times and chemical structures of (1) arteannuin B, (2) artemisitene, (3) 
artemisinin, (4) artemisinic acid and (5) the internal standard artemether. This chromatogram is the result of the 
analysis by electrospray QTOF-MS/MS of an analytical standard containing 1.2 µg/ml of each analyte and 0.4 
µg/ml IS. 
 
4.3.5. Specificity 
In contrast with [M+Na]+ adducts, the [M+H]+ and [M+NH4]+ adducts were easily 
fragmented with low collision energies. Figure 3 shows the fragmentation spectrum of 
artemisinin at an optimal collision energy of only 7eV. Between 3 and 4 fragments were 
chosen to be monitored for each analyte. Using the sum of several fragments for MS/MS 
quantitation, has the advantage of increased signal strength and enhanced signal stability, but 
the disadvantage of lower specificity. As fragments with higher m / z values tend to be more 
specific, fragments with the highest m / z values were selected. 
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To check the specificity of the method, chloroform extracts of Mentha piperita, Mentha 
spicata and Artemisia absinthium were analyzed. These three plant species also have 
epidermal glands on their leaves, but are not reported to produce artemisinin. In these control 
extracts, no MS/MS signal could be detected for the components of interest. 
 
 
Figure 3: This spectrum shows the fragmentation of artemisinin (m/z 283) with the optimal collision energy of 7 
eV. The MS/MS signal is calculated as the sum of the fragments with m/z 219, 229, 247 and 265. The molecular 
formulas show that the fragments are mainly formed by dehydration of their parent ion. 
 
4.3.6. Ion suppression (matrix effect) 
To check for interferences from other compounds by ion suppression (matrix effect) a 
standard curve obtained from standards prepared in mobile phase was compared to a standard 
curve obtained from standards made in mobile phase spiked with matrix (10 µl chloroform 
extract of Mentha piperita /ml). HPLC-MS/MS analysis (3 measurements for each sample) of 
these standards, resulted in almost identical measurements for the spiked and the non-spiked 
standards. The statistical method of Bland et al.[20] was used for assessing the agreement 
between the two methods. The p-values for the t-test with the nulhypothesis that the mean of 
the differences between both methods is equal to zero, were 0.53, 0.26, 0.67 and 0.74 for 
arteannuin B, artemisinin, artemisitene and artemisinic acid respectively. No significant 
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difference could be found for any of the analytes, meaning that no ion suppression could be 
detected.  For this reason, in the final method, standards were not spiked with chloroform 
extract to include matrix. 
 
4.3.7. Accuracy, precision, limit of detection (LOD) and lower limit of 
quantitation (LLOQ) 
The definitions for accuracy, precision, LOD and LLOQ were adopted from the FDA 
guidelines for bioanalytical method validation[21]. The LOD was defined as the lowest 
observable peak response for an analyte above the background noise, 3 times the system noise 
in the matrix. The LLOQ was defined as the lowest concentration for an analyte with a 
response signal 5 times the system noise in the matrix, a precision of 20% and an accuracy of 
80-120%. Within-day accuracy and precision were calculated with three determinations on 
one day. Between-day accuracy and precision were calculated from 7 determinations on 3 
days spanning a two week period. Accuracy and precision were calculated for each of 7 
spiked concentrations (0.1; 0.2; 0.4; 0.8; 1.2; 2.0 and 3.0 µg/ml) within the range of the 
standard curve. Within the range of the standard curve, coefficient of variation (CV%) was 
<15% and accuracy was between 85% and 115% for all analytes and all 7 spiked 
concentrations (Table 3). 
Within- and between-day variation was also calculated for unspiked A. annua samples. 
Twenty equal samples of one gram fresh leaf material were prepared and kept between 4°C to 
8°C until extraction. Ten of these samples were extracted with chloroform on day 1, five on 
day 2 and again five on day 3. The extracts were stored at -20°C until HPLC-MS/MS analysis. 
The first 10 extracts (extraction on day one) were analyzed in one day allowing calculation of 
within-day variation. The other 10 extracts were analyzed on two different days spanning a 
two week period. All 20 independent samples were used to calculate the between-day 
variation. The within- and between-day variation of the complete procedure (extraction and 
quantitation by MS/MS) is <20 % (Table 3) for all analytes except for artemisitene for which 
the amount present in the unspiked samples was below the LLOQ. The variation for the 
unspiked samples is higher than for the spiked samples. A possible reason is variation in the 
release of the analytes out of the glandular trichomes. Another possibility is an actual 
variation in the 20 samples as the leaves for these samples were collected from three different 
plants. 
 
 134
 arteannuin B artemisitene artemisinin artemisinic acid 
Within Between Within Between Within Between Within Between 
LOD (µg/ml) 0.001 (S/N: 3) 0.0005 (S/N: 5) 0.0001 (S/N: 9) 0.04 (S/N: 4) 
LLOQ (µg/ml) 0.1 (S/N: 86) 0.1 (S/N: 52) 0.1 (S/N: 22) 0.1 (S/N: 5) 
Accuracy at LLOQ 108±9% 111±8% 107±13% 111±8% 114±10% 112±6% 104±7% 108±8% 
CV% at LLOQ 8.5% 7.5% 12.6% 6.7% 8.4% 5.1% 6.6% 7.1% 
Accuracy (0.1 – 3 µg/ml spiked) 94 - 108% 94 - 111% 89 - 107% 85 - 110% 90 - 113% 85 - 111% 97 - 104% 96 - 107% 
CV% (0.1 – 3 µg/ml spiked) 1.0 - 8.5% 0.9 - 7.5% 2.0 - 
12 5%
1.3 - 8.5% 1.1 - 
13 9%
1.3 - 
10 3%
0.8 - 7.1% 0.9 - 7.1% 
Mean unspiked extracts (µg/ml) 0.36 0.33 0.07 0.08 0.16 0.15 0.39 0.36 
St. dev. unspiked extracts (µg/ml) 0.05 0.06 0.02 0.02 0.03 0.03 0.06 0.07 
CV% unspiked extracts 14% 19% 24% 22% 15% 19% 17% 20% 
Table 3. Accuracy, precision, LOD and LLOQ
LOD and LLOQ are presented with peak-to-peak signal-to-noise ratio. Within- and between-day accuracy and 
precision are presented at LLOQ and for 7 spiked concentrations (0.1; 0.2; 0.4; 0.8; 1.2; 2.0 and 3.0 µg/ml) 
within the range of the standard curve. Within- and between-day variation was also calculated for 20 unspiked A. 
annua samples. Quantities are presented as the concentration after sample preparation. 
 
 
4.3.8. Dynamic range and polynomial regression 
Based on the LLOQ and dynamic range of the MS/MS signal, standard curves were 
established from 0.1 to 3.00 µg/ml for artemisinin, arteannuin B, artemisitene and artemisinic 
acid. Several regression models were evaluated to establish these curves. For the range of 0.1 
– 3 µg/ml, a best-fitted second-order polynomial regression (y = Ax²+Bx+C) described the 
measurements of the analytical standards at best (typically R² > 0.99). Limiting the range to 
0.1 – 0.8 µg/ml, a linear regression (y = Ax+B) would also be acceptable with R² > 0.99, but 
still a second-order polynomial regression describes this range better with R² > 0.999. In 
practice, the use of a second-order polynomial regression not only extended the useful 
dynamic range, but also reduced the between-day variation. 
The range of the standard curves may not extend high enough to analyze high yielding 
plants[7]. Dilutions can be made from the extracts of these plants. To check if these dilutions 
do not present any ill effects, a sample of one gram fresh leaf material from A. annua was 
spiked with 16 mg of artemisinin in a methanol solution. After evaporation of the methanol, 
the artemisinin was extracted and prepared with the standard sample preparation procedure. 
Immediately before HPLC – MS/MS analysis, the sample was diluted 16 fold with methanol 
– ammonium acetate buffer (50 – 50 v/v) containing 0.4 µg/ml of the internal standard. The 
diluted sample was measured 3 times; recovery was 100.0% ± 8.4%. 
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4.4. Conclusions 
This study reports the development and validation of a rapid, sensitive and selective assay for 
the quantitation of artemisinin, arteannuin B, artemisitene and artemisinic acid in A. annua L. 
by reversed phase HPLC ESI Q-TOF MS/MS. An absolute recovery of >97% was achieved 
by immersing one gram of plant material in chloroform for one minute. This result supports 
the hypothesis that artemisinin and some of its structural analogs present in the leaves of A. 
annua L. are localized entirely in the subcuticular space of the glands on the surface of the 
leaves. We validated the use of this chloroform extract for quantitative MS/MS without 
additional sample preparation steps. No ion suppression (matrix effect) resulting from 
interference with other compounds was detected. To check the specificity of the method, 
chloroform extracts of Mentha piperita, Mentha spicata and Artemisia absinthium were 
analyzed. These three plants also have epidermal glands on the leaves, but do not synthesize 
artemisinin. No signal for the components of interest was detected in these control extracts. 
With a LOD of at least 0.04 µg/ml, a LLOQ of 0.10 µg/ml and a dynamic range from 0.10 to 
3.00 µg/ml for each analyte, the method has enough sensitivity and flexibility to measure low 
and high yielding cultivars.  For every concentration within the range of the standard curve 
(0.1 to 3.00 µg/ml), accuracy was between 85% and 115%. Within- and between-day 
variations for the analysis of unspiked A. annua L. samples were <20%. 
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SUMMARY 
 
PART I: Polymorphism association with Obsessive-Compulsive Disorder 
Currently OCD is viewed mainly as a neuropsychiatric disease. The current definition 
opposes obsessions (anxiety inducing) to compulsions (anxiety reducing), which patients 
recognise as excessive or unreasonable. Recent prevalence studies report prevalence rates 
around 3 %. OCD is treated only in a minority of the cases. The main reason for this “hidden 
epidemic” is that the patients want to keep their disease secret and don’t want to disclose their 
“crazy” symptoms.  
 
Currently the most effective treatment for OCD is a combination of behaviour therapy and 
pharmacotherapy. This combined approach improves the condition of most patients 
substantially, and occasionally leads to a complete recovery. All Serotonin Reuptake 
Inhibitors (SRIs) have shown to be effective in OCD. Their exclusive efficacy has given 
grounds to the “serotonin hypothesis” that serotonin plays an important role in the 
pathogenesis of OCD. However, this serotonin hypothesis is too limited. It is clear that the 
dopaminergic system is also involved in the pathogenesis of OCD. In case of non-response or 
partial response to SRIs, evidence has accumulated that the addition of antipsychotic drugs to 
SRIs might lead to symptom improvement.  
 
Twin studies showed a concordance rate of approximately 50–60% in monozygotic twins, 
compared to 10% in dizygotic twins. Family studies show a significant aggregation of illness 
within families compared to population prevalence. This evidence suggests a genetic basis for 
OCD, but also shows that obsessive and compulsive behaviours are influenced by non-genetic 
and environmental factors. 
 
During the last 2 decades, a large number of association studies have been dedicated to 
disentangle the genetic components that may be involved in OCD. The preliminary and 
frequently inconsistent nature of the data represented in the majority of OCD genetic-
association studies may seem discouraging. Failure to confirm previously identified 
susceptibility loci could result from a number of reasons, including the potential for 
population admixture, the clinical heterogeneity of OCD, small sample sizes (and subsequent 
lack of statistical power) or epistasis (genetic interaction).  
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In light of the putative role of the serotonergic, dopaminergic and possibly (nor)adrenergic 
system in OCD, following polymorphisms were analysed in a sample of >100 OCD patients 
and a control sample of >100 ethnically matched Caucasian subjects by means of a case-
control study: 
• Taq IA polymorphism in the non-coding region flanking the 3’ end of the dopamine 
D2 receptor (DRD2) gene 
• Catechol-O-Methyl Transferase (COMT) NlaIII high/low activity polymorphism 
• 1438 A/G polymorphism within the promoter region of the postsynaptic 5-HT2A 
receptor 
• 5-HT1Dβ G861C polymorphism: silent G-to-C substitution at nucleotide 864 of the 
coding region of the 5-HT1Dβ  autoreceptor gene 
• 5-HTTLPR: serotonin transporter gene (5-HTT) promoter 44-bp deletion/insertion 
 
We found indication towards an association of the 5-HTTLPR S-allele with female OCD 
patients, and toward an association of the 5-HT2A G-allele and GG genotype with patients 
with a positive family history of OCD and an early onset of disease. There was a significant 
predominance of the DRD2 A2A2 genotype (p = 0.049), a higher frequency of the DRD2 A2 
allele (p = 0.020) and a higher frequency of the low-activity COMT allele (p = 0.035) in male 
OCD patients compared to male controls. In addition, we observed an association of the 
DRD2 A2A2 genotype in patients with an early onset of OCS (age ≤ 15 years) (p= 0.033).  
 
Research by which the treatment of patient is tuned on the basis of their genotype, is called 
pharmacogenetics. Strong evidence suggests that genetic variation plays an important role in 
inter-individual differences in medication response and toxicity. We studied whether 
polymorphisms of the 5-HTT, 5-HT1Dβ and 5-HT2A genes affect the efficacy of venlafaxine 
and paroxetine treatment in OCD. The results of this study strongly suggest that response in 
paroxetine treated OCD patients is associated with the GG genotype of the 5-HT2A 
polymorphism (χ2 = 8.66, df=2, p=0.013). In venlafaxine treated OCD patients, response is 
associated with the SL genotype of the 5-HTTLPR polymorphism (χ2 = 9.71, df=2, p=0.008). 
This study demonstrates that pharmacogenetics could solve the current trial and error 
approach with different SRIs for the treatment of OCD. 
 
 
 140
 PART II: proteomics on Artemisia annua 
 
Three strategies were followed to discover genes of the plant Artemisia annua L. that are 
involved in the production of the antimalarial artemisinin: a proteome analysis, a quantitative 
cDNA amplified fragment length polymorphism analysis (cDNA AFLP) and the construction 
of full length Expressed Sequence Tag (EST) cDNA libraries. The results of these 3 strategies 
can be compared and complemented with each other. 
 
The proteome of A. annua was investigated to discover candidate genes related to artemisinin 
production. We identified proteins that were differentially expressed between trichomes and 
whole leaf tissue. We also identified differentially expressed proteins between lower and 
upper leafs of A. annua plants. In a third proteome analysis, we explored the proteins present 
in a one-minute chloroform extract of A. annua plants. Trichomes are considered to be the 
artemisinin factories of A. annua. Upper leafs produce more artemisinin than the lower leafs. 
Proteins that are upregulated in these samples might thus be involved in artemisinin 
production. With the chloroform extraction, the content of the capitate glands of the trichomes 
is extracted. These glands possibly contain proteins involved in artemisinin production. 
 
Proteins of interest were identified by tandem mass spectrometry. The fragmentation spectra 
were searched against the public Mass Spectrometry protein sequence DataBase (MSDB) and 
against three Expressed Sequence Tag (EST) libraries (one from flower buds of A. annua, one 
from the trichomes on the flower buds and one being the result of a cDNA subtraction of both 
plant tissues). To narrow down the results to the most valid gene candidates, the proteome 
data was compared with a cDNA AFLP analysis that investigated samples of A. annua leafs, 
taken at different time points during a 72h time period after exposure to jasmonic acid. We 
were able to compile a list of EST candidates, which could be useful for further investigation. 
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To be able to find which plant hormones trigger A. annua to produce more artemisinin, to 
check the correlation between artemisinin content of A. annua leafs and the number of 
trichomes on these leafs, and to be able to check transformed plants or shoot cultures for 
enhanced artemisinin production, a quantitation method for artemisinin and its bioprecursors 
had to be developed. A recovery of >97% for all analytes was achieved by immersing one 
gram of fresh plant material in chloroform for one minute. This result supports the hypothesis 
that artemisinin and some of its structural analogs are localized entirely in the subcuticular 
space of the glands on the surface of the leaves. We validated the use of this chloroform 
extract, without additional sample preparation steps, for quantitative HPLC – ESI – QTOF  
MS/MS. No ion suppression (matrix effect) resulting from interference with other compounds 
was detected. For every concentration within the range of the standard curve (0.1 to 3.00 
µg/ml), accuracy was between 85% and 115%. Within- and between-day variations for the 
analysis of A. annua samples were <20%. We can conclude that this one minute lasting 
extraction procedure is a good alternative for other time consuming extraction procedures. 
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SAMENVATTING 
 
DEEL I: Associatie van polymorfismen met obsessieve-compulsieve stoornis 
De obsessieve-compulsieve stoornis (OCS) wordt tegenwoordig beschouwd als een 
neuropsychiatrische ziekte. OCS wordt gekarakteriseerd door zowel obsessies (angst 
inducerend) als compulsies (angst verminderend). De patiënten voelen deze obsessies en 
compulsies zelf aan als excessief of redeloos. De incidentie van OCS in de algemene 
bevolking bedraagt 3%. Slechts een minderheid van de gevallen wordt behandeld. Een 
belangrijke reden voor deze “verborgen epidemie” is het feit dat patiënten hun ziekte geheim 
houden en beschaamd zijn over hun symptomen.  
 
De meest effectieve behandelingsmethode voor OCS combineert gedragstherapie met 
farmacotherapie. De toestand van de meeste patiënten verbetert opmerkelijk door deze 
combinatietherapie en occasioneel treedt zelfs volledige genezing op. De effectiviteit van 
Serotonine Reuptake Inhibitoren (SRIs) voor de behandeling OCS heeft de basis gelegd voor 
de “serotonine hypothese”, namelijk dat serotonine een belangrijke rol speelt in de 
pathogenese van OCS. Deze serotonine hypothese is echter te beperkt, aangzien het duidelijk 
is dat het dopaminerge systeem ook betrokken is in de pathogenese van OCS. Er is 
toenemende evidentie dat de combinatie van SRIs met een antipsychotisch geneesmiddel de 
symptomen verbetert in geval van ontoereikende respons op SRIs. 
 
Tweeling-studies tonen een concordantie van ongeveer 50–60% in monozygotische 
tweelingen, vergeleken met 10% in dizygotische tweelingen. Familie-studies tonen een 
significante aggregatie van OCS binnen éénzelfde familie. Deze feiten suggereren een 
genetische basis voor OCS, maar tonen ook dat obsessief en compulsief gedrag beïnvloed 
wordt door omgevingsfactoren. 
 
Gedurende de laatste 2 decennia, werden een groot aantal associatiestudies uitgevoerd om de 
genetische componenten te ontrafelen die betrokken zijn in OCS. Een groot deel van de uit 
deze associatiestudies afkomstige resultaten lijken tegenstrijdig. Geïdentificeerde 
susceptibiliteitsloci worden meestal niet geconfirmeerd. Dit kan het gevolg zijn van een aantal 
factoren, zoals mogelijke vermenging van de OCS-populatie met andere populaties, de 
klinische heterogeniteit van OCS, analyse van een te kleine groep patiënten (en een daaruit 
volgend gebrek aan statistische power) of epistase (genetische interactie).  
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In het kader van de zoektocht naar de mogelijke rol van het serotonerge, dopaminerge en 
(nor)adrenerge systeem in OCS, werden volgende polymorfismen geanalyseerd in een 
steekproef van >100 OCS-patiënten en >100 etnische aangepaste controle stalen: 
• Taq IA polymorfisme in de niet-coderende regio die het 3’ uiteinde van het dopamine 
D2 receptor (DRD2) gen flankeert 
• Catechol-O-Methyl Transferase (COMT) NlaIII hoge/lage activiteit polymorfisme 
• 1438 A/G polymorfisme in de promotor regio van de postsynaptische 5-HT2A receptor 
• 5-HT1Dβ G861C polymorfisme: stille G-naar-C substitutie op nucleotide 864 van de 
coderende regio van het 5-HT1Dβ  autoreceptor gen 
• 5-HTTLPR: 44-bp deletie/insertie in de promotor regio van het serotonine transporteur 
gen (5-HTT) 
 
Onze studie leverde aanwijzingen voor een associatie van het 5-HTTLPR S-allele met 
vrouwelijke OCS-patiënten, alsook voor een associatie van het 5-HT2A G-allel en GG 
genotype met patiënten met een familiale OCS historiek en een vroeg begin van de ziekte. Er 
was een significant overwicht van het DRD2 A2A2 genotype (p = 0.049), een hogere 
frequentie van het DRD2 A2 allel (p = 0.020) en een hogere frequentie van het lage-activiteit 
COMT allel (p = 0.035) in mannelijke OCS-patiënten vergeleken met mannelijk controle-
patiënten. Daarenboven observeerden we een associatie van het DRD2 A2A2 genotype in 
patiënten met een vroeg begin van de ziekte (leeftijd ≤ 15 jaar) (p= 0.033).  
 
Farmacogenetica is een onderzoeksdomein waardoor de behandeling van de patiënt kan 
afgesteld worden op basis van zijn genotype. Genetische variatie speelt een belangrijke rol in 
inter-individuele verschillen in reactie op, en toxiciteit van medicatie. Vanuit deze invalshoek 
bestudeerden we of polymorfismen van de 5-HTT, 5-HT1Dβ en de 5-HT2A genen een effect 
hebben op de werkzaamheid van venlafaxine en paroxetine in de behandeling van OCS. Een 
positieve respons van OCS-patiënten op paroxetine behandeling blijkt sterk geassocieerd met 
het GG genotype van het 5-HT2A polymorfisme (χ2 = 8.66, df=2, p=0.013), terwijl een positieve 
respons op venlafaxine geassocieerd blijkt met het SL genotype van het 5-HTTLPR 
polymorfisme (χ2 = 9.71, df=2, p=0.008). Deze studie promoot farmacogenetica als een 
veelbelovend alternatief voor de huidige proefondervindelijke behandeling van OCS met 
verschillende SRIs. 
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 DEEL II: proteomics op Artemisia annua 
 
Drie strategieën werden gevolgd met als doel de identificatie van genen betrokken in de 
productie van het antimalaria middel artemisinine door de plant Artemisia annua: een 
proteoom analyse, een kwantitatieve “cDNA geAmplificeerde Fragment Lengte 
Polymorfisme analyse” (cDNA AFLP) en de aanmaak van EST- (Expressed Sequence Tag) 
banken. De resultaten van deze 3 strategieën zijn complementair en kunnen met elkaar 
vergeleken worden. 
 
Het proteoom van A. annua werd onderzocht om kandidaat genen te identificeren die in 
verband staan met artemisinine productie. We identificeerden proteïnen die differentieel tot 
expressie komen in klierharen t.o.v. volledig blad-materiaal. We identificeerden ook proteïnen 
die differentieel tot expressie komen in hoog t.o.v. laag gelokaliseerde bladeren van A. annua. 
In een derde proteoom analyse, deden we onderzoek naar de proteïnen die aanwezig zijn in 
een chloroform extract van A. annua. De klierharen worden beschouwd als de “artemisinine 
fabrieken” van A. annua. Hoge bladeren produceren meer artemisinine dan lage bladeren. 
Proteïnen die meer tot expressie komen in deze stalen zijn dus mogelijks betrokken in de 
productie van artemisinine. Door middel van chloroform extractie, wordt de inhoud van de 
blaasjes op de klierharen geëxtraheerd. Deze blaasjes bevatten mogelijks proteïnen die 
betrokken zijn in de productie van artemisinine. 
 
Mogelijks interessante proteïnen werden geïdentificeerd door middel van nano-
vloeistofchromatografie gekoppeld aan tandem massaspectrometrie. De fragmentatie spectra 
werden vergeleken met de publieke MassaSpectrometrie proteïne sequentie DataBank 
(MSDB) en met 3 EST-banken (één van de bloemknoppen van A. annua, één van de 
klierharen op de bloemknoppen en één die resulteert na cDNA subtractie van de 2 
voorgenoemde plantweefsels). Om een selectie te maken van de meest verdedigbare 
resultaten, werden de proteoom data vergeleken met een cDNA AFLP analyse van stalen van 
A. annua bladeren, genomen op verschillende tijdspunten gedurende een periode van 72 uur 
na blootstelling aan jasmonaat. Deze vergelijking heeft geleid tot een lijst van EST-
kandidaten die interessant zijn voor verder onderzoek. 
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We ontwikkelden een kwantificatiemethode voor artemisinine en zijn bioprecursors om te 
kunnen nagaan welke planthormonen een verhoogde artemisinine productie teweeg brengen, 
om te kunnen nagaan of er een correlatie is tussen artemisinine inhoud van A. annua bladeren 
en het aantal klierharen op deze bladeren, en om te kunnen nagaan of getransformeerde 
planten of kiemculturen een verhoogde artemisinineproductie vertonen. Een recuperatie van 
>97% voor alle analyten werd bekomen door één gram vers plantmateriaal gedurende 1 
minuut onder te dompelen in chloroform. Dit resultaat ondersteunt de hypothese dat 
artemisinine en sommige van zijn structurele analogen volledig gelokaliseerd zijn in de 
subcuticulaire ruimte van de blaasjes op de oppervlakte van de bladeren. We valideerden het 
gebruik van dit chloroform extract, zonder bijkomende staalvoorbereidende stappen, voor 
kwantitatieve HPLC – ESI – QTOF  MS/MS. Er werd geen ionisatie onderdrukking (matrix 
effect) door interferentie met andere componenten gedetecteerd. Voor elke concentratie 
binnen het bereik van de standaard curve (0.1 tot 3.00 µg/ml), lag de accuraatheid tussen 85% 
and 115%. De dag-tot-dag variatie voor de analyse van A. annua stalen was <20%. We 
kunnen concluderen dat deze zeer korte extractieprocedure een goed alternatief is voor andere 
arbeidsintensieve procedures.  
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Appendix 1  
 
Identified proteins in the trichomes-versus-whole leafs proteome study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note:  
Protein spots that identified as histones, chaperonins, proteasomes, DNA binding proteins, 
porins, Ribulose-1,5-bisphosphate carboxylase and ATPases, were omitted from the list. 
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Code 
spot
D I Mascot 
Score
Proteïne Code 
Proteïne
Interpro GSTSUB AAGST AAFB 
3409 194 184 0  005-F08: metallothionein 1 [Aster tripolium] 
 009-D09: At1g05600 [Arabidopsis thaliana] 
4908 151 161 101 Methionine synthase.- Glycine max (SoybeaQ71EW8_SOYBN Methionine synthase    
151 161 55 Hypothetical protein.- Medicago truncatula ( Q1SW13_MEDTR Hypothetical   
5826 238 170 103 Cytosolic phosphoglucomutase.- Populus toQ6S3D6_9ROSI Phosphoglucomutase and phosphomannom055 C09 051-C10  
7109 92 96 97 Putative 33kDa oxygen evolving protein of pQ943W1_ORYSA Photosystem II manganese-stabilizing prote  021-A02: pathogenesis-related protein [Zinn007-G01: Oxygen-evolving enhancer protein
 010-B08: pathogenesis-related protein [Zinn
8419 168 160 36 PSA17329 NID: - Pisum sativum CAA76741 Calreticulin/calnexin 015 E02  007-G01: Oxygen-evolving enhancer protein
047 D03: heat stress transcription factor [Ly   
8909 29 231 75 Protein disulfide-isomerase (EC 5.3.4.1) preISAASS Disulphide isomerase / Thioredoxin 073 E11: putative gag-pol polyprotein [Solan050-D08: human RAN binding protein 16-lik  
045 D10: retrotransposon protein, putative, 032-D10: 3-beta-hydroxy-delta5-steroid deh  
3316 250 219 0 009 G05: amorpha-4,11-diene synthase [Art  
5822 193 189 198 AP004338 NID: - Oryza sativa (japonica cul BAC83515 Fumarate reductase/succinate dehydrogena   014-D08: WAV2; catalytic [Arabidopsis thali
193 189 50 Putative CCT chaperonin gamma subunit.- OQ5Z6U5_ORYSA Chaperonin     
8209 118 233 66 Pathogenesis-related protein.- Zinnia eleganQ8LNX9_ZINEL Bet v I allergen 061 H06: ribosomal protein L14 [Helianthus 021-A02: pathogenesis-related protein [Zinn014-H08: pathogenesis-related protein [Zinn
 014-A10: pathogenesis-related protein [Zinn
 010-B08: pathogenesis-related protein [Zinn
9505 33 245 89 Heat shock protein 80 (Fragment).- SolanumQ8LRU7_SOLTU Heat shock protein 007 F05: Ycf3 [Ranunculus macranthus] 029-G08: cytochrome c oxidase subunit 6b- 003-D02
33 245 87 Sequence 65 from Patent WO0168863 (Fra CAC93759 Heat shock protein 050-B05: RPL15 [Arabidopsis thaliana] dbj|B001-F10: unknown protein [Arabidopsis thal
1204 241 192 0 056 F02: Integrase, catalytic region [Medica 006-F04  
047-G07  
2506 190 202 118 G protein beta subunit-like protein.- SolanumQ38JI7_SOLTU WD40 / Quinonprotein alcohol dehydrogena   012-E01: NADPH quinone oxidoreductase-l
190 202 110 GTP-binding regulatory protein beta chain h T02300 WD40   
190 202 91 Guanine nucleotide regulatory protein - rapeS48839   
3818 196 180 71 43.6K hypothetical protein F10O5.4 - ArabidE86480 Bacterial surface antigen  047-D07  
196 180 71 Outer envelope membrane protein homolog T12975 Bacterial surface antigen / Chloroplast enve    
5703 22 218 40 Cytochrome P450.- Vigna radiata Q9LKH7_9FABA Cytochrome_P450 032-A11: monodehydroascorbate reductase 
5824 229 188 98 Succinate dehydrogenase (EC 1.3.99.1) flavT51815 Fumarate reductase/succinate dehydrogena   
6816 138 122 173 Malate oxidoreductase (malic enzyme) [imp E84508 Malic enzyme 034 F04 028-A07: 2,3-bisphosphoglycerate-independ001-G05: cyclin-dependent protein kinase [A
138 122 50 Phosphoglycerate mutase (EC 5.4.2.1), 2,3-S44373 Phosphoglucomutase / Metalloenzyme   021-F02: cofactor-independent phosphoglyc 
138 122 47 Hypothetical protein OSJNBa0077M12.113. Q8H334_ORYSA Kinase 018-B10: caffeic acid O-methyltransferase I  
2711 54 240 145 Glyceraldehyde-3-phosphate dehydrogenasQ8VWP4_CAPAN Glyceraldehyde 3-phosphate dehydrogenas  034-H10: phi-1 [Nicotiana tabacum] 022-D02: glyceraldehyde-3-phosphate dehy
54 240 101 Putative RNA-binding protein.- Arabidopsis Q8LAU2_ARATH NAD-dependent epimerase/dehydratase   020-B11 007-E08: glyceraldehyde-3-phosphate dehy
54 240 84 RNA binding protein, putative, expressed.- OQ2QSR7_ORYSA RNA 030-G08: putative cinnamyl alcohol dehydro017-H08: hypothetical protein MtrDRAFT_A
2805 3 178 274 Catalase 3 (EC 1.11.1.6).- Helianthus annuuQ9M503_HELAN Catalase 072 E07: CPRD12 protein [Vigna unguiculat029-C10: catalase 2 [Helianthus annuus] 009-A04: OSJNBb0024F06.20 [Oryza sativa
3 178 91 AlaT1.- Vitis vinifera (Grape). Q45RS3_VITVI 1-aminocyclopropane-1-carboxylate synthas043 H03: Integrase, catalytic region [Medica  
001 H08: glutathione peroxidase [Helianthus  
3508 3 178 31 Hypothetical protein OSJNBa0077M12.113. Q8H334_ORYSA Kinase    
4714 156 133 133 DnaK-type molecular chaperone LIM18 - truJC2215 Heat shock protein   
156 133 57 GDHB glutamate dehydrogenase (EC 1.4.1 Q1HDV6_VITVI Glu/Leu/Phe/Val dehydrogenase   
6107 119 246 53 Emb|CAA71173.1 (Hypothetical protein At5gQ9LTE1_ARATH Heavy metal transport/detoxification protein   014-A11: ribulose-1,5-bisphosphate carboxy
4702 64 234 327 Phosphoglycerate kinase.- Medicago truncaQ1SNT1_MEDTR Phosphoglycerate kinase 072 E07: CPRD12 protein [Vigna unguiculat010-E10: cytosolic phosphoglycerate kinase015-A12: protein binding / serine-type endop
026 A03: GCPE protein [Catharanthus roseu015-H05 004-B03: expressed protein [Oryza sativa (ja
025-E08 008-E01
001-A01: ribosomal protein L37 [Glycine ma 
055-G01: fructokinase-like [Solanum tubero  
6708 246 186 65 Phosphoglycerate kinase.- Medicago truncaQ1SNT1_MEDTR Phosphoglycerate kinase 032-A11: monodehydroascorbate reductase 
8809 89 130 397 Protein At4g24190.- Arabidopsis thaliana (MQ1NZ06_ARATH Cytokine / ATPase / Endoplasmic reticulum    011-C10
89 130 53 Lipoxygenase (EC 1.13.11.12).- AdelostemmQ4FCM5_9GENT Lipoxygenase   
2509 174 172 0  022-F12
7113 145 132 51 Putative polynucleotide phosphorylase.- OryQ69LE7_ORYSA RNA 062 G09: amorpha-4,11-diene synthase [Art032-F11: MADS-box transcription factor CD  
009 C06   
026 C12   
063 C09   
8905 47 211 535 Chaperonin 60 alpha subunit.- Canavalia lin Q9ZTV1_CANLI Chaperonin 073 F09  006-E09: early tobacco anther 1 [Medicago 
47 211 69 Glycosyl transferases-like protein (AT3g159 Q9LSB5_ARATH Cytochrome b5 / Glycosyl transferase      
9105 63 168 0 021-A02: pathogenesis-related protein [Zinn 
   030-G06: 1-deoxyxylulose 5-phosphate syn  
030-B02: peroxiredoxin [Hyacinthus oriental  
1622 56 225 57 OSJNBa0053K19.11 protein.- Oryza sativa Q7XPR2_ORYSA Glycine cleavage T-proteins   
3703 105 206 59 Aspartate aminotransferase-like.- Solanum tQ2XTE6_SOLTU Aspartate aminotransferase 022-E11: hypothetical protein MtrDRAFT_A  
105 206 73 NADH-ubiquinone oxidoreductase 49 kDa s NUCM_ARATH NADH dehydrogenase / NADH-ubiquinone o   
5817 232 212 126 NADH2 dehydrogenase (ubiquinone) (EC 1 S52737 NADH dehydrogenase / NADH-ubiquinone o042 B11: RuBisCo large subunit [Cucumis s  
232 212 115 Transketolase (EC 2.2.1.1) precursor, chloroT09015 Transketolase (DXP synthase) 047 A04: glucose acyltransferase [Solanum   
9316 71 119 179 Putative 14-3-3 protein.- Zea mays (Maize). Q5XPI0_MAIZE 14-3-3 (protein binding) 032-B11: 70 kDa heat shock cognate protein014-F05
71 119 73 Plastid-lipid-associated protein pap - commoT03635 Plastid lipid-associated proteins (PAPs) /  fib 007-B04: 14-3-3-like protein [Helianthus ann 
71 119 52 Heat shock protein 70 (Hsc70-5) - Arabidop T49939 Chaperonin 014-H02: 3-oxoacyl-[acyl-carrier protein] red 
5823 245 228 159 AP004338 NID: - Oryza sativa (japonica cul BAC83515 Fumarate reductase/succinate dehydrogena  014-D08: WAV2; catalytic [Arabidopsis thali
245 228 44 Putative CCT chaperonin gamma subunit.- OQ5Z6U5_ORYSA Chaperonin   
2706 59 204 204 NADH-glutamate dehydrogenase (EC 1.4.1 Q8W1X4_LYCES Glu/Leu/Phe/Val dehydrogenase 008-G03: chloroplast photosystem I reaction 
3417 179 213 69 Putative peroxidase (EC 1.11.1.7) (FragmenQ5QQS6_ZINEL Peroxidase   
4907 172 173 58 NADH2 dehydrogenase (ubiquinone) (EC 1 S52737 NADH dehydrogenase / NADH-ubiquinone o   
5706 46 238 461 Phosphoglycerate kinase-like.- Solanum tubQ2V9B3_SOLTU Phosphoglycerate kinase 063 D12 029-C10: catalase 2 [Helianthus annuus] 004-B03: expressed protein [Oryza sativa (ja
46 238 68 DP000009 NID: - Oryza sativa (japonica cul ABF93789  Glyceraldehyde 3-phosphate dehydrogenas 001 C08 027-D09 022-D12: unknown protein [Arabidopsis thal
46 238 60 NB-ARC domain containing protein, expressQ2QPV5_ORYSA Disease resistance 003 F04: polyprotein [Cynara scolymus] 027-C08  
010-E10: cytosolic phosphoglycerate kinase 
035-B09  
026-D11  
5917 19 208 139 Transketolase (EC 2.2.1.1) precursor - pota S58083 Transketolase (DXP synthase) 013-H10: thioredoxin/transketolase fusion p  
051-B03: cytosolic ascorbate peroxidase [N  
6601 62 239 105 Fructose-bisphosphate aldolase (EC 4.1.2.1ADSPAP Fructose-bisphosphate aldolase 005-H04 017-H03: plastid fructose bisphosphate aldo
62 239 97 Putative fructose bisphosphate aldolase.- TrQ2PER4_TRIPR Fructose-bisphosphate aldolase 021-E09: fructose-bisphosphate aldolase [A 013-C07: plastidic aldolase NPALDP1 [Nico
 017-B05: unknown protein [Arabidopsis thal
1312 140 162 0 035 A10: Lipolytic enzyme, G-D-S-L [Medica  
1609 40 187 234 Putative NADH-ubiquinone oxireductase (HyQ9SK66_ARATH NAD-dependent epimerase/dehydratase 011 C12 005-C12: malate dehydrogenase [Vitis vinife004-F11: putative mitochondrial NAD-depen
40 187 122 Malate dehydrogenase (EC 1.1.1.37) precurT51311 L-lactate/malate dehydrogenase 042 B11: RuBisCo large subunit [Cucumis s025-F12: succinyl-CoA ligase alpha 1 subun011-B10: rbcL [Oryza sativa (indica cultivar-
1807 285 Glycine hydroxymethyltransferase (EC 2.1.2S40212 Glycine hydroxymethyltransferase 016-F12: At4g28450/F20O9_130 [Arabidops003-E12: glycine hydroxymethyltransferase 
56 Catalase 4 (EC 1.11.1.6).- Helianthus annuuQ9M502_HELAN Catalase   
3612 230 223 213 Malate dehydrogenase (EC 1.1.1.37).- LupinQ8GZN3_LUPAL L-lactate/malate dehydrogenase 030-G08: putative cinnamyl alcohol dehydro007-B03: malate dehydrogenase [Plantago 
230 223 102 Glyceraldehyde-3-phosphate dehydrogenasQ8VXM5_CHAVU Glyceraldehyde 3-phosphate dehydrogenas  008-G09: glyceraldehyde 3-phosphate dehy 
029-E12: malate dehydrogenase [Plantago  
030-G04  
4822 201 207 112 AP004338 NID: - Oryza sativa (japonica cul BAC83515 Fumarate reductase/succinate dehydrogena  015-C11: BiP-isoform D [Glycine max] 
8302 13 242 107 Chlorophyll a/b-binding protein Lhcb2 [impo T52322 Chlorophyll A-B binding protein   
13 242 74 S46215 NID: - Lactuca sativa AAB23371 Triosephosphate isomerase   
13 242 53 NADH:ubiquinone oxidoreductase-like.- SolaQ38M79_SOLTU NADH dehydrogenase / NADH-ubiquinone o   
2815 219 158 226 Formate-tetrahydrofolate ligase, FTHFS.- M Q1SCS3_MEDTR Formate-tetrahydrofolate ligase 048-A12: putative yeast pheromone recepto 
4717 236 229 53 Acyl-CoA dehydrogenase.- Medicago truncaQ1RWA6_MEDTR Acyl-CoA dehydrogenase   
236 229 44 Glyceraldehyde-3-phosphate dehydrogenasDEPMNB Glyceraldehyde 3-phosphate dehydrogenas    
5825 239 175 100 Succinate dehydrogenase (EC 1.3.99.1) flavT51815 Fumarate reductase/succinate dehydrogena042 B11: RuBisCo large subunit [Cucumis s  
239 175 54 Cytosolic phosphoglucomutase.- Populus toQ6S3D6_9ROSI Phosphoglucomutase and phosphomannom   
1718 162 128 120 Aspartate transaminase (EC 2.6.1.1), cytosoT14311 Aspartate aminotransferase  016-B11: putative acid phosphatase [Oryza 
 023-G12: polygalacturonase inhibitor [Actini
5210 0  007-H11: cytosolic ascorbate peroxidase [Fr
6108 110 221 0 055 C09   
060 H09   
6819 0 028-A07: 2,3-bisphosphoglycerate-independ007-D07
3311 170 197 104 Carbonic anhydrase (Fragment).- Striga asiaQ1PG92_9LAMI Carbonic anhydrase   
3724 127 149 0 034-B07: unknown protein [Arabidopsis thal  
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Appendix 2  
 
Identified proteins in the upper-versus-lower leafs proteome study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note:  
Protein spots that identified as histones, chaperonins, proteasomes, DNA binding proteins, 
porins, Ribulose-1,5-bisphosphate carboxylase and ATPases, were omitted from the list. 
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Code 
spot
D I Mascot 
Score
Proteïne Code 
Proteïne
Interpro GSTSUB AAGST AAFB
2505 22 20 247 Malate dehydrogenase (EC 1.1.1.37) precurT51311 L-lactate/malate dehydrogenase 042 B11: RuBisCo large subunit [Cucumis 005-C12: malate dehydrogenase [Vitis vin 004-F11: putative mitochondrial NAD-depe
5207 16 22 0 012-G03: peroxiredoxin [Ipomoea batatas 007-G01: Oxygen-evolving enhancer prote
055-F02: putative peptidylprolyl isomerase 007-H09: calcium ion binding [Arabidopsis
048-F10
701 31 34 342 Glycolate oxidase.- Brassica napus (Rape). Q3L1H0_BRANA Alpha-hydroxy acid dehydrogenase 015-D05: glycolate oxidase/ oxidoreductas
007-D02: BURP [Medicago truncatula] 
4207 20 19 0 Putative Rieske Fe-S protein (Fragment).- CQ6E4A8_CYNDA Rieske iron-sulfur protein (cytochrome C link 015-H07: chloroplast Rieske FeS protein [
6 4205 18 37 141 Photosystem II oxygen-evolving complex pr JS0771 Photosystem II oxygen evolving complex pro 
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Identified proteins in the one-minute chloroform extract proteome study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note:  
Protein spots that identified as histones, chaperonins, proteasomes, DNA binding proteins, 
porins, Ribulose-1,5-bisphosphate carboxylase and ATPases, were omitted from the list. 
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Code 
spot
Mascot 
Score
Proteïne Code 
Proteïne
Interpro GSTSUB AAGST AAFB
G1 0 025 G09: IVD (ISOVALERYL-COA-DEHYD 028-G03
G15 48 Beta-galactosidase.- Sandersonia aurantiac Q6EM02_SANAU Glycoside hydrolase 044 H09 026-D02: glucose-6-phosphate isomerase [L021-F11
G15 0 Gcyc (Fragment).- Goyazia rupicola. Q6UQK6_9LAMI transcription factor 023-D06
G18 010-C02: caffeic acid O-methyltransferase [  
G19 70 Polygalacturonase-like protein.- Fragaria an Q84LI7_FRAAN Glycoside hydrolase 010-C02: caffeic acid O-methyltransferase [ 013-B01
G22 0 031-F06: lipid transfer protein precursor [Go 
G26 51 LEXYL1 protein.- Lycopersicon esculentum Q76MS5_LYCES Glyceraldehyde 3-phosphate dehydrogenas  
G27 75 LEXYL1 protein.- Lycopersicon esculentum Q76MS5_LYCES Glyceraldehyde 3-phosphate dehydrogenas  
G28 127 LEXYL1 protein.- Lycopersicon esculentum Q76MS5_LYCES Glyceraldehyde 3-phosphate dehydrogenas  055-G02
G28 67 beta-xylosidase-like protein - Arabidopsis th T49925 Glycoside hydrolase
G29 132 LEXYL1 protein.- Lycopersicon esculentum Q76MS5_LYCES Glyceraldehyde 3-phosphate dehydrogenas  
G29 69 beta-xylosidase-like protein - Arabidopsis th T49925 Glycoside hydrolase
G31 0 023-G12: polygalacturonase inhibitor [Actini
G32 0  005-H03
G33 0 005-H03
G37 0 026 C12 009-D09: At1g05600 [Arabidopsis thaliana] 
G40 020-B07: putative hypersensitive-induced re004-H06
G48 0 026 C12 001-B10: beta-ketoacyl-ACP synthase I [Pe 007-B06
G48 005 E12: At1g19360 [Arabidopsis thaliana] r006-F12: isoflavone-7-o-methytransferase 9021-A09
G48 052-G06: gag-pol polyprotein-related [Medic034-E02: nodule-enhanced malate dehydrog013-C09
G49 0 001-B10: beta-ketoacyl-ACP synthase I [Pe  
G56 0 034-D11: poly(A)-binding protein [Nicotiana  
G56 031-B04: O-methyltransferase/ S-adenosylm 
G56 010-C02: caffeic acid O-methyltransferase [  
G57 055-G02
G66 56 Polygalacturonase-like protein.- Fragaria an Q84LI7_FRAAN Glycoside hydrolase
G68 0 047 H03 037-B12: violaxanthin deepoxidase [Chrysa  
G68 053 C08: cyclopropane fatty acid synthase [ 014-C03: transaldolase [Solanum tuberosum 
G68 026 C12
G79 0 010-C05: hypothetical protein MtrDRAFT_A 017-D09: chloroplast hypothetical protein [Z
G81 64 Galactan:galactan galactosyltransferase 1.- Q6TW99_AJURE Glycoside hydrolase
G91 0 013-B09: transposon protein, putative, Pong
O1 0 009 C06 002-G03: clp-like energy-dependent proteas022-E08: unknown [Hyacinthus orientalis] 
O1 033-B03 001-B10: beta-ketoacyl-ACP synthase I [Pe  
O1 047-D11 032-F11: MADS-box transcription factor CD  
O10 0 054 A02 006-D08
O10 010-A06: thiosulfate sulfurtransferase [Datis
O13 0 039-B12 008-H10: plastid ribosomal protein S9 precu 
O14 039-B12 020-F06: putative thioredoxin peroxidase 1 
O8 0 015-G03: synptobrevin-related protein [Pyru006-D08
R141 0 009-D09: At1g05600 [Arabidopsis thaliana] 
R16 51 Polygalacturonase-like protein.- Fragaria an Q84LI7_FRAAN Glycoside hydrolase
R42 50 MTD2.- Medicago truncatula (Barrel medic).Q9LLM2_MEDTR Zinc finger
R46 0 020 D11
R55 0 058-A04 012-C06: fiber protein Fb19, putative, expre  
R71 47 Hypothetical protein OSJNBa0077M12.113. Q8H334_ORYSA transferase 061 C02: polyprotein [Cynara scolymus]  013-A04
R71 0 043 G08: (3R)-linalool synthase [Artemisia a 014-H05: Chlorophyll a-b binding protein, ch
R78 001-A01
R79 010-C02: caffeic acid O-methyltransferase [  
R125 010-C02: caffeic acid O-methyltransferase [  
R126 001-A01
R129 010-C02: caffeic acid O-methyltransferase [  
R143 053-G02
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BLAST results for the trichomes-versus-whole leafs proteome study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note:  
BLAST results with proteins that identified as histones, chaperonins, proteasomes, DNA 
binding proteins, porins, Ribulose-1,5-bisphosphate carboxylase and ATPases, were omitted 
from the list. 
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BLASTN 2.2.15 [Oct-15-2006] 
 
Database: TrichomesVsLeafs.txt 
    Posted date:  Oct 23, 2006  4:22 PM 
  Number of letters in database: 399,230 
  Number of sequences in database:  432 
 
 
Query= AA186         (430 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
8302  Chlorophyll a/b binding protein – A. thaliana           107   7e-025 
 
 
Query= AA202         (495 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
8302  Chlorophyll a/b binding protein – A. thaliana           100   2e-022 
 
 
Query= AA693         (215 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
8302  Chlorophyll a/b binding protein – A. thaliana            72   2e-014 
 
 
Query= AA320         (553 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
8302  Chlorophyll a/b binding protein – A. thaliana            64   1e-011 
 
 
Query= AA321         (535 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
8302  Chlorophyll a/b binding protein – A. thaliana            56   3e-009 
 
 
Query= AA785         (323 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
8302  Chlorophyll a/b binding protein – A. thaliana            58   4e-010 
 
 
 
• Matching for spot 8302: 
o MASCOTscore107: chlorophyll a/b-binding protein Lhcb2 [imported] - Arabidopsis 
thaliana 
o MASCOTscore74: S46215 NID: Lactuca sativa (Triosephosphate isomerase) 
o MASCOTscore53: NADH:ubiquinone oxidoreductase-like - Solanum tuberosum (Potato) 
o    No match with GSTSUB, AAGST and AAFP 
• This data supports the selection of AAFB 014_H05: Chlorophyl a/b binding protein (See Blast 
analysis for the chloroform extract proteome experiment) 
 
 159
 
Query= AA201         (113 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
GSTSUB_UP_047_A04_26OCT2005_032.ab1                             46   5e-007 
 
 
Query= AA244         (464 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
AAGST_UP_013_H10_25AUG2004_066.ab1                             684   0.0   
5817  Transketolase precursor, chloroplast – spinach            90   2e-019 
 
 
Query= AA323         (330 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
AAGST013_H10                                                    98   5e-022 
5817  Transketolase precursor, chloroplast – spinach            68   5e-013 
 
 
Query= AA332         (369 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
AAGST013_H10                                                   155   3e-039 
5817  Transketolase precursor, chloroplast – spinach           141   4e-035 
 
 
 
• Matching for spot GR5917 en R5917: 
o MASCOTscore139: Transketolase precursor - potato (DXP synthase) 
o AAGST_013_H10: Thioredoxin/transketolase fusion protein [synthetic construct]  
o AAGST_051_B03: Cytosolic ascorbate peroxidase [Nicotiana tabacum] 
• Matching for spot GR5817 en R5817: 
o MASCOTscore126: NADH2 dehydrogenase (ubiquinone) 76K chain precursor - potato 
o MASCOTscore115: Transketolase precursor, chloroplast – spinach (DXP synthase) 
o MASCOTscore85: AT3g60750/T4C21_160 - Arabidopsis thaliana (DXP synthase) 
o GSTSUB_042_B11: RuBisCo large subunit [Cucumis sativus]  
o GSTSUB_047_A04: Glucose acyltransferase [Solanum berthaultii] 
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Query= AA243         (563 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
6601  Fructose-bisphosphate aldolase precursor                 52   5e-008 
 
 
Query= AA551         (144 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
AAFB013_C07                                                   107   2e-025 
6601  Fructose-bisphosphate aldolase precursor                 36   7e-004 
 
 
Query= AA564         (217 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
AAFB_UP_017_H03_06DEC2005_017.ab1                             272   1e-074 
AAFB013_C07                                                   172   7e-045 
6601  Fructose-bisphosphate aldolase precursor                170   3e-044 
AAFB017_H03                                                   153   6e-039 
AAFB003_E06                                                   153   6e-039 
 
 
Query= AA763         (136 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
AAFB013_C07                                                    92   1e-020 
 
 
Query= AA764         (163 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
AAFB013_C07                                                   143   5e-036 
6601  Fructose-bisphosphate aldolase precursor                 48   2e-007 
 
 
• Matching for spot 6601: 
o MASCOTscore105: Fructose-bisphosphate aldolase precursor, chloroplast - 
spinach 
o AAGST_005_H04 
o AAGST_021_E09: Fructose-bisphosphate aldolase [Arabidopsis thaliana]  
o AAFB_017_H03: Plastid fructose bisphosphate aldolase [Stevia rebaudiana] 
o AAFB_013_C07: Plastidic aldolase NPALDP1 [Nicotiana paniculata]  
o AAFB_017_B05: unknown protein [Arabidopsis thaliana] gb|AAM47942.1| unknown 
protein [Arabidopsis thaliana] gb|AAL62377.1| unknown protein [Arabidopsis thaliana] 
dbj|BAB03030.1| unnamed protein product [Arabidopsis thaliana]  
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Query= AA282         (371 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
AAGST_UP_018_B10_26AUG2004_078.ab1                            339   9e-095 
AAGST018_B10                                                   50   1e-007 
 
 
Query= AA610         (128 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
AAGST018_B10                                                   44   2e-006 
 
 
Query= AA633         (370 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
AAGST_UP_018_B10_26AUG2004_078.ab1                            385   e-108 
AAGST018_B10                                                   62   3e-011 
 
 
• Matching for spot 6816: 
o MASCOTscore173: malate oxidoreductase (malic enzyme) [imported] - Arabidopsis 
thaliana 
o MASCOTscore50: phosphoglycerate mutase (EC 5.4.2.1), 2,3-bisphosphoglycerate-
independent - common tobacco Phosphoglucomutase / Metalloenzyme 
o MASCOTscore47: Hypothetical protein OSJNBa0077M12.113.- Oryza sativa (japonica 
cultivar-group). kinase 
o GSTSUB_ 034 F04 
o AAGST_028_A07: 2,3-bisphosphoglycerate-independent phosphoglycerate mutase 
(Phosphoglyceromutase) (BPG-independent PGAM) (PGAM-I) gb|AAA33499.1| 2,3-
bisphosphoglycerate-independent phosphoglycerate mutase  
o AAGST_018_B10: caffeic acid O-methyltransferase II [Nicotiana tabacum]  
o AAGST_021_F02: cofactor-independent phosphoglyceromutase [Apium graveolens] 
o AAFB_001_G05: cyclin-dependent protein kinase [Arabidopsis thaliana] gb|AAC27476.1| 
putative PREG1-like negative regulator [Arabidopsis thaliana] gb|AAY57312.1| 
At2g44740 [Arabidopsis thaliana] gb|AAY17415.1| At2g44740 [Arabidopsis thaliana] 
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Query= AA340         (460 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
8809  Protein At4g24190.- A. thaliana                         141   5e-035 
 
 
Query= AA327         (225 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
9505  Sequence 65 from Patent WO0168863                       141   3e-035 
8809  Protein At4g24190 - A. thaliana                          52   2e-008 
9505  Heat shock protein 80                                    44   4e-006 
 
 
• Matching for spot 9505: 
o MASCOTscore89: Heat shock protein 80 (Fragment).- Solanum tuberosum (Potato). 
o MASCOTscore87: Sequence 65 from Patent WO0168863 (Fragment).- Lycopersicon 
esculentum (Tomato). (Heat shock protein like: reacts with geminivirus products) 
o GSTSUB_ 007_F05: Ycf3 [Ranunculus macranthus] (large substrates, multiple functions) 
o AAGST_029_G08: cytochrome c oxidase subunit 6b-1 [Oryza sativa] 
o AAGST_050_B05: 50S ribosomal protein L15, chloroplast precursor [Arabidopsis 
thaliana] 
o AAFB_003_D02 
o AAFB_001_F10: unknown protein [Arabidopsis thaliana] gb|AAP88362.1| At5g02050 
[Arabidopsis thaliana] emb|CAB82978.1| putative protein [Arabidopsis thaliana] 
• Matching for spot 8809 
o MASCOTscore397: Protein At4g24190.- Arabidopsis thaliana (cytokine / ATPase / 
Endoplasmic reticulum targeting sequence / Heat shock protein) 
o MASCOTscore53: Lipoxygenase (EC 1.13.11.12) - Adelostemma gracillimum 
o AAFB_011_C10 
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Query= AA254         (616 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
2805  1-aminocyclopropane-1-carboxylate synthase              264   7e-072 
 
 
Query= AA328         (107 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
AAGST029_C10                                                   82   9e-018 
 
 
 
• Matching for spot 2805: 
o MASCOTscore277: Catalase 3 (EC 1.11.1.6) - Helianthus annuus 
o MASCOTscore91: AlaT1 - Vitis vinifera 1-aminocyclopropane-1-carboxylate 
synthase 
o GSTSUB_ 043_H03: Integrase, catalytic region [Medicago truncatula]  
o GSTSUB_ 072_E07: CPRD12 protein [Vigna unguiculata] (oxidoreductase)  
o GSTSUB_ 001_H08: glutathione peroxidase [Helianthus annuus] 
o AAGST_029_C10: catalase 2 [Helianthus annuus] 
o AAFB_009_A04: OSJNBb0024F06.20 [Oryza sativa (japonica cultivar-group)]  
 
• Matching for spot 5706: 
o MASCOTscore461: Phosphoglycerate kinase-like - Solanum tuberosum  
o MASCOTscore68: DP000009 NID: Oryza sativa (GAPDH) 
o MASCOTscore60: NB-ARC domain containing protein - Oryza sativa (Disease 
resistance) 
o GSTSUB_063_D12 
o GSTSUB_001_C08 
o GSTSUB_003_F04: polyprotein [Cynara scolymus] 
o AAGST_029_C10: catalase 2 [Helianthus annuus]  
o AAGST_027_D09  
o AAGST_010_E10: cytosolic phosphoglycerate kinase 1 [Populus nigra]  
o AAGST_027_C08 
o AAGST_035_B09 
o AAGST_026_D11 
o AAFB_004_B03: gb|AAT81723.1| striated muscle activator-like protein [Oryza sativa] 
o AAFB_022_D12: gb|ABE65868.1| auxin-responsive family protein [Arabidopsis thaliana] 
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Query= AC8         (136 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
AAGST_UP_032_A11_27AUG2004_095.ab1                            151   2e-038 
 
 
• Matching for spot 5703: 
o MASCOTscore40: Cytochrome P450.- Vigna radiata 
o AAGST_ 032_A11: monodehydroascorbate reductase [Mesembryanthemum 
crystallinum] 
• Matching for spot 6708: 
o AAGST_ 032_A11: monodehydroascorbate reductase [Mesembryanthemum 
crystallinum] 
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Query= AC9          (867 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
AAGST_UP_008_G09_07MAY2004_067.ab1                             52   7e-008 
 
 
• Matching voor spot GR3612 en R3612: 
o MASCOTscore217: Malate dehydrogenase (EC 1.1.1.37).- Lupinus albus 
o MASCOTscore112: Putative GAPDH (Fragment).- Orobanche minor 
o AAGST_029_E12: malate dehydrogenase [Plantago major]  
o AAGST_008_G09: glyceraldehyde 3-phosphate dehydrogenase [Linum usitatissimum]  
o AAGST_030_G04 
o AAGST_030_G08: putative cinnamyl alcohol dehydrogenase [Zinnia elegans]  
o AAFB_014_007_B03: malate dehydrogenase [Plantago major] 
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Appendix 5  
 
BLAST results for the upper-versus-lower leafs proteome study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note:  
BLAST results with proteins that identified as histones, chaperonins, proteasomes, DNA 
binding proteins, porins, Ribulose-1,5-bisphosphate carboxylase and ATPases, were omitted 
from the list. 
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BLASTN 2.2.15 [Oct-15-2006] 
 
Database: UpperVsLowerCDS.txt 
    Posted date:  Oct 23, 2006  4:23 PM 
  Number of letters in database: 44,506 
  Number of sequences in database:  54 
 
 
Query= AA296         (230 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
AAFB_UP_015_H07_06DEC2005_049.ab1                              34   5e-004 
 
 
Query= AA682         (261 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
AAFB_UP_015_H07_06DEC2005_049.ab1                              34   6e-004 
 
 
• Matching for spot 4207: 
o MASCOTscore 59: Putative Rieske Fe-S protein (Fragment).- Cynodon dactylon 
(Bermuda grass). 
o AAFB_015_H07: chloroplast Rieske FeS protein [Pisum sativum] 
sp|P26291|UCRIA_PEA Cytochrome b6-f complex iron-sulfur subunit, chloroplast 
precursor (Rieske iron-sulfur protein) (Plastohydroquinone:plastocyanin 
oxidoreductase iron-sulfur protein) (ISP) (RISP) 
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Query= AA786         (152 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
AAFB015_D05                                                    96   1e-022 
0701  Glycolate oxidase.- Brassica napus (Rape)                96   1e-022 
 
 
Query= AC11         (377 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
0701  Glycolate oxidase.- Brassica napus (Rape)               214   4e-058 
AAFB015_D05                                                   198   2e-053 
 
 
 
 
• Matching for spot 0701: 
o MASCOTscore 342: Glycolate oxidase.- Brassica napus (Rape). 
o AAFB_015_D05: glycolate oxidase/ oxidoreductase [Arabidopsis thaliana] 
ref|NP_188060.1| glycolate oxidase/ oxidoreductase [Arabidopsis thaliana] 
gb|AAL69528.1| AT3g14420/MOA2_2 [Arabidopsis thaliana] gb|AAL16164.1| 
AT3g14420/MOA2_2 [Arabidopsis thaliana] gb|AAK96642.1| AT3g14420/MOA2_2 
[Arabidopsis thaliana] dbj|BAB01334.1| glycolate oxidase [Arabidopsis thaliana] 
sp|Q9LRR9|GOX2_ARATH Probable peroxisomal (S)-2-hydroxy-acid oxidase 2 
(Glycolate oxidase 2) (GOX 2) (Short chain alpha-hydroxy acid oxidase 2)  
o AAFB_007_D02: BURP [Medicago truncatula]  
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Appendix 6  
 
BLAST results for the one-minute chloroform extract proteome study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note:  
BLAST results with proteins that identified as histones, chaperonins, proteasomes, DNA 
binding proteins, porins, Ribulose-1,5-bisphosphate carboxylase and ATPases, were omitted 
from the list. 
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BLASTN 2.2.15 [Oct-15-2006] 
 
Database: ChloroformExtractCDS.txt 
    Posted date:  Oct 23, 2006  4:22 PM 
  Number of letters in database: 47,895 
  Number of sequences in database:  61 
 
 
 
Query= AA86         (309 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
AAGST_UP_020_B07_26AUG2004_061.ab1                            531    e-153 
AAGST020_B07                                                  147   1e-037 
 
• Matching for spot G40: 
o AAGST_020_B07: putative hypersensitive-induced response protein [Oryza sativa] 
o AAFB_004_H06 
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Query= AA104M         (70 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
GSTSUB_UP_009_C06_20AUG2004_044.ab1                            32   6e-004 
 
 
Query= AA699         (265 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
AAGST032_F11                                                   36   2e-004 
 
 
• Matching for spot O1: 
o GSTSUB_009_C06 
o AAGST_002_G03: clp-like energy-dependent protease [Fritillaria agrestis]  
o AAGST_001_B10: beta-ketoacyl-ACP synthase I [Perilla frutescens]  
o AAGST_032_F11: MADS-box transcription factor CDM41 [Chrysanthemum x 
morifolium]  
o AAFB_022_E08: unknown [Hyacinthus orientalis] 
 
• Matching for spot 7113 
o MASCOTscore51: Putative polynucleotide phosphorylase.- Oryza sativa (japonica 
cultivar-group). 
o GSTSUB_062_G09: amorpha-4,11-diene synthase [Artemisia annua]  
o GSTSUB_009_C06 
o GSTSUB_026_C12 
o GSTSUB_063_C09 
o AAGST_032_F11: MADS-box transcription factor CDM41 [Chrysanthemum x 
morifolium]  
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Query= AA282         (371 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
AAGST010_C02                                                   36   3e-004 
 
 
• Matching for spot G18, R79, R125 en R129: 
o AAGST_010-C02: caffeic acid O-methyltransferase [Rosa chinensis var. spontanea] 
 
• Matching for spot G19: 
o MASCOTscore70: Polygalacturonase-like protein [Fragaria ananassaca] 
o AAGST_010-C02: caffeic acid O-methyltransferase [Rosa chinensis var. spontanea] 
o AAFB_013-B01  
 
• Matching for spot G56: 
o AAGST_034-D11: poly(A)-binding protein [Nicotiana tabacum]  
o AAGST_031-B04: putative caffeoyl-CoA O-methyltransferase [Arabidopsis thaliana] 
o AAGST_010-C02: caffeic acid O-methyltransferase [Rosa chinensis var. spontanea] 
 
Remark: 
• E-value is higher than 0.0001 
• 6 spots are linked to AAGST010_C02 
• 3 AFLP sequences in the link to “caffeic acid O-methyltransferase” in the Blast analysis for 
the trichomes-versus-whole leaf experiment 
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Query= AA294         (105 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
AAGST_UP_010_C05_07MAY2004_043.ab1                             48   2e-008 
AAGST010_C05                                                   40   4e-006 
 
 
Query= AA322         (69 letters) 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
AAGST_UP_010_C05_07MAY2004_043.ab1                             98   1e-023 
AAGST010_C05                                                   58   1e-011 
AAFB017_D09                                                    46   4e-008 
 
 
• Matching for spot G79: 
o AAGST_010-C05: hypothetical protein MtrDRAFT_AC151668g11v1 [Medicago 
truncatula]  
o AAFB_017-D09: chloroplast hypothetical protein [Zea mays] ref|YP_588293.1| 
chloroplast hypothetical protein [Zea mays subsp. mays]  
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Query= AA312M         (177 letters) 
 
                                                             Score    E 
Sequences producing significant alignments:                  (bits) Value 
 
AAFB_UP_014_H05_06DEC2005_033.ab1                             212   8e-058 
AAFB014_H05                                                    90   8e-021 
 
 
• Matching for spot R71: 
o MASCOTscore47: Hypothetical protein OSJNBa0077M12.113.- Oryza sativa 
(japonica cultivar-group). 
o GSTSUB_061_C02: polyprotein [Cynara scolymus]  
o GSTSUB_043_ G08: (3R)-linalool synthase [Artemisia annua] 
o AAFB_013_A04 
o AAFB_014_H05: Chlorophyll a-b binding protein, chloroplast precursor (LHCI type II CAB) 
gb|AAA33711.1| chlorophyll binding protein precursor prf||1503272A chlorophyll binding 
protein 
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mensen was dit onderzoek niet mogelijk geweest.  
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uiteenlopende onderzoeken en technieken in contact kwam. De overvloed aan strategieën en 
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OCS patiënten. Hierdoor kwam ik in aanraking met de medische genetica, een 
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